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Abstract
The overall aim of this project was to investigate the synthesis and activity of
a range of compounds based on the benzo[b]thiophene-2-carboxamide structural
motif as potential new antimalarial agents, and to a lesser extent as antibacterial
agents.
In order to

subsequently

explore

any structure-biological activity

relationships, the first part of the project involved the systematic synthesis of some
39

non-fused

substituted

tetrahydroisoquinolines,

benzo[b]thiophene

tetrahydro-β-carbolines,

amide

derivatives

dihydropyrroles,

including
piperazines,

piperidines and other bridged ring systems as part of the amide-nitrogen component.
Methods for the synthesis of the new amide derivatives were developed based on
benzo[b]thiophene

acid

chloride

and

amine

reactions,

or

on

dicyclohexylcarbodiimide-mediated carboxylic acid amine coupling reactions.
Further substitution reactions were also undertaken on tetrahydro-β-carboline
amides (55, 56, and 57) with the introduction of an N-benzyl group and an N-onitrobenzyl group in the case of 55. The N-boc protected piperazine amide 63 also
served as a precursor for other N-substituted piperazine amide derivatives. A single
crystal X-ray structure on amides 63 and 73 confirmed the amide rotamer geometry
in the solid state with these compounds.

xiv

The second part of the project incorporated the synthesis of fused analogues
which

were

more

conformationally

restricted

while

still

retaining

the

benzo[b]thiophene amide structural motif. A new free radical cyclisation approach
to the benzo[b]thieno[2,3-c]pyridin-1-one system in compound 92 was developed,
together with the corresponding model isoquinolinone analogue 95. The reaction
was based on the use of tributyltin hydride and AIBN to produce the required free
radical intermediate from an arylbromide precursor.
The free radical cyclisation reaction was extended to synthesise N-benzyl and
substituted N-benzyl analogues of 92. The dihydroxylation of the N-allyl substituent
in 92 was achieved using potassium osmate and N-methylmorpholine-N-oxide
(NMO). A further free radical cyclisation route to the N-benzo[b]thien-2-oyl
derivatives 112 was also achieved.
The synthesis of the novel 9-membered ring containing fused derivatives 120
and 121 was also achieved. This synthesis involved ring closing metathesis
methodology using the bis-allyl amides 118 and 119 and Grubbs’ I ruthenium
catalyst. The polymer supported version of this catalyst gave better yields of the
cyclisation products. A single crystal X-ray structure of 120 confirmed the cis
geometry of the double bond in the 9-membered ring. In the course of preparing the
required precursor 119 for the 9-membered ring synthesis, a new imine allylation
reagent combination was discovered involving zinc, allyltributyltin and boron
trifluoride etherate. This reaction is worthy of further investigation to determine its
wider synthetic utility.
xv

Ring closing metathesis reactions also afforded the dihydropyrrole amides
113 and 114 in good yields.
A palladium-mediated cyclisation approach to the new benzo[b]thieno[2,3c]pyrrolo[2,3-a]indol-11-one system in 126 was also accomplished based on the Nacyl indoles 124 and 125.
A number of the compounds were tested for their possible in vitro
antimalarial activity against two strains of Plasmodium falciparum (K1 CB1 and
TM4/ 8.2) and two active leads, the benzo[b]thienoquinolinone derivatives 95 and
102, were discovered. Some potential structure-activity trends for the tested
benzo[b]thiophene derivatives were observed (Chapter 4).
Antibacterial testing of a few benzo[b]thiophene compounds against
Staphylococcus aureus and vancomycin-resistant Enterococcus faecium strains was
also done, and the benzo[b]thienoquinolinone derivative 92 exhibited promising
activity against Staphylococcus aureus.
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Chapter 1 Introduction
1.1. General
Malaria is the single most serious and widespread parasitic disease affecting humans.
There are an estimated two billion people at risk from malaria in tropical and
subtropical regions of the world. Around 300-500 million cases of malaria occur
annually, causing the death of roughly 2.3 million people. Almost all of these deaths
occur in Sub-Saharan Africa where a lack of development can be directly attributable to
the prevalence of the disease.1,2 It drains limited health care infrastructures and depleted
financial resources. The remainder of malaria cases is largely restricted geographically
to South and Southeast Asia and some parts of South America.3 The distribution of the
disease is depicted in Figure 1.1. The gravity of the malaria problem has been
significantly aggravated in recent years due to several reasons. The disease has extended
into new regions as a result of changing land usage. This has caused epidemics in areas
previously known to be free from the disease.3 The failure of appropriate control
measures in regions of conflict in Africa and Southeast Asia has also contributed to an
increase of malaria cases in areas where it was previously considered to be under
control.3

1.2. Background
Hippocrates described the symptoms of malaria as early as the 5th Century BC.4
Plato and Aristotle both identified outbreaks of a disease with the exact symptoms of
malaria during their lifetimes (427 to 347 BC and 384 to 322 BC respectively).5 In the
2nd Century AD, malaria was first associated with swamps and marshes, in fact a
Spanish scholar of that era, Lucius Junius Moderatus alluded to insects being the
disease transmitters e.g. malaria.
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Figure 1.1 The Distribution of malaria worldwide indicating drug resistant areas.
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Areas of chloroquine/ mefloquine resistant P. falc.
Malaria either not endemic or is eradicated

Chloroquine resistant P. falciparum.

Chloroquine sensitive malaria.

“Buildings however, should not be built near a swamp because it exudes
harmful poison and gives birth to creatures which are armed with menacing stings and
fly in dense swarms against human beings … From their stings one often acquires
occult diseases whose origin is not even known to doctors.”5
For the next fifteen centuries no new advances in the knowledge of malaria
occurred.6 In the middle ages, it was thought that malaria was spread by stale air; in
fact the word ‘malaria’ is derived from the Italian mala aria meaning bad or evil air.7
As a means of combating the distribution of the disease, carers installed pots of sweet
smelling flowers by the bedside of the patients, unaware that in doing so they were
providing the very breeding site for the mosquitoes responsible for the propagation of
the disease bringing together the vector and the host.
The discovery of cinchona bark (the bitter bark of Cinchona ledgeriana) as a
useful therapeutic agent in the treatment of malaria in the 17th Century became the next
key step forward in the study of malaria.8,9
In the early 19th Century, post mortem examinations of the bodies of malaria
victims revealed a characteristic brownish malarial colouration of some organs, which
was referred to as melanemia.
It was not until 1880 that the French surgeon, Alphonse Laveran, working in
Algeria, discovered malarial parasites in the blood of a malaria patient. This was a
significant discovery in light of the fact that at the time the bacterium Bacillus malariae
was considered to be the cause of malaria.6,10
Six years later, the Roman physician Camillo Golgi described in detail two
human malarial protozoal parasites, Plasmodium vivax and Plasmodium malariae.4 A
further four years after this discovery, Marchiava and Celli described Plasmodium
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falciparum.4,10 Later a fourth malarial parasite, Plasmodium ovale, was discovered.11,12
A discussion of the mode and severity of infection of these species is deferred to later in
the chapter.
Solving the mystery of Plasmodium transmission was the next key focus in
malaria research.

The popular long-held opinion towards the end of the 19th Century

was that malaria was either airborne or waterborne. This belief was finally refuted with
the discovery by Ronald Ross in 1897 of the role of the mosquito as a vector in the
spread of malaria.13

1.3. Treatment
1.3.1. Traditional remedies
Throughout history, many societies have used traditional methods to treat and
control the spread of malaria. One prominent example is the infusion of an herbal
preparation,14 qinghaosu (Artemesia annua), used in China for at least 2000 years. As
mentioned above, cinchona bark had been used in the treatment of malaria as early as
the 17th Century. Furthermore, the antifebrile properties of cinchona bark were known
in Peru at least before the 15th Century AD.8,9,15,16

1.3.2. Controlling the spread
It is believed by some researchers that many of the greatest advances in
combating malaria have come through the development of methods of mosquito control,
rather than in techniques which target the Plasmodium parasite itself.17 Although
unaware of the origin of malaria and its mode of transmission, people have been using
protective measures against the mosquito for many centuries. For example, Herodotus
noted in 485 BC that inhabitants of swampy areas in Egypt slept in tall, tower-like
structures beyond the reach of mosquitoes, while others slept in the same region under
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nets.18-20 This method of constructing houses on stilts has been independently adopted
even in recent times to control malaria in countries such as North Vietnam, Sao Tome
and some regions in Africa.18,21 More recently in other regions of the world, techniques
for mosquito control have focused on eradicating the larvae by such means as
minimizing breeding grounds, clearing of bush land, covering still water with oil or
netting and the introduction of larvae eating fish such as Gambusia affinis.
Insecticides became prevalent during the 1940s when DDT was widely used in
attempts to eliminate mosquitoes and their larvae from malaria infected regions.9
Repellents have also been employed to aid in preventing the carrying mosquito from
coming into contact with humans.
Another recent advance is the development of insecticide-treated bed nets
(ITBN) as a measure in controlling the spread of malaria.22-24 In a series of independent
trials carried out in three countries with high infant mortality rates, the percentage
reduction of total infant mortality with the usage of ITBN decreased significantly. The
results of these studies are outlined in Table 1.1.
Table 1.1 – Percentage reduction in total child mortality with the use of ITBNs

Country

% Reduction in
Total Child
Mortality

Project Organizer

The Gambia

63

Medical Research Council
Laboratories, The Gambia

The Gambia

25

Gambian National Bed net
Impregnation Programme

Kenya

33

WHO organized trials

Ghana

17

WHO organized trials
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Clearly, ITBNs are highly effective in bringing about a decline in the mortality
of children in malaria stricken regions.24 They are, however, costly and uncomfortable
in the hot and humid tropics so their practicality in warmer climates where malaria is
prevalent and where poverty rates are high must also be evaluated. Alternatives such as
insecticide-impregnated curtains have been considered. However while this proposal
may alleviate the comfort issues it does little to reduce economic considerations so vital
to any strategy affecting the spread of the disease in the developing world. There are
however growing concerns that the mosquitoes may eventually develop resistance
towards the insecticides used to impregnate the nets hence making the nets less effective
in managing the disease.24

1.3.3. The Plasmodium parasite
As mentioned previously, there are four known species of human malarial
parasite of worldwide medical significance. However, modern molecular methods have
recently aided the discovery of the existence of other potential species or morphological
and geographical variants. Sequencing of the gene for the circumsporozoite surface
protein, for example, showed that some individuals apparently infected with P. vivax
were, in fact, infected with a distinct species more closely related to a malaria parasite
known to infect apes. Also, molecular analysis indicate that some morphological
variants are distinct parasites related to P. malariae and P. brasilianum the latter being
another simian parasite.
Although each of the four major human Plasmodium parasites is known to cause
malaria, they each cause symptoms of differing severity and duration.

Table 1.2

summarizes the disease severity and duration for the four major human malarial
parasites.
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Table 1.2 - Disease severity and duration from each of the four major human malarial
parasites25

Disease Severity and Duration
Initial
Paraoxysm
Severity
Average
Parasitemia (mm3)
Maximum
Parasitemia (mm3)
Symptom
Duration
(untreated)
Maximum
Infection Duration
(untreated)
Anaemia
Complications

Vivax
Moderate
to severe

Ovale
Mild

Malariae
Moderate to
severe

Falciparum
Severe

20,000

9,000

6,000

50,000

30,000

20,000

50,000500,000
2,500,000

3-8+
weeks

2-3 weeks

3-24 weeks

2-3 weeks

5-8 years

12-20
months

20-50+
years

6-17 months

++
Renal

++++
Cerebral

++

+

Modified from Markell and Voge's Medical Parasitology.25

Significantly, infections by P. falciparum are known to be the most severe and
consequently give rise to the highest mortality and morbidity rates. As a result of this
observation, P. falciparum is the focus of the majority of antimalarial research around
the world and forms the basis for the current discussion.

1.3.4. Lifecycle
In order to understand the mechanism by which mosquitoes spread Plasmodium
species, it is important to understand the lifecycle of this mosquito-borne parasite. In
Figure 1.2 the complete lifecycle of Plasmodium falciparum is represented, but other
Plasmodium species have the same lifecycle. The parasites lifecycle begins as male and
female gametocytes in the female anopheles mosquito where they combine to develop
into a zygote in the salivary gland.1 They then migrate into the gut where they form
7

oocytes in which sporozoites develop. Once the sporozoites have matured the oocytes
rupture releasing them into the system of the mosquito, which then transfers them into a
human host by biting the victim during a blood meal (step 5).

Figure 1.2- The life-cycle of the Plasmodium falciparum parasite.26
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Once introduced into the blood stream by the Anopheles mosquito, the newly
released sporozoites rapidly invade the liver where they adopt the form of liver
schizonts (step 6). During the next two weeks, the intracellular parasite multiplies
within a liver cell reaching numbers as high as 200,000. These schizonts invade red
blood cells forming trophozoites on maturation. It is at this stage that the first clinical
symptoms of malaria manifest themselves as chills, fever, prostration and anaemia.
Severe disease can include delirium, metabolic acidosis, cerebral malaria and multiorgan system failure; coma and death may follow.1,27 On maturation, the trophozoites
form schizonts (step 8), which rupture to release merozoites into the blood where they
invade more human erythrocytes. In these red blood cells the parasite matures asexually
to produce another cycle of merozoites which are in turn released into the blood to
invade still more red cells (step 9a). The rupture of schizonts leads to the formation of
male and female gametocytes, which are then taken up by another female anopheles
mosquito during a blood meal to begin the cycle again1,27 (step 9b).

1.3.5. Modern approaches
Although traditional medicines often form the foundation for modern drugs, a
sound knowledge of the lifecycle of the infecting organism allows the scientific
community a greater scope for a suitable methodology. For example, cinchona bark had
been used for the treatment of malaria for centuries in Peru and, until recently, its main
active component quinine, and the related semi-synthetic derivatives chloroquine and
mefloquine, held a large share of the worldwide antimalarial agent market.8,9 However,
their mode of action has remained problematic. Quinine and the various semi synthetic
quinoline-based antimalarial agents were once thought to achieve their effect by
plasmodial DNA intercalation after being concentrated in parasite-affected erythrocytes.
However, these effects could occur only at concentrations greater than that achieved in
9

vivo; moreover, a non-specific effect on plasmodial DNA could not explain the action of
these compounds at such precise points in the lifecycle of the parasite. The knowledge
and understanding of the biochemistry of malaria-causing parasites has led to
identification of many potential targets for newer drugs and to the identification of
possible mode(s) of action of the drugs already in use to manage malaria27,28 (Figure
1.3).
Clarification of the mode of action of these compounds, in the past, proved
difficult, but current thinking suggests that chloroquine and related compounds act
primarily by inhibiting haem polymerase, and hence prevent detoxification of
ferriprotoporphyrin IX, which is produced by erythrocytic haemoglobin in the food
vacuole of the parasite. Ferriprotoporphyrin IX, a metabolite toxic to the parasite, is
normally rendered harmless by being polymerised. In fact, malarial pigmentation is
caused by granules of this polymer.
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Figure 1.3-

Illustration of a red blood cell P. falciparum trophozoite denoting key
parasite cell organelles and the sites of action of some of the major
drugs for malaria.27

Because they are weak bases, quinine, chloroquine and mefloquine are
concentrated to very high levels in the food vacuole of the malarial parasite greatly
enhancing their activity.29 However, quinine and mefloquine do not achieve the same
levels of concentration as chloroquine, and consequently have significantly less effect
on haem polymerisation, giving rise to the possibility that these compounds act on
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multiple targets.30,31 It has been documented that although quinine itself acts as a blood
schizonticide, it also has gametocidal activity against P. vivax and P. malariae.
Pyrimethamine and primaquine are tissue schizonticides. These drugs act on the
primary tissue forms of the plasmodia which, after growth within the liver, initiate the
erythrocytic stage. By blocking this stage, further development of the infection might be
preventable. However given that it is impossible to predict infections before clinical
symptoms begin, this mode of therapy is more exploratory.

Pyrimethamine and

primaquine can act however, in preventing relapse, as tissue schizonticides during the
hypnozoite stage of P. vivax and P. ovale in the liver which can cause a recurrence of
the disease.
Chloroquine, quinine, mefloquine, halofantrine, pyrimethamine, sulfadoxine,
sulfones, and tetracyclines among others, also act as blood schizonticides. These drugs
primarily focus on the blood forms of the parasite thereby terminating clinical attacks of
malaria, and are useful in the treatment of malaria.
Chloroquine and quinine act also during the gametocyte stage of the lifecycles of
P. vivax and P. malariae. These drugs destroy the sexual forms of the parasite in the
blood thereby preventing transmission of the infection to the mosquito and helping to
control its spread. It is perhaps interesting to note that these drugs do not have this
mode of action against P. falciparum. Primaquine, however, has gametocidal activity
against all plasmodia, including P. falciparum. Primaquine and chloroguanide also act
as sporontocides. They prevent the development of oocysts in the mosquito and thus
inhibit transmission.
Given each of the above antimalarial agents has one or more specific stages of
the parasite’s life-cycle with a particular mode of action, and these stages of life-cycle
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and modes of action are so varied, it is reasonable to assume that the drugs would
represent a range of structures.
Quinine (1) and quinidine, both alkaloids extracted from cinchona bark, along
with mefloquine (2) and halofantrine (3), are all aryl amino alcohols.
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Chloroquine (4) and amodiaquine (5) are 4-aminoquinoline derivatives.
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There are two types of folate synthesis inhibitors, those that competitively
inhibit dihydropteroate synthase including the sulphones and sulphonamides, and those
that inhibit DHFR including the biguanides like proguanil (6), chlorproguanil (7) and
diaminopyrimidines like pyrimethamine. This whole class represents the antifolics and
antifolinics.
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Primaquine (8) and the potentially radical curative and causal prophylactic
drug32 ,WR238 605 (Tafenoquine) (9), belong to the class of 8-aminoquinolines.
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Artemisinin (10) derived from the Artemisia annua and its derivatives and
analogues: artemether, (11) arteether, (12) artesunate, and artelinic acid are all cyclic
peroxides. Detailed studies33-35 on artemisinin and related peroxidic antimalarial agents
have suggested that these compounds exert their parasiticidal activity subsequent to
reductive activation by haem, which is released as a result of haemoglobin digestion by
the Plasmodium parasite.
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This irreversible redox reaction produces carbon-centred free radicals, that lead to
alkylation of haem36 and proteins (enzymes)37. One such enzyme is the sarcoplasmicendoplasmic reticulum ATPase PfATP638, a cell organelle that is thought to be crucial
for the survival of the Plasmodium parasite.39
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Atovaquone (13) is an example of a naphthoquinone, a highly lipophilic molecule that
supposedly interferes with the mitochondrial electron transport and thereby ATP and
pyrimidine biosynthesis and in Plasmodia, it is found to target cytochrome bc1 complex.
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The compound, desferrioxamine (14) acts as an iron-chelating agent.
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1.3.6. Antibiotics and malaria
Antibiotics also play a major role in the treatment of malaria. Tetracycline and
chloramphenicol are well tolerated and effective as antimalarial drugs.40,41 Tetracycline
(17) and its analogues doxycycline (18), azithromycin (15) and clindamycin (16) are
known to block bacterial translation by binding reversibly to the 30S subunit and
distorting it in such a way that the anticodons of the charged tRNAs cannot align
properly with the codons of the mRNA.
16
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At present, combination treatment of severe cases of malaria can be made with
antibiotics such as clindamycin (16), lincomycin, minocycline, doxycycline (18) and
aziththromycin that are known to act as tissue schizonticides. Minocycline and 18 have
been successfully used as potent antimalarials and are both used for management and
17

prophylaxis especially on the liver stages of the parasites life cycle, but parasitological
response is slow to 16 and recovery rates are reported as higher.41-43 Cure rates have
been reported to improve with the use of quinine (1) and 17 combinations in areas
where response to 1 has declined.
The use of quinolone antibiotics in malaria chemotherapy, has also been
reported41,44,45
Combinations of 19 and 17 have been shown to have a modest additive effect in
P. falciparum cultures. While clinical trials in India have been reported to be successful
with the use of norfloxacin, it has been shown otherwise in Thailand where no benefits
to patients were apparent with multidrug resistant malaria. This finding may be linked
to the decreased sensitivity that is known to exist with chloroquine resistant strains.46,47

1.4.

Resistance

1.4.1. General resistance
The problem of drug resistance in the treatment of infectious diseases such as
respiratory infections, HIV/AIDS, dysentery, tuberculosis and malaria, the leading
killers among the infectious diseases, has proven to be a major dilemma in the
community. In fact, resistance to front-line drugs has been observed in all of these
infections, and in some cases the level of drug resistance has enforced a change to more
expensive second or third-line chemotherapeutic agents. Resistance to drugs can be
considered as a natural reaction to the selective pressure of the drug in use.
Nevertheless, drug resistance has been worsened by several factors which include abuse
of the antimicrobial drugs such as, their under use and misuse, poor patient compliance
and the poor quality of readily available drugs.48
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In 1929, Sir Alexander Fleming observed the inhibition of Staphylococcal
growth on an agar plate, which was contaminated by a Penicillium mould and this
marked the discovery of the first antibiotic, penicillin. This discovery was particularly
significant because of its application to wound infections resulting from conflict during
World War II. Penicillin, at the time, had an unprecedented ability to kill these Grampositive bacterial pathogens without causing any observable harm to their host. It was
also widely available, and economically viable. Significantly, a considerable fraction of
all human infections are caused by these two bacteria (e.g., strep throat, pneumonia,
septicaemia, dermal related infections, wound infections, scarlet fever, toxic shock
syndrome etc). Interestingly, penicillin has never been shown to be effective against
most Gram-negative pathogens (e.g. Salmonella, Shigella, Bordetella pertussis, Yersinia
pestis, Pseudomonas) with the notable exception of Neisseria gonorrhoeae. This
resistance to penicillin by the Gram-negative bacteria can be attributed to the cell wall
protection of the bacteria by an outer membrane that prevents permeation of the
penicillin molecule.
The age of antibiotic chemotherapy came into dominance in the late 1940s and
the early 1950s, marked by the discovery and introduction of streptomycin,
chloramphenicol and tetracycline as new antibiotics. These new, broad-spectrum
antibacterial agents were effective against both Gram-positive and Gram-negative
bacteria, intracellular parasites, and the tuberculosis bacillus.
However, by 1953, during a Shigella outbreak in Japan, a strain of the dysentery
Bacillus was isolated which was shown to exhibit multiple drug resistance, including
resistance to chloramphenicol, tetracycline, streptomycin, and the sulfanilamides. There
was also evidence suggesting that bacteria could pass genes for multiple drug resistance
between strains and even between species. It was also apparent that Mycobacterium
19

tuberculosis was capable of rapidly developing resistance to streptomycin, a drug which
had become a core in tuberculosis therapy.
Antibiotic resistance exists to the present day and even with the introduction of
new and better antibacterial drugs there is constant apprehension that new strains will
emerge, which exhibit even greater resistance to currently available antibiotics. New
semi-synthetic penicillin derivatives, which act by inhibiting bacterial cell wall
synthesis, and are also known to be unaffected by β-lactamase (penicillase), came into
use: examples of such antibiotics included vancomycin, nafcillin and oxacillin.
In 1975, cases were reported describing methicillin resistant Staphylococcus
aureus (MRSA). During this time, most of the strains of Staphylococcus aureus were
now showing complete resistance to the drug methicillin especially to patients who
were immuno-compromised.
In 1988, the first case of vancomycin resistant enterococci (VRE) was recorded.
Vancomycin, a glycopeptide antibiotic acts by preventing transglycosylation and the
cross linking of peptidoglycan layer in Gram-positive bacteria, is generally considered
to be the last line of antibiotic defence.
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Figure 1.4- Graph showing the gradual decline in response to antimalarial drugs
since 1976.

1.4.2. Resistance and malaria
In the majority of the world where malaria is either emerging or is already
endemic, resistance to the already available drugs that are recommended for the
treatment of the disease is proving to be a concern. Since the 1960s the sensitivity of the
Plasmodium parasites to chloroquine (16), which had been the most widely used drug of
choice for the treatment of malaria, has been on the decline (Figure 1.4 shows the
declining response to antimalarial drugs since 1976). To tackle this problem of
antimalarial resistance, newer drugs have been developed and tested.

However,

difficulties such as unwanted side effects, prohibitive costs and the tendency for the
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parasites, particularly, P. falciparum, to show resistance to these drugs as well, have
diminished the efficacy of these new agents.

1.4.3. Definition of antimalarial drug resistance
Antimalarial drug resistance has been defined as “the ability of a parasite strain
to survive and/or multiply even with the appropriate administration and absorption of a
drug given in equal to or higher doses than that usually recommended but usually within
the tolerance limit of the parasite.”42 The definition has been broadened to include the
provision that the antimalarial drug in question must “gain access to the parasite or the
erythrocytes infected by the Plasmodium parasites for the time that is necessary for its
normal mode of action” 49-51
Several factors have been implicated with the emergence of resistance to
antimalarial drugs. These factors include longer half-life, single mutation causing
resistance, poor patient compliance, host immunity and the number of patients using
these drugs. So far, resistance to antimalarial drugs has been more evident and
pronounced in P. falciparum with sporadic cases of resistance also reported for the
P.vivax strain. This resistance is more widely reported for the antimalarial drug
chloroquine compared to other drugs in which resistance has also been reported.

1.4.4. Classification of the mechanism of drug resistance
The study of the mechanism of drug resistance can be approached from two
main perspectives: where the drug target is unchanged or where there is an alteration in
drug targets. From the former perspective, two drug resistance mechanisms are possible,
firstly resistance by exclusion, where there is loss of the drug accumulation (decreased
import) or, on the other hand, an increased elimination of a drug such that it has little or
no effect. Secondly, resistance can result from the metabolism of an active drug into an
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inactive compound, for example when penicillin is converted by penicillases to an
inactive metabolite. The metabolic inactivation of prodrugs is also classified under this
resistance mechanism. This is where, under ideal conditions, the drug is administered
in the form of an inactive prodrug which is then converted by the pathogen into an
active metabolite; an example of this form of resistance is the resistance to purine
analogues in cancer cells.
In the second major approach to the study of the mechanism of drug resistance
where there is considered to be an alteration of the drug targets, several changes may
occur in a particular drug target which offer an explanation for drug resistance; these
include cases where there is complete elimination of a drug target which the organism
makes redundant by developing an alternative pathway. There can also be an alteration
of the target in question such that the drug in use has a reduced affinity.
In other reported cases, overproduction of a drug target, for example by gene
amplification, may render drugs being useless during chemotherapy and finally an
accumulation of metabolite antagonistic to the drug being used may occur with paraaminobenzoic acid (PABA) overproduction by pneumococci bacteria.
The development of antimalarial drug resistance can thus be perceived to take
place gradually or in a number of separate steps. One or more of the mechanisms
mentioned above can be used to explain the origin of drug resistance which results in an
adaptation of organisms or cells when continually stressed by exposure to sub-optimal
and thus sub-lethal levels of drugs.
The exposure to sub-optimal drug levels through self-prescription of medication,
in an effort to manage the early symptoms of malaria in developing countries where
malaria is a problem is seen to be one of the most important reasons for the presence of
(multiple) drug resistant malaria.
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Single malaria isolates have been found to be made up of heterogeneous
populations of parasites that can have widely varying antimalarial drug response
characteristics, which vary from highly resistant to completely sensitive.52 Similarly,
within a geographical area, malaria infections show a range of antimalarial drug
susceptibility and over time, drug resistance becomes well established in the population
and can be very stable, persisting long after specific drug pressure has been removed.
The biochemical mechanism of resistance has been well detailed for the
antimalarial drugs chloroquine (4), and with antifolate combination drugs and
atovaquone.

1.4.5. Resistance to Chloroquine
The treatment of malaria was revolutionized with the discovery of the drug
chloroquine (4), but it was not until the early 1960s that resistance emerged from two
epicenters, Columbia and Thailand, and since then the resistance to 4 has spread
worldwide. Resistance to 4 has since been found to be conferred by a stable mutation
which is carried forward to the progeny and involves multiple genetic transformations
suggesting that this form of resistance need not be complete but can also be a partial
resistance.
The resistance of P. falciparum to 4 has been associated with an increased
capacity of the Plasmodium parasite to expel the drug at an unusual rate preventing 4
being concentrated at levels required to inhibit haem polymerization.53 The process is
characterized by the digestion of haemoglobin by the malarial parasite, which ends with
the formation of toxic by-products that are then polymerized in the Plasmodium food
vacuole to produce non-toxic haemozoin. The drug efflux from the Plasmodium is seen
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to take place at a rate of 40 to 50 times faster among the chloroquine resistant P.
falciparum than the sensitive parasites.54

1.4.6. Anti-folate resistance
Antifolate drug combinations such as sulfadoxine plus pyrimethamine are
known to act via sequential and synergistic blockade of the enzymes involved with the
folate synthesis within the parasite. Pyrimethamine and its analogues inhibit the step
that is mediated by dihydrofolate reductase (DHFR) while sulfones and the
sulfonamides inhibit the step mediated by the enzyme dihydropteroate synthase
(DHPS). It is with these two key enzymes that specific gene mutations have been
identified which can explain the resistance to this class of antimalarial drugs. The
varying degrees of drug resistance known to occur among the antifolates can further be
attributed to specific combinations of the above-mentioned types of mutations.42,55

1.4.7. Atovaquone
The antimalarial drug, atovaquone (13), acts through the inhibition of electron
transport at the cytochrome bc1 complex.42,56 It has been observed that when used alone
during the treatment of malaria, resistance develops more rapidly, but when it is used in
combination with a second drug, such as proguanil or a tetracycline antibiotic,
resistance to it develops gradually. Resistance to 13 is conferred by a single point
transformation at the cytochrome-b gene.42

1.4.8. Preventing drug resistance
Contributions which aim at preventing resistance to drugs generally, are more
concerned with reducing the drug pressure through more selective drug use for the
treatment and management of a disease. Measures aimed at stopping or reducing drug
resistance and its spread can be controlled by observing sound medical practices such
25

as; improving the manner in which the drug(s) in question is used, by monitoring and
improving the prescription of the drug; follow up practices and patient compliance; the
use of drug combination therapy which could then reduce the rate or eliminate the
conditions in which resistance of the drug could develop or could facilitate the spread of
resistant parasites.
Concerning the reduction in the overall drug pressure, the treatment and
management of a disease follows a more limited drug use and prescribing practice. This
routine between patient and physician limits the introduction, spread, and intensification
of resistance to the drug being used.
Direct observation therapy has gained recognition as a means of ensuring a high
degree of compliance in patients. Even though this practice has not received much
attention in relation to malaria treatment and management, the use of drugs with singledose therapies such as sulfadoxine/pyrimethamine and mefloquine could potentially
make direct observation therapy feasible.42 Another approach is to closely follow up and
re-treat patients. The success of this method would rely on the availability of diagnostic
tools to initially identify illnesses and confirm the failure of the treatment in question.
Even though this method is not widely adopted, it could help minimize the development
and spread of drug resistance by simply identifying the patients who fail to comply with
treatment for any given reason. The identified patients can then be re-treated until they
are free from the parasite.
A strategy that has recently received much attention is the multi-drug
combination therapy in the treatment and management of malaria. Specific antimalarial
drugs have been used in combination with an artemisinin57 derivative to offer a
considerable degree of success in malaria chemotherapy.27,42,58 (for example,
amodiaquine/artesunate59,mefloquine/artesunate60, chloroproguanil/dapsone/artesunate61
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or lumefantrine/artemether62)27. The success of this drug combination therapy emanates
from the artemisinin drugs, which have been proven to be highly effective, and rapidly
acting, their modes of action39 also operate against a wider range of the Plasmodium
parasites at particular developmental stages in their life cycle. Some good results have
been observed with the multi-drug therapy involving the use of artemisinin compounds.
When used in combination with longer acting antimalarial drugs, there is a reported
rapid reduction of the Plasmodium parasite density to levels low enough to allow the
concentration of the longer acting antimalarial drug to be at its maximum efficacy. This
in turn greatly reduces both the possibility of the malarial parasite surviving the initial
treatment on exposure to the drug and the chances that the parasite will be exposed to
sub-optimal levels of the longer acting drug.27,42
The use of artemisinins has been shown to reduce gametocytogenesis by 8 to 18
fold42,63 suggesting that there are fewer chances of the plasmodial gametocytes which
carry the gene responsible for drug resistance being passed onwards, and this may
potentially reduce the rate at which malaria is transmitted. In countries where malaria is
endemic, the use of combination therapy to treat malaria has been associated with the
slowing down of the development of resistance towards the drug mefloquine. In malaria
endemic areas, especially in Africa where the need for antimalarial drugs is greatest but
resources are limited, other courses of therapy, offering combinations of inexpensive
and available drugs (for example, chloroproguanil/ dapsone61 or amodiaquine plus
sulfadoxine/ pyrimethamine64), might be appropriate therapy approaches in managing
malaria.27
Future antimalarial therapies may be expanded greatly by combining drug treatment
with vaccines65 (or other drugs) designed to specifically inhibit the transmission of
malaria.
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These “transmission-blocking” vaccines or combinations of drugs could
significantly diminish the onward transmission of malaria parasites in particular
gametocytes that have been identified as carriers for the genes encoding for antimalarial
drug resistance, even if a large number of these parasites survive the early treatment.
This form of chemotherapy would be successful if the drug(s) or vaccine(s) employed
for the management of malaria have a high degree of specificity as anti-gametocides
(such as primaquine and its analogues), or drugs that non-specifically reduce the
possibility of gametocytes developing (as seen with artemisinin and its analogues). The
use of antimalarial drugs showing similar modes of action to the combination of
atovaquone and proguanil, which is known to interfere with the sexual reproduction and
infection of the parasite within the mosquito when taken up during a blood meal, can be
used for the treatment and management of malaria, hence minimizing the occurrence of
drug resistance.

1.4.9. Target selection and malaria
Antimalarial drugs that are currently in use are known not to have been initially
discovered based on any rationally identified targets. Ideally an appropriate target is one
that is essential for the survival of the pathogen and is located at a critical step in a
particular metabolic pathway making the pathogen vulnerable. Moreover it should be
exclusively expressed by the pathogen to minimise the health risk to the host.
Researchers and health planners expect their best chance lies in a multifaceted attack,
drawing upon a variety of weapons suited to the local environment to then combine
several approaches, both long-standing and the most up-to-date, which would give the
hope of possibly outmanoeuvring the persistent and deadly malarial parasite.
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Biological drug targets that have been identified to be common to both the
parasite and the human host offer a good approach for drug therapy for malaria,
especially if structural variations involving the two can be exploited. A good approach
to this sort of target validation would be the proper identification of targets within
enzymes or pathways present within the parasite but not known to exist within the
human host.27 In some cases, parasite drug targets might be mutual with other microbial
organisms for which classes of drug inhibitors have been generated and can hence be
screened for possible similarity in their mode of action. A classic example is the use of
the antibiotics 17 and 16, which are well known to inhibit prokaryotic protein synthesis
and can also be used in the management and treatment of malaria. These compounds, in
all probability, selectively act against the Plasmodium malarial parasite because of their
action against remnants of plant and bacterial organisms known as the apicoplasts66-68
(Figure 1.3). This essential organelle is thought to have arisen through the
endosymbiosis of an algal cell which had previously incorporated a cyanobacterium. It
is due to its origin that the apicoplast is important to researchers given that it contains
numerous metabolic pathways that differ radically from those found in human hosts
hence offering a wide range of possible targets for drug therapy using antimicrobial
drugs.
Recently identified possible selective targets for antimalarial drugs include the
components of type II fatty acid biosynthesis69 and mevalonate-independent isoprenoid
synthesis. The two pathways are well known targets for the existing antibacterial drugs
hence could be useful leads to novel antimalarial drugs for a similar target.
The discovery that the apicoplast was the site of fatty acid biosynthesis
completely altered the initial view that the Plasmodium parasites were incapable of
synthesizing their own fatty acids.69 The first indication of fatty acid synthesis (FAS) in
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the apicoplast was the finding of nucleus-encoded FAS genes whose products were then
targeted to the apicoplast. These included acyl carrier proteins (ACP), ß-ketoacyl-ACP
synthases III (FabH) and I/II (FabB/F), and enoyl ACP reductase (FabI).69 In 1996 a
global programme was launched aimed at sequencing the P. falciparum genome70 with
the hope that it would open new channels for malaria research.
The genome sequence is now complete 70,71 for the P. falciparum parasite and a
number of other plasmodial species,72 and this should assist significantly the drug
discovery process by allowing rapid recognition of crucial plasmodial targets which are
related to already known target proteins from other research systems.27

Other recent technologies that have contributed to validating drug targets include
genomics and proteomics. Genomic technology offers the opportunity to assess
transcription processes in the plasmodial life cycle27,73,74, and could shed light onto the
transcriptional impact of target inhibition and if functionally related genes have a
common transcription profile other pathways of interest may be identified. Proteomic
knowledge on the other hand requires the separation of thousands of proteins and
permits direct study of the biochemical impact of known drugs as potential
antimalarials. It can also help researchers to discover the mode of action of older drugs,
confirm mechanisms that were not known for new drugs and finally, suggest new drug
use approaches.27,75-77

1.4.10. Malaria vaccine development
The development of a malaria vaccine has so far proven to be difficult and
challenging due to several factors. Firstly, the size and complexity of the malaria
parasite means that each infection introduces millions of antigens into the human
immune system and identifying which type of antigen for drug targeting has been
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difficult.65 Secondly, in infected humans, the Plasmodium parasite undergoes
maturation at different stages which introduces a different subset of antigen molecules
for the immune system to attack. Thirdly, the parasite has developed strategies that
mislead the host immune system and finally, it is possible to have multiple malarial
infections from different species and strains of mosquito at the same time.
Much of the current malaria vaccine research is focused on methods of
reproducing immunity in a safe and successful way. An effective malaria vaccine must
offer protective immune responses equal to, or better than, those provided by natural
immunity or immunization. Due to the severity of the malaria caused by P. falciparum,
particular attention has been turned to this species with an aim of producing a single
vaccine against it. The vaccine would have to be tailored for different risk groups living
in P. falciparum endemic areas. The vaccine requirement has generated at least four
approaches for the species: An anti-infection vaccine aimed at giving protection to
travellers or residents from low endemic areas from acquiring malaria; an antidisease/anti-mortality vaccine targeting children, pregnant women and migrants
occupying endemic areas and finally an anti-mosquito stage vaccine which will aim at
preventing malaria transmission amongst humans65,78 or a toxin neutralizing vaccine
designed to counteract toxins produced by the parasite and hence masking the malaria
symptoms. However, a vaccine such as RTS S/ASO2A, which is currently under phase
IIb in vivo clinical, trials provides the first real hope for protection against malaria.79,80

To date, about thirty P. falciparum antigens are being evaluated for use in
vaccines, and several have been tested in clinical trials. Partial protection with one
vaccine has been reported in a field setting.81 The successful completion of genome
sequencing for P. falciparum70,72 should also stimulate vaccine progress by the
identification of potential antigens that could be scanned for desired properties such as
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surface expression or limited antigenic diversity. This could be combined with data on
stage-specific expression obtained by micro-array and proteomics75,76 analyses to
identify potential antigens that are expressed in one or more stages of the parasite’s life
cycle.

1.5. Project aims
1.5.1 Background and significance
In spite of the availability of currently effective drugs, the continuing battle
against infectious diseases is far from over. Harmful microbes are exclusively
responsible for a large number of infections and death, particularly in developing
countries. The emergence and spread of resistance is now threatening to challenge the
human capability to treat infections and save lives. This challenge has forced the
scientific community to go to greater lengths to improve antimalarial drug design and
development. In particular structurally different compounds are needed, hopefully with
new modes of action.

1.5.2 Aims
The overall aim of this project was to investigate possible new antimalarial
agents82 based on benzo[b]thiophene amide derivatives. Preliminary studies83 on
compounds of type (A) carried out at the Institute for Biomolecular Science and
Department of Chemistry (University of Wollongong) have shown that they possess
moderate antibacterial activity.83-85 There have been no previous reports of structures of
this type having any such activity. In view of the fact that some antibacterial agents also
show antimalarial activity, it was thus decided to explore the potential antimalarial
activity of compounds of this general type.
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The more specific aims of this project were thus:
1. To prepare analogues of the benzo[b]thiophene based compounds (B) and (C) in which
R, and R1 were systematically varied as substituents to include hydrophobic, aromatic,
H-bond donor/ acceptor and ionisable groups. Enantiomers were also to be studied
where possible. Conformationally restricted analogues, for example (D) and (E), were
also to be investigated. Ring fused derivatives of type (D) and (E) would still preserve
the benzo[b]thiophene amide motif. Approaches to such systems were to include free
radical and ring closing metathesis procedures, exemplified by the synthesis of
compounds of type (E) from precursors of type (F).
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2. To assess the antimalarial potency, spectrum of activity and human cell
toxicity of all the new heterocyclic derivatives synthesised. The assessment of
some antibacterial activity was also to be undertaken.
3. To develop structure-activity relationships with a view to optimising activity.
4. To identify the mode of action of these compounds.
5. To identify possible compounds for pre-clinical development as novel
antimalarial agents.
In this thesis, Chapter 2 primarily focusses on the synthesis of non-fused
benzo[b]thiophene amides using specific coupling methods while Chapter 3 covers the
synthesis of novel fused benzo[b]thiophene derivatives mainly through free radical
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cyclisation and ring closing metathesis methodologies. Chapter 4 reports on the
biological activities of various benzo[b]thiophene compounds covered in Chapter 2 and
Chapter 3 against cultured malarial parasites, as well as antibacterial activity for some
specific benzo[b]thiophene amides. The experimental data is covered in Chapter 6.
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Chapter 2 Synthesis of Non-Fused Benzo[b]thiophene
Amides
Introduction
For the purposes of this discussion benzo[b]thiophene amide derivatives will be
divided into two classes of compounds: fused derivatives, and non-fused derivatives.
The basis for the differentiation between the two groups is whether or not a linking
group exists between the C3 position on the benzo[b]thiophene ring and the carbon α to
the nitrogen of the amide group attached to the C2 carbon of the same ring.
A detailed discussion of the synthesis of the fused class of compounds is
deferred until Chapter 3. This chapter, however, focusses on benzo[b]thiophene amide
derivatives containing a variable substituent in the C3 position, and with the amide
nitrogen incorporated within a ring (Figure 2.1).
Varied
substituents
X
3

S

N

2

Varied ring and
substituents

1

O

Figure 2.1 Generic benzo[b]thiophene amide structure.

2.1.1. Target amides
The synthetic procedures developed during this study enabled the synthesis of a
wide range of compounds within the above framework. However, this section will be
concerned primarily with molecules incorporating a Cl, Br, H or allyl group in the C3
position (X in Figure 2.1) and the nitrogen-containing ring structures are limited to
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tetrahydroisoquinolines, tetrahydro-β-carbolines, dihydropyrroles, piperazines,
piperidines and other bridged ring systems.

General Approach to Synthesis
The overall synthetic strategy adopted towards the C3-substituted non-fused
benzo[b]thiophene amide derivatives involved the conversion, in cases requiring chloro
substitution in the C3 position, of the commercially available (E)-cinnamic acid into the
corresponding 3-chloro-benzo[b]thiophene-2-carbonyl chloride (Scheme 2.1; Step
2.1b).

The 3-bromo substituted target (Step 2.1a) was prepared by the direct

bromination at the C3 position of the commercially available benzo[b]thiophene-2carboxylic acid (20).
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23 R = H, R1 = Cl, X = Cl
24 R = OMe, R1 = Cl, X = Cl
25 R = H, R1 = OH, X = Br

21 R = H
22 R = OMe
Scheme 2.1

General procedure for generating target amides from precursors with
R1 = OH or Cl.
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In the above approach (Scheme 2.1), Step 2.2 was carried out differently
depending on the nature of the R1 group. In the case where the R1 group was chloro,
the desired amide derivatives were synthesized by the direct acylation of a secondary
amine with the acid chloride with the appropriate substituent at the C3 position. Where
the carboxylic acid (R1 = OH) was the precursor a coupling agent was used, namely,
dicyclohexylcarbodiimide (DCC). In the case of the acid chloride, the basic nitrogen of
the amine acts as a nucleophile, attacking the carbonyl carbon on the acid chloride, and
displacing the chloro group as a chloride ion. The resulting hydrogen chloride is
neutralized with a suitable base. The choice of base here was preferably potassium
carbonate. The neutralization reaction generates CO2 gas increasing entropy and
engendering irreversibility. The discussion of the preparation of each individual amide
derivative synthesised in this manner is deferred until later in this chapter.
Amide derivatives where the halogen present in the benzo[b]thiophene ring was a
bromine (3-bromo-benzo[b]thiophene derivatives) were synthesized via a different
pathway, which involved amide coupling between the carboxylic acid and the
appropriate amine facilitated by dicyclohexylcarbodiimide (DCC)86,87 in the presence of
1-hydroxybenzotriazole (HOBt)88,89,90(Step 2.2). The acid-amine coupling reactions
giving rise to the 3-bromo benzo[b]thiophene amide derivatives are referred to as DCCcoupling reactions in the following chapters. DCC is often used to mediate coupling
reactions between carboxylic acids and appropriate amines to form amide linkages. The
HOBt assists adduct formation between the carboxylic acid and DCC. The highly
reactive ester intermediate is then able to couple with the amine, leading to the cleavage
of the ester bond and the formation of the desired amide. The other product of this
procedure is dicyclohexyl urea, which is precipitated during the reaction in
dimethylformamide (DMF) (Scheme 2.2).
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Scheme 2.2 Proposed mechanism for the HOBt/DCC facilitated Acid/Amine
coupling reaction.
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The formation of dicyclohexylurea in this reaction is potentially problematic as it leads
to extra purification steps required to isolate the pure amides. An alternative coupling
method would be the use of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI)91
and 4-dimethylaminopyridine (DMAP)92,93, however, in this case, as discussed below,
the DCC / HOBt system gave higher yields.

2.2.1. Generation of acid chlorides
Synthesis of 3-chlorobenzo[b]thiophene acid chloride
The commercially available (E)-cinnamic acid (21) and (E)-3-methoxycinnamic
acid (22) were used to prepare the starting 3-chloro- substituted acid chlorides 23 and
24, respectively, for subsequent direct coupling with the appropriate amines.
Although the preparation of acid chlorides from carboxylic acids with thionyl
chlorides is a well-known and commonly used method, this reaction is of particular
interest as it includes the sulfur from the thionyl chloride in the final benzo[b]thiophene
product83. This reaction, although taking place through a multi-step pathway, is a singlepot, relatively high-yielding reaction, which proceeds smoothly to the final cyclized
product within twelve hours (Scheme 2.3). Although the acid chloride may be
considered susceptible to hydrolysis, it was stable enough to be flash chromatographed
on silica gel, recrystallised from dichloromethane and kept in a desiccator for long
periods

of

time

without

hydrolysis

occurring.

The

3-chloro-5-

methoxybenzo[b]thiophene-2-carbonyl chloride 24 was the only acid chloride
substituted at the C5 position used for the synthesis of some of the benzo[b]thiophene
amide derivatives described below.
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SOCl2
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23 R = H, 24 R = OMe

Cl

O

The proposed steps involving the generation of the acid chlorides
from (E)-cinnamic acids.

During the synthesis of 24 the formation of trace amounts of 3-chloro-5methoxybenzo[b]thiophene-2-carboxylic acid were detected by mass spectrometry.
However, the acid could be removed by saturated sodium bicarbonate solution.

Other acid chlorides
Benzo[b]thiophene-2-carbonyl chloride (26), and 3-bromobenzo[b]thiophene-2carbonyl chloride (27), required for the synthesis of benzo[b]thiophene derivatives
described later in Chapter 3 were synthesised via their corresponding benzo[b]thiophene
carboxylic acids 20 and 25 on reaction with thionyl chloride and a catalytic amount of
pyridine in refluxing toluene (Scheme 2.4). The synthesis of the acid chloride 26 was
achieved in 62 % yield and it was used immediately to avoid hydrolysis. The 3-bromobenzo[b]thiophene substituted acid chloride 27 was also prepared in good yield (67 %)
by this method.
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20 X = H

26 X = H

25 X = Br

27 X = Br

Conversion of benzo[b]thiophene carboxylic acids 20 and 25 to their
corresponding acid chlorides 26 and 27.

The synthesis of a benzo[b]thiophene acid derivative with a bromo- substituent
at the C3 position was crucial for this project as it formed the basis for the synthesis of
other benzo[b]thiophene amide derivatives including fused derivatives.

Given the

success in the synthesis of the acid chlorides 23 and 24, the possibility that an analogous
bromo substituted acid bromide derivative might be achieved in a corresponding
manner was investigated. A similar reaction to that used for the synthesis of 23 was
attempted in which (E)-cinnamic acid was reacted with thionyl bromide in the presence
of a catalytic amount of pyridine and the mixture heated at reflux in dry toluene for two
and half days.
Br

COOH
SOBr2, Toluene,
Pyridine, reflux

21
Scheme 2.5

Br

S

28

O

The attempted synthesis 3-bromobenzo[b]thiophene-2-carbonyl
bromide (28) from (E)-cinnamic acid (21).

However none of the expected 3-bromobenzo[b]thiophene-2-carbonyl bromide
(28) was obtained from this reaction (Scheme 2.5).
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Although pure product was isolated, its spectroscopic characterisation did not
correspond to the data expected for the desired product. The identity of the isolated
product was not ascertained within the time constraints of the current project. The
failure of this reaction to give 28 prompted the search for an alternative method for
accessing the required compound. The carboxylic acid 20 was seen as a means of
acquiring the desired compound, and a method based on its bromination was followed.
The synthesis of the precursor acid, 3-bromobenzo[b]thiophene-2-carboxylic
acid (25) was achieved through the direct bromination of the commercially available
acid 20 (Scheme 2.6). The bromination technique was adopted from literature methods
for the bromination of 2-methylbenzo[b]thiophene-5-carboxylic acid methyl ester to 3bromo-2-methylbenzo[b]thiophene-5-carboxylic acid methyl ester and also the
conversion of 2-methylbenzo[b]furan-5-carbonitrile to 3-bromo-2-methylbenzo[b]furan5-carbonitrile94. In the bromination reaction of 20, despite using three equivalents of
bromine only one brominated product was isolated in good yield. This observation can
be explained by the fact that benzo[b]thiophene is known to preferentially substitute at
the C3 position during electrophilic aromatic substitution reactions even though the acid
substituent might be expected to deactivate the C3 position in this case.

S

Br

Br2, CH3COOH,
CH3COONa, 55oC

3

OH

2

20
Scheme 2.6

OH

S

1

O

25

O

Direct bromination of benzo[b]thiophene-2-carboxylic acid.
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The 1H-NMR spectrum of 25 confirmed the non-appearance of a signal for the
H3 peak, which was present at 8.27 ppm in the case of 20. The

13

C-NMR spectra

showed the same number of carbons for both reactant and product with the carbonyl
carbon peaks at 161.9. The mass spectrum of the product confirmed the molecular mass
for 25 with the characteristic isotopic mass distribution for the presence of single
bromine being observed.

2.2.2. Amine bases
Tetrahydroisoquinolines
It had been shown previously that the isoquinoline amide 29 and its derivatives
showed mild activity against cultures of the Gram-negative bacterium Escherichia coli
and the Gram-positive bacterium Staphylococcus aureus83. The analogous amide
derivative

with

methoxy

groups

at

the

C6

and

C7

positions

of

the

tetrahydroisoquinoline ring and another methoxy at the C6 position of the
benzo[b]thiophene ring, together with compound 29, were reported to be active against
E. coli at 100 µg/ mL, although no MIC values were determined.
Amines having a methyl group at the C1 position, and methoxy groups at the
C1, C6 and C7 positions of the tetrahydroisoquinoline ring coupled to the acid chloride
substituted with a methoxy group or fluorine at the benzo[b]thiophene C6 position gave
amide derivatives that had very weak bacteriostatic activity towards S. aureus (1,000
µg/ mL)83.
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A search of the literature was undertaken to determine the potential for
tetrahydroisoquinoline derivatives of benzo[b]thiophene to act as antimalarial agents.
This investigation revealed that no previous work had been carried out in the area of
synthetic tetrahydroisoquinoline amide derivatives of benzo[b]thiophene acting as antimalarial agents. In the light of this, and in consideration of their observed antibacterial
properties, it was thought that a series of compounds in this class might also potentially
provide some new antimalarial lead compounds. Benzo[b]thiophene amides based on
the framework 29 and 30 were thus prepared. Substituents were varied in both rings of
the tetrahydroisoquinoline moiety to give a range of compounds which were to be
screened for biological activity. Since the synthetic strategy towards the appropriate
acid or acid chloride has been mentioned previously, this discussion will concentrate on
the synthesis of the tetrahydroisoquinoline bases used in the coupling reaction.
Bases 31 and 33 were purchased from Sigma Aldrich®. In cases where R =
allyl, and R1 = H (32) or –OMe (34), synthetic strategies were devised to prepare them
as starting materials. The 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (33) was
purchased as the hydrochloride salt and was subsequently converted to the free base
before being used in the amide coupling reaction. The syntheses of the 1-allyl-1,2,3,445

tetrahydroisoquinoline (32) and 6,7-dimethoxy-1-allyl-1,2,3,4-tetrahydroisoquinoline
(34) intermediates are outlined in Scheme 2.7.
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Zinc powder,
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NH

32 R = H
34 R = OMe
Scheme 2.7

The zinc/ allyl bromide approach to 1-allyl-1,2,3,4tetrahydroisoquinolines.

The amine, 32, and its 6,7-dimethoxy analogue 34, were synthesized from the
commercially available tetrahydroisoquinolines 31 and 33 which were oxidized to their
respective 3,4-dihydroisoquinolines with N-bromosuccinimide (NBS)95. These reactions
produced product yields of around 80 %. Due to their instability, these imine
intermediates were reacted immediately with allyl bromide in the presence of activated
zinc to synthesize both the 1-allyl-1,2,3,4-tetrahydroisoquinolines.

This process

involved the initial formation of an allylzinc bromide complex followed by the addition
of this reagent to the imine (Scheme 2.7). The reaction involving 32 proceeded
smoothly with good yields achieved in a relatively short time; however the synthesis of
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34 did not proceed as smoothly as with 32. This reaction took more time to complete
and in some cases there was little product isolated. A possible explanation is the
electron donating effect of the methoxy groups reducing the susceptibility of the cyclic
imine to nucleophilic attack.

Other bases
Other bases used to generate the target amides mentioned in this chapter were
purchased from commercial suppliers.

These included isoquinolines, such as the

1,2,3,4-tetrahydroisoquinoline (31) and the (S)-(-)-N-tert-butyl-1,2,3,4-tetrahydro-3isoquinolinecarboxamide (45), carbazoles such as 1,2,3,4-tetrahydro-9H-pyrido[3,4b]indole (40) , piperazines such as 4-chloropiperazine (42), 1-Boc-piperazine (44), 1(2-pyridyl)piperazine (38), 1-benzylpiperazine (48) , 1-(2-pyrimidyl) piperazine (39)
and bridged piperazine such as (1S,4S)-(-)-4-(chlorophenyl)-2,5-diazabicycloheptane
(43), and finally the piperidine 4-(4-chlorophenyl)-4-hydroxypiperidine (41). Some of
these bases, for example the carbazoles and the piperazines, also had the capacity for
further functionalisation allowing for an even wider range of target compounds.
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2.2.3 Coupling Methods
Two methods were used for the generation of the target amides from the
secondary amines outlined above: direct coupling with an acyl chloride and the use of a
diimide coupling reagent with a carboxylic acid. The use of the reagent 1-(3dimethylaminopropyl)-3-ethylcarbodiimide (EDCI) in the presence of a base catalyst
such as 4-dimethylaminopyridine (DMAP) has been widely used as an alternative
approach to coupling reactions as it offers some advantages over the DCC method,
notably the production of a water-soluble urea by-product. The use of DCC as a
coupling reagent in the current study provided better reaction yields and hence was
preferred over the EDCI/ DMAP approach. Compounds 77 and 78 were synthesised as
precursors for further cyclisation chemistry, and as such they are discussed in detail in
Chapter 3; they are, however, included here for the discussion involving the coupling
chemistry.

Direct coupling with acid chloride
Reactions involving the direct coupling of the acid chloride 23 with amine bases
gave optimized isolated amide yields ranging from 33–97 %.

The results are

summarized in Table 2.1, the data for which is also represented graphically in Figure
2.2. In the case where the amine was the parent 31, the yield was moderate (58 %)
whereas with two methoxy groups in the C6 and C7 positions of 33 the yield was 85 %.
This increase may be due to the electron donation by resonance of the two methoxy
groups causing a subsequent increase inductively in nucleophilicity of the basic
nitrogen. There is very little regularity in the pattern in yields for the acid chloride
reaction with each of the bases listed in Table 2.1. Figure 2.2 shows that, while there is
a large range of isolated yields, there are minimal differences structurally that could
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account for the wide range in isolated yields. After the 3-chlorobenzo[b]thiophene
amides were synthesized and purified they were fully characterised using spectroscopic
techniques.
Table 2.1 -

Amide reaction yields for secondary bases coupled with 23.
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Amide % Yield
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Figure 2.2- Graphical representation of isolated amide yields for the reaction of the acid 23 with the specified secondary amines.
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When an allyl group was present in the starting tetrahydroisoquinoline base at
the C1 position, adjacent to the nitrogen, the yield diminished to 47 %, probably as a
result of steric interference. It was expected that the presence of the allyl group might
also have some bearing on the relative energies of the two most probable amide
rotamers (Figure 2.3). An AM196 model study of the both isomers showed only a slight
energy advantage of 2.1 kcal mol-1 for the rotamer with the allyl group on the same side
of the amide bond as the carbonyl oxygen. 1H-NMR spectra of 52 at 298 K showed the
existence of two amide rotamers (Figure 2.3).

Figure 2.3- 3D model structures (AM1) showing the two possible rotamers of
benzo[b]thiophene derivative 52.

The

representation

of

the

preferred

conformation

of

the

non-fused

benzo[b]thiophene amides was confirmed by an X-ray crystallographic study of amide
73 (Figure 2.4). This confirmed the chair conformation of the piperazine based amide.
The carbonyl group was observed to orient itself away from the plane of the
benzo[b]thiophene ring to reduce steric hindrance (Figure 2.4).
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Figure 2.4- X-ray structure of amide 73 representing the non-fused benzo[b]thiophene
amides and confirming their preferred conformation.
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Apart from the direct coupling of 23 and 32 to give the C1 allylated amide 52,
other methods reported in the literature that would lead to 52 were also investigated.
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Scheme 2.8

The attempted one-pot synthesis of (1-benzyl-3,4dihydroisoquinolin-2(1H)-yl)(3-bromobenzo[b]thiophen-2yl)methanone (52) and the isolated by-products
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One such method was the coupling of 3-chlorobenzo[b]thiophene-2-carbonyl chloride
(23) with the imine 36 which would hopefully give an activated intermediate 87 which
could react further with allylzinc bromide generated in situ to afford 52 (Scheme 2.8).
However, in the event, only a small amount (5 %) of the desired product 52 was
obtained with the majority of the mass balance of the reaction being found in two major
by-products; a TLC analysis of the reaction mixture showed these by-products had Rf
values of 0.5 and 0.75, while 52 had an Rf of 0.6. From the low resolution mass
spectrometric data, the major product (Rf 0.5) had an M+ peak at m/z 344, while the
second M+ peak at m/z 326 was consistent with 52, and finally an M+ peak at m/z 241
was assigned to the other major product (Rf 0.75). The m/z values of the peaks for the
two major by-products, m/z 344 and m/z 241, were identified as those belonging to an
aldehyde and an ethyl ester respectively. However, the mechanism of the formation of
the ethyl ester of the initial acid chloride, in this case ethyl 3-chlorobenzo[b]thiophene2-carboxylate (86), remains unclear. Compound 86 may have been formed during
chromatography when the compound came into contact with the solvent system which
in this case was a mixture of ethyl acetate and hexane or most probably due to the
compound coming into contact with chloroform which contains traces of ethanol
normally added to stabilise the solvent.
To

confirm

the

structure

of

the

ethyl

ester

by-product,

ethyl

3-

chlorobenzo[b]thiophene-2-carboxylate (86) was synthesised from 23 and the 1H-NMR
data for this authentic product was shown to be the same as that for the suspected ethyl
ester. An analysis of the two using thin layer chromatography was also consistent with
this finding. Prolonging the one-pot coupling reaction (Scheme 2.8) from three hours to
twelve hours, gave the aldehyde compound as the dominant major product and only
traces of the ethyl ester by-product was formed. The aldehyde was identified as N-(256

formylphenethyl)-3-chlorobenzo[b]thiophene-2-carboxamide (88). The formation of the
product 88 may take place as a result of adventitious moisture being present which
would hydrolyse the iminium ion intermediate 87 to the aldehyde 88 through the
mechanism proposed in Figure 2.3.
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88
Figure 2.5- Possible mechanism for the formation of the aldehydic by-product 88
during the attempted synthesis of 52.

Evidence of metal mediated allylation of carbonyl compounds in appropriate
media to achieve the corresponding homoallylic alcohols have been reported using a
variety of metals, particularly indium97. However the indium-mediated allylation of
aldimines to give the corresponding homoallylic amines has not been reported in
detail97. Such reactions are performed in aqueous media where imines are subject to
hydrolysis even before the allylation can take place.

Furthermore aldimines are

generally less electrophilic than the corresponding carbonyl compounds. In organic
solvents, however, such indium-mediated additions to imines are feasible97.
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The synthesis of 52 was thus attempted via a one pot system from 23, allyl
bromide and the imine 36. The reactants were stirred together in tetrahydrofuran into
which, at low temperature, indium powder was added and the mixture then stirred
overnight (Scheme 2.9).
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Scheme 2.9

The indium-mediated one pot approach to 52 also showing the byproducts identified in the reaction.

After workup, a preliminary TLC analysis of the reaction showed the presence of the
desired product 52 as a minor component.
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A mass spectrum (CI+) of the crude residue showed peak signals
corresponding to 52 at m/z 368 as well as peaks at m/z 344, m/z 326 and m/z 386 which
did not correspond to any possible fragments of 52. The m/z 326 peak was assigned to
the 2-(3-chlorobenzo[b]thien-2-oyl)-1,2,3,4-tetrahydroisoquinoline (29); this product
may have resulted from reduction of 36 to 31, and then the reaction of the latter with 23.
The peak at m/z 344 was consistent with N-(2-(hydroxymethyl)phenethyl)-3chlorobenzo[b]thiophene-2-carboxamide (89) formed by the indium-mediated reduction
of the aldehyde 88. Other spectroscopic evidence confirmed the structure of 89.
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Scheme 2.10 The synthesis of a 5-methoxy substituted benzo[b]thiophene
derivative (57) and its subsequent derivatisation to (58).
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A methoxy-substituted benzo[b]thiophene derivative 57 was also synthesised
(92 %) by the reaction of 3-chloro-5-methoxybenzo[b]thiophene-2-carbonylchloride
(24) (Scheme 2.3) and the amine 40 in boiling THF under basic conditions, (Scheme
2.10). Further functionalisation of 57 was then investigated by substituting the indolic
proton with a benzyl group. This was achieved by reacting 57 with benzyl bromide in
the presence of sodium hydride at low temperature in dimethylformamide. The desired
compound

5-methoxy-2-(3-chlorobenzo[b]thiene-2-oyl)-1,2,3,4-tetrahydro-9-benzyl-

pyrido[3,4-b]indole (58) was then isolated and the crude residue was purified by flash
column chromatography (Scheme 2.10). The spectroscopic data for 58 was consistent
with N-benzylation, and the molecular formula was determined by HRMS analysis.

DCC /HOBt assisted coupling
The carbodiimide DCC was also used in the presence of HOBt to synthesize the
desired 3-bromobenzo[b]thiophene amide derivatives from the acid 25. The target
products (see pg 49-50) were obtained in good yields after a series of purification steps
designed to eliminate the precipitated by-product, dicyclohexyl urea (Table 2.2). The 3bromo- substituted derivatives were generally obtained in higher yields than their 3chloro- substituted analogues prepared via the direct acylation of the desired amine by
the acid chloride.
The prime motivation for synthesising the bromo- substituted derivatives was
that they were predicted to be more reactive towards further derivatisation than their
chloro- substituted counterparts, thus offering the opportunity for a wider range of
potential new derivatives to be acquired via free radical or palladium-mediated
reactions. A comparison between the chloro- substituted amide series and the bromosubstituted series across a range of secondary amines (Figure 2.6) indicates that with
some exceptions, in most cases relatively comparable yields were achieved. Where a
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low yield existed for the acid chloride synthetic route, a similarly low yield was
observed if the DCC coupling reaction was used to carry out the reaction. Where steric
or electronic considerations might affect the yield in a direct acylation reaction, they
would also play the same role in a DCC coupling reaction.
Table 2.2 -

Amide reaction yields for secondary bases coupled with 25 in the
presence of DCC, HOBt

Free Base

Amide % Yield
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For comparison purposes two cases where the acid to be coupled was not halogenated
were included, and they gave the amides 54 and 74.
Significant differences in yields between the two methods might be explained by
a number of different rationales. The different workup may affect the overall yield. For
example, the direct acylation reactions gave cleaner products, which required less
workup than the bromo- substituted series, which required steps specifically to remove
the urea by-product associated with the DCC coupling method. The choice of solvent
may also have a marked effect; for example, the preparation of the series of 3chlorobenzo[b]thiophene amide derivatives required the use of tetrahydrofuran which
upon

workup

was

easy

to

evaporate

under

reduced

pressure

whereas

dimethylformamide was used in the DCC coupling reactions and was difficult to
eliminate hence requiring extra water washings to remove. This additional purification
process coupled with that required to remove dicyclohexyl urea may have led to lower
yields of some amide products. In cases where the yield of the directly acylated product
was significantly lower than that of the DCC coupled product differences in yields may
have been a result of product stability under the reaction conditions.
With 37 as the base, the presence of a halogen on the starting acid or acid
chloride had little effect on the amide yield from the coupling reaction, whereas with the
amine 32 there was a significant increase in the yield when there was a halogen in the
C3 position of the benzo[b]thiophene moiety.
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Figure 2.6- A comparison of the yields of the amide reactions involving direct acylation of (chloro acid chloride) 23 and DCC coupling of 25
(bromo- acid) to various amine bases as specified. Two results for benzo[b]thiophene-2-carboxylic acid (20) are also included.
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Preparation of amide 49
The amide 49 was made from the amine 35 which was synthesised in turn by
converting 31 to 36 with NBS in dry dichloromethane as shown in Scheme 2.7 followed
by the reaction of the 3,4-dihydroisoquinoline (36) with benzyl bromide in the presence
of activated zinc powder (Scheme 2.11). This reaction was expected to follow a similar
mechanism to that outlined for the synthesis of 32 (Scheme 2.7), in which a benzylzinc
bromide complex is generated and subsequently attacks the imine carbon, thereby
adding the benzyl group.
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Benzyl bromide,
Zinc powder,
THF, reflux.

Br
DCC/ HOBt, DMF
Br

N

S
O

HN
OH

S
O

49

35

Scheme 2.11 The synthesis of 2-(3-bromobenzo[b]thiophene-1-benzyl- 1,2,3,4tetrahydroisoquinoline (49).

The preparation of the amine 35 through this method gave the desired product in
a low yield of 29 %, much lower than the yield obtained with the 1-allyl equivalent
(32). A possible reason for this might be the faster rate of allylzinc bromide formation.
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2.2.4. Further amide derivatisation
Some of the bases studied allowed for further derivatisation of the amides
synthesized. The boc-protected amides 62 and 63 were deprotected allowing further
chemistry to be performed on the resulting secondary amino group. The indolic proton
on the amides with a tetrahydro-β-carboline moiety (55 and 56) could be deprotonated
with a strong base permitting further functionalisation, for example by introduction of a
benzyl or o-nitrobenzyl group to give the amides 59 and 60.
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Scheme 2.12 Pathway to benzo[b]thiophene derivatives with substituted piperazine
rings.
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The diallylamine group on 47 affords access to ring closing metathesis reactions
as well as the potential for addition across the double bonds. Furthermore the 3-bromosubstituted amide containing 1-allyl-tetrahydroisoquinoline functionality could undergo
radical initiated ring fusion chemistry.
Probably the most important amides synthesized in terms of allowing further
chemistry were the N-boc protected amides 62 and 63 which were precursors to several
compounds prepared using the resulting secondary nitrogen upon deprotection. For
example, removal of the boc group in 63 was carried out using trifluoroacetic acid to
afford 65 in high yield (Scheme 2.12). Compound 65 was then converted by standard
methods into its N-benzyl (67), N-phenacyl (69), and N-fmoc (77) derivatives for
biological testing (Scheme 2.12).
A single crystal X-ray crystallographic analysis of the amide 63 was also carried
out. This analysis revealed the presence of major and minor rotamers disordered in a
70:30 ratio over two sets of site, in the crystal lattice (Figure 2.7). This work was
undertaken by Professor A.H White, University of Western Australia.

66

Figure 2.7- The X-ray crystallographic data of amide 63 showing the major (top) and
minor (middle) rotamers in a 70:30 ratio as well as both components
together (bottom).
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Chapter 3 Synthesis of Fused Benzo[b]thiophene
Amides
Introduction
The previous chapter focussed primarily on target amides prepared by
coupling methods and their derivatisation by substitution reactions. This chapter will
concentrate on amide derivatives which were further transformed by using free radical
cyclisation reactions, ring closing metathesis and palladium-mediated cyclisation to
produce fused-ring systems.

The rationale behind the synthesis of such amide

derivatives was that they could offer greater conformational restriction, and then
afford better specificity in their biological activity. The molecules were still based on
the benzo[b]thiophene amide structural motif (Figure 3.1)

3.1.1. Current project
In order to increase the breadth of benzo[b]thiophene amide derivatives
synthesised, it was proposed that a C3 bromo- substituent in the benzo[b]thiophene
would have the potential to form a free radical, enabling a free radical initiated ring
closure to form a lactam (Figure 3.1).
Ring formation

N

S
O

Cyclic or
non cyclic

Figure 3.1- Generic fused benzo[b]thiophene amide structure.
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Compounds with multiple olefinic groups such as 118 and 119 were also
prepared as precursors for ring-closing metathesis reactions as a means to create
larger, conformationally restricted ring systems. Furthermore, a pyrrolidine derivative
was synthesised from a diallylamine-based parent molecule 79 using ring closing
metathesis methodology.

R
N

S
O

Br

R

N

S
O

118 R = H

79

119 R = OMe

3.1.2. Free radical reactions
A free radical is formed when a covalent bond between atoms is broken
leaving an electron with each atom. Free radicals are initiated via homolytic bond
cleavage within molecules with relatively weak covalent bonds. Chemical processes
where a free radical species is generated from non-radical reactants are known as
initiator reactions. A good example of a widely used initiator for free radical reactions
is azobis(isobutyronitrile) (AIBN).
A free radical species can also be propagated; the radical can either undergo
abstraction (as in cyclisation reactions) (Scheme 3.1) or can undergo addition (as in
the case of polymerisation processes) and in both cases a new atom in the molecule
being formed becomes the radical centre, thereby relocating the radical electron.
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Finally, there is a termination process, which is in competition with propagation
reactions.

H

Initiator

(AIBN)

SnBu3

SnBu3

NC

Br

H

Bu3Sn

SnBu3

X

X

X = CH2, N, O

+

SnBu3

Regenerated

X

Scheme 3.1- Cyclisation involving the reaction of tributyltin hydride (Bu3SnH) with
unsaturated alkyl halide in the presence of a radical initiator (AIBN).

Free radical reactions have been widely used in heterocyclic synthesis98-100,
and commonly involve the use of tributyltin hydride (Bu3SnH). Other
triorganostannanes have been used, but owing to the cheap availability, preparation,
purification and ease of storage, tributyltin hydride is more widely employed, the only
major drawbacks beings handling and toxicity. Reaction conditions for these radical
cyclisation are generally similar, using a small excess of tributyltin hydride with a
smaller

equivalent

(10-25

%)

of

a

suitable

radical

initiator,

usually

azobis(isobutyronitrile) (AIBN). The cyclisation reactions are normally carried out in
dry refluxing benzene or toluene for periods ranging between 1-10 hours and require
an inert atmosphere.
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Synthetic Studies
3.2.1 Ring formation via free radical cyclisation
To further extend the range of benzo[b]thiophene-based compounds, a new set
of derivatives were prepared using free radical cyclisation methods to incorporate a
conformationally restricted lactam motif. Some of these new compounds also had the
potential for further functionalisation. The chemistry of the cyclisation involved free
radical formation at C3 of the benzo[b]thiophene moiety followed by the addition to
an allyl group on the amide nitrogen to give cyclised compounds with a skeleton as
shown in the general structure in Figure 3.1. The synthesis of the starting amide 79,
required for the free radical cyclisation reaction, is discussed in Chapter 2.
The proposed radical cyclisation of 79 (Scheme 3.2) was predicted to proceed
smoothly because of the existence of an allyl group on either side of the C-N amide
bond, negating any steric difficulties associated with any inflexibility of this bond.

Br

N

S

Bu3SnH/ AIBN
Dry toluene, reflux

N

S

O

79

O

92

Scheme 3.2- Radical cyclisation of 79 to the corresponding conformationally
restricted lactam 92.

The radical cyclisation reaction for the amide was carried out using standard
radical reaction conditions involving tributyltin hydride, and a radical initiator, AIBN.
An anhydrous toluene solution of tributyltin hydride and AIBN was slowly added to a
toluene solution at reflux of the starting material. This slow addition of the reagents
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ensured that there were small amounts of the hydride being continually used up
generating more Bu3SnBr in a cycle. The reaction mechanism proceeds via the steps
depicted in Scheme 3.1.
Before subjecting the amide 79 to radical cyclisation, however, a model
reaction was carried out in order to gauge the synthetic viability of the process
(Scheme 3.3).

Br

2% LiOH,
THF, 1hr

Br

Br
DCC / HOBt

+
OH

Cl
O

O

91

93

HN

DMF

N
O

47

94
Bu3SnH / AIBN
Toluene, reflux

N
O

95

Scheme 3.3- Free radical cyclisation of N,N-diallyl-2-bromobenzamide (94).

The model reaction involved the free radical cyclisation of the structurally analogous
N,N-diallyl-2-bromobenzamide (94) to give the new isoquinolinone derivative 95 in
good yield (Scheme 3.3). This represents a new approach to this ring system, although
related fused systems have been made in this way98.

72

OH

S

Br

Br2, CH3COOH
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DCC / HOBt,
DMF

Br

Bu3SnH, AIBN
Toluene, reflux

N

S

N

S
O

O

92
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Scheme 3.4- Radical cyclisation of N,N-diallyl-3-bromobenzo[b]thiophene-2carboxamide (79) giving 2-allyl-4-methyl-1,2,3,4tetrahydrobenzo[b]thieno[2,3-c]pyridin-1-one (92).

Following this model study, the radical cyclisation of N,N-diallyl-3bromobenzo[b]thiophene-2-carboxamide (79) was accomplished under similar
conditions in toluene at reflux (Scheme 3.4). The required fused product 92 was
obtained in moderate yield (48 %).
The 1H-NMR spectrum of 92 confirmed the presence of the methyl protons
with a doublet signal at 1.33 ppm while the allylic protons were ascribed to the peaks
at 5.81-5.90 (m, 1H, CH), 5.19-5.31 (m, 2H, = CH2) and 3.98 ppm (d, J = 6.6 Hz, 2H,
-CH2). A multiplet peak at 4.36- 4.38 ppm was ascribed to the methine proton in the
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six-membered ring. This radical cyclisation route represents a new approach to the
benzo[b]thieno[2,3-c]pyridin-1-one system101.
As an adjunct to this particular study, focus was directed towards the
functionalisation of the allylic double bond in 92 in order to introduce hydrogen bond
donor/ acceptor groups. Dihydroxylation was thus investigated using the Sharpless
reagent (AD-mix®), and osmium tetroxide102. Several attempts to model the
preparation of the asymmetric diol compound 96 using the appropriate AD-mix® α
reagent with 95 proved unsuccessful. In fact, even an attempt to model the
dihydroxylation on a far simpler analogue, allyl bromide (97) to the corresponding 3bromopropane-1,2-diol (98) failed (Scheme 3.5). No explanation for the lack of
success with this reaction with 95 was apparent, as all prescribed steps for the use of
the Sharpless reagent were followed102,103. In this case only AD-mix-α was used to
attempt the dihydroxylation103,104.
However, an effort to synthesise the diol 99 from 92 using osmium tetroxide
was successful with an overall yield of 80 %.

This reaction though is not

stereospecific (Scheme 3.6). The dihydroxylation reactions were carried out using
standard literature methods105, with potassium osmate (10 %), 2.5 equivalents of Nmethylmorpholine-N-oxide (NMO), acetone and water (Scheme 3.6).
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AD-mix-α, MeSO2NH2
1:1 tBuOH-H2O

OH
N

N
O

O

95

96
AD-mix-α, MeSO2NH2
1:1 tBuOH-H2O

Br

OH

OH
OH

Br

97

98

Scheme 3.5- Attempted dihydroxylation of the allylic compounds 95 and 97 using
AD-mix® α.

When the osmium tetroxide dihydroxylation reaction was attempted using the
model compound 95, dihydroxylation also proceeded smoothly to give the expected
product dihydroisoquinoline 96.

10 % K2OsO4, NMO
Acetone, H2O

OH

N

N

O

OH

O

95

96

10 % K2OsO4, NMO
Acetone, H2O

N

S

OH
N

S

O

92

OH

O

99

Scheme 3.6- The dihydroxylation of the model compound 95 and the
benzo[b]thiophene derivative 92 using the potassium osmate/ NMO
method.
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However, it was noted that even with a high crude yield (74 %), upon using
silica gel column chromatography for compound purification the yield dropped to 30
%. Furthermore, the decomposition of the potassium osmate in air caused the crude
product to turn black, possibly also breaking down the desired product in the mixture
thus affecting yields and necessitating further purification.
Another variation on 92 which was undertaken was the replacement of the
allyl group with a benzyl group. The number and variety of substituents possible on a
benzyl substituent make it an excellent candidate for any biological SAR studies.

Br

Br

R

DCC/ HOBt
R R1 NH
COOH

S

N

S

R1

O

79 R = R1 = allyl
100 R = H, R1 = benzyl
Bu3SnH, AIBN
Toluene, reflux

101 R = Allyl, R1 = benzyl
102 R = H, R1 = p-methoxybenzyl
103 R = Allyl, R1 = p-methoxybenzyl

Deprotection

N

S

R2

O

92 R2 = allyl

Alkylation

NH

S
O

106

104 R2 = benzyl
105 R2 = p-methoxybenzyl
Scheme 3.7- Synthesis of the new benzo[b]thiophene compounds 92, 104, 105 and
106.

76

The removal of the allyl group in 92 could also afford opportunities for further
functionalisation.

Other electrophilic groups could then be attached easily after

deprotonation of the secondary amide. The removal of an allyl group from an amide
had some precedent in the literature. Two approaches for replacing the allyl group
with a benzyl moiety in the cyclised molecule 92 were proposed. The first approach
involved the removal of the allyl group from 92, which would leave the lactam
nitrogen ring amenable to subsequent alkylation.
The second approach proposed was the synthesis of a 3-bromobenzo[b]thiophene amide bearing a benzyl group and an allyl group about the
nitrogen which could then be cyclised via the free radical methodology. The second
method involved three synthetic steps starting with the bromination of 20 and
subsequent DCC/ HOBt coupling with either benzylamine followed by alkylation
with allyl bromide to give the cyclisation precursor, or the reverse sequence involving
DCC/ HOBt coupling with allyl amine followed by N-alkylation with benzyl bromide.
The proposed synthetic pathways are illustrated in (Scheme 3.7).
Rhodium(III) chloride has been noted to remove an allyl group from an
amide106, however with this method, secondary amide yields were low. The specific
reaction is shown in Scheme 3.8, where the non-cyclic de-allylated product was
obtained in only 34 % overall yield.
Two methods were attempted for the removal of the allyl group from the
lactam 92. Firstly, the reaction of 92 with rhodium(III) chloride106, at reflux in
ethanol. However, none of the expected deallylated lactam 106 (Scheme 3.7) was
obtained.

77

RhCl3
N
R

O

+

+
N
R

O

N
R

O

NH

O

R

Scheme 3.8- The reported use of rhodium chloride in the deprotection of the allyl
group in amides, (R = CH3, C2H5, i-C3H7)106.

In the second method, the lactam 92 was heated in formic acid in the presence
of triphenylphosphine and palladium(II) acetate, following the general reported
methods107 for the deallylation of N-allylethers108, and N-allylamides109 (pg-63). The
reaction mixture was difficult to workup but ultimately the required lactam 106 was
obtained in low yield (25 %). The 1H-NMR spectrum of 106 confirmed the absence of
signals for the allyl group protons, and the retention of other signals which could be
ascribed to the ring protons and the methyl substituent group.
At this point, approaches to the synthesis of N-benzyl-1-allyl amine (107)
were then considered. The first involved the reaction of benzyl bromide with
allylamine and the second, of allyl bromide with benzylamine. In both cases the
amine needed to be in excess to minimise tertiary amine 108 formation and the
reactions needed to be performed in the presence of a base to act as a proton sink. For
the purposes of the current project the second allylation method with allyl bromide
was chosen and gave 107 in good yield (76 %); an excess of benzylamine was used in
this reaction. After coupling of 107 with 25 using DCC/ HOBt, the amide 101 was
isolated in 16 % yield along with small amounts of the undesired tertiary amine 108
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as a side product carried over from the synthesis of the secondary amine (Scheme
3.9).

THF, K2CO3

+ Br

+

HN

N

107

108

NH2
DCC/ HOBt
DMF

Br
OH

S

Br

25

O

N

S
O

101
Scheme 3.9- The synthesis of 101 from 107 and 25, from coupled benzyl amine and
allylbromide.

An alternative synthesis of 101 was also investigated. This involved the DCC/
HOBt coupling of 25 with benzylamine which gave 100 in high yield (97 %) (Scheme
3.10). This compound was easy to work with and purify, the only issue being its
relative insolubility in chromatographic solvents resulting in a tendency to crystallise
in the chromatographic column. To overcome this problem a shorter column was
used and flash column chromatography performed, which then gave 100 as a pure
solid. The next step involved reaction of 100 with allyl bromide. This was done by
first deprotonating the secondary lactam in 100 with sodium hydride at low
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temperature, and subsequent nucleophilic substitution on nitrogen by reaction of the
amide anion with allyl bromide to give 101 (Scheme 3.10).
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O
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102 R = OMe
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Br

R
N

S
O

101 R = H
103 R = OMe

Scheme 3.10- The synthetic pathway for benzo[b]thiophene cyclisation precursors

The same general approach was then used to make the p-methoxy substituted
compound 103. The reactions involving coupling with DCC/ HOBt and N-allylation
were again high yielding (97 % and 72 % respectively) (Scheme 3.10). The final step
was the radical cyclisation of the amide precursors 101 and 103 using Bu3SnH/ AIBN
in boiling toluene. This afforded the benzylated cyclised products 104 and 105 in
moderate yield (Scheme 3.7).
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Free radical cyclisation involving the tetrahydroisoquinoline moiety
Work was also undertaken directed towards the synthesis of radically cyclised
amide compounds with conformationally restricted isoquinoline groups but lacking
fusion with the benzo[b]thiophene moiety. The cyclisation reaction was based on the
o-bromobenzoyl model reaction (Scheme 3.11) previously developed in the Bremner
laboratory110,100. This reaction was repeated to refine reaction conditions.

CH2=CH-CH2Br

Zn,THF, 2d

NBS, DCM

NH

N

NH

31

36

32

o-bromobenzoylchloride, Et3N,
DMAP, DCM.

Br
Bu3SnH / AIBN

NBz

Toluene, Heat

N

110
O

+

109

N
O

111
Scheme 3.11- N-benzyl-7-methyl-6,7,8,9-tetrahydro-5H-benzocycloheptane-5,8imine (110) synthesis via free radical cyclisation of 2-(obromobenzoyl)-1-(2-propenyl)-1,2,3,4-tetrahydroisoquinoline (109)110.
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The amide 2-(o-bromobenzoyl)-1-(2-propenyl)-1,2,3,4-tetrahydroisoquinoline (109)
was reacted with tributyltin hydride and AIBN in toluene at reflux to afford 110 and a
trace amount of the reduced component 111 (Scheme 3.11).
In pursuit of the bridged amide N-benzo[b]thienoyl-7-methyl-6,7,8,9tetrahydro-5H-benzocycloheptene-5,8-imine (112), free radical cyclisation of
compound 53 was then undertaken. The precursor 53 was obtained from the amine 32
and the acid 25 (Scheme 3.12). The cyclisation of 53 with tributyltinhydride/ AIBN at
reflux in toluene gave exclusively the 5-exo-trig product 112 in relatively high yield
(89 %) as a mixture of diastereomers. The reduced product was also detected but in
trace amounts. The structure of 112 was confirmed using spectroscopic techniques.
The NMR of the compound showed the expected peak signals for the methyl protons
at 1.02 ppm and the H3 proton signal of the benzo[b]thiophene ring system at 7.81
ppm.
CH2=CH-CH2Br
Zn,THF, 2d

NBS, DCM

NH

N

NH

31

36

32
25, DCC,
HOBt, DMF

O

Br

Bu3SnH, AIBN,
Toluene

N
S

N

S
O

112

53

Scheme 3.12- The synthesis and ensuing free radical cyclisation of 53.

The methylene and methyl groups in 112 were confirmed by DEPT
experiments while the

13

C-NMR confirmed the expected peaks for the characteristic
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carbonyl carbon (168 ppm) and the other carbons. High-resolution mass spectroscopy
gave a molecular formula for the MH+ ion peak (C21H19NOS) consistent with that
expected for 112.

3.2.2. Ring closing metathesis reactions
The term metathesis comes from the Greek words meta meaning change and
tithemi meaning place. From a chemical perspective, it refers to the exchange of
atoms between two molecules. In olefin chemistry, it expresses the formation of a
carbon-carbon double bond from what were initially two double bonds. This type of
metathesis is of particular interest because no additional reagents are employed with
the exception of a small amount of a metal carbene complex catalyst. The by-product
of the reaction is an easily removed, highly volatile olefin.

Ph
Ph

+

Ph

Ph

Exchange

+

O

O
Cross metathesis

+

Ring opening metathesis
polymerization

-CHCH2CH2CH-

Ring closing metathesis

+

Scheme 3.13- The four categories comprising the metathesis process111.
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This form of metathesis can be broadly categorised into four groups111
comprising exchange reactions, cross metathesis (CM), ring opening metathesis
polymerization (ROMP) and ring closing metathesis (RCM) as depicted in Scheme
3.13. Of these four groups, ring-closing metathesis is of particular interest in terms of
the current project.

3.2.3. Discovery of olefin metathesis
Olefin metathesis112 was first reported in the 1950s. In 1956 Herbert S.
Eleutrio, synthesized a propylene-ethylene copolymer from propylene passed over a
molybdenum-on-alumina catalyst113,114. The output gas was analysed and found to be
composed of propylene, ethylene and 1-butene, an observation that was also reported
by other chemists working in other petrochemical companies. Later in 1960, a U.S
patent113,114 was assigned to The Standard Oil Company of Indiana (USA), which
recorded that propylene in presence of molybdenum oxide on alumina, treated with
tri-isobutyl alumina, gave ethylene and butanes as products. In 1964, Phillips
Petroleum reported the breakdown of propylene to ethylene and butanes using
molybdenum hexacarbonyl on alumina (Scheme 3.14)113,115

+
Mo

+
Mo

Mo

Mo

+

Scheme 3.14- Breakdown of propylene using molybdenum hexacarbonyl on
alumina113
In 1967, Nissim Calderon and others at Goodyear Tyre and Rubber sought an
explanation for the unexpected by-products from the reactions mentioned above. They
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suggested that the by products were due to the cleavage and reformation of double
bonds within the olefins. The Goodyear researchers hence termed the reaction “olefin
metathesis”116 This marked the beginning of olefin metathesis as a potential new
chemical synthetic methodology.
Since then, ring closing metathesis reactions have been widely employed in
organic synthesis117,118. However, of prime importance is the type of catalyst used. A
well defined catalyst should offer flexibility over a wide range of functional groups
and at the same time be reactive towards a range of substrates leading to high yields in
reactions involving a wide range of functional groups. Two such catalysts have been
widely used to date, the Schrock catalyst 112a and Grubbs’ catalysts, 112b and 112c.
They have a major advantage over the previously used catalysts for olefin metathesis
reactions in that they are highly active, are longer lasting and do not require Lewis
acids, co-catalysts or promoters114.
The ruthenium-carbene114 catalysts 112b and 112c are now preferred over the
molybdenum complex catalyst 112a. The molybdenum complex possesses some
shortcomings, which include poor functional group tolerance, high sensitivity to
moisture, air and impurities present in solvents, thermal instability, and high
production costs. However, the molybdenum complex catalyst has reactivity over a
spectrum of substrates, which have steric and electronic variations114.

MeS

Pri
(F3C)2MeCO
(F3C)2MeCO

i

Pr

N

N

N

SMe

Cl
Cl

Ru

Mo

PCy3

112a

112b

Ph

Cl

PCy3

Ph

Ru
Cl

PCy3

112c

85

The ruthenium-carbene catalysts show reactivity towards a variety of ring
closing metathesis processes under mild conditions and exhibit tolerance towards a
range of organic functional moieties119. Unlike their molybdenum based counterpart,
the sensitivity of the ruthenium catalysts are not significantly reduced when exposed
to air, moisture, or minor impurities.

R

Initiation

M

R
M

R

+

Catalytic cycle

M=CH2

M
M

M
H2C

CH2

Scheme 3.15- The catalytic cycle showing the mechanism of ring closing
metathesis111,112.

They can be stored over a period of weeks without showing severe signs of
decomposition and they are readily available and easy to use. The only negative
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aspect is that they often show relatively lower rates of propagation, particularly with
sterically bulky substrates120.
The mechanism for ring closing metathesis follows a process involving the
formation of a metallacyclobutane which is a key intermediate in these ring closing
metathesis reactions. The metallacyclobutane intermediate formed can undergo
cycloreversion either to products or back to starting materials. When the olefins of the
substrate are terminal, the driving force for ring closing metathesis in this case is the
removal of ethene from the reaction mixture117,118 (Scheme 3.15).

3.2.4. Current project and metathesis reactions
Ring closing metathesis
Ring closing metathesis plays an important role in the synthesis of complex
molecules111,113,121,122 which incorporate annular double bonds. It offers efficient
routes in which the numbers of chemical transformations are minimal. In relation to
the current project, it offered a facile route to novel benzo[b]thiophene compounds
which had potential for further chemical manipulation at the resultant olefinic
functionality. In the syntheses of novel fused benzo[b]thiophene compounds, ring
closing metathesis is preferable to alternative processes in terms of ease of availability
of substrates, number of steps, synthetic flexibility, the purity of products and yields.
Ring closing metathesis was considered for the synthesis of a number of target
compounds incorporating the benzo[b]thiophene moiety in a range of molecular
environments. Of the simpler molecules, 78 and 79 were potential candidates for
intramolecular ring closing metathesis reactions as the two allyl groups were spaced
in a manner that would easily afford a 5-membered ring after metathesis.
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For

reactions

involving

these

compounds,

benzylidene-

bis(trichlorohexylphosphine)dichlororuthenium (112c), commonly referred to as
Grubbs’ catalyst (or Grubbs’ I catalyst), was used. In the literature, 5 -10 mol % of
Grubbs’ I catalyst is generally used for the ring closing reaction with dry
dichloromethane as the solvent123. For reactions involving 78 and 79 (Scheme 3.16),
10 mol % of Grubbs’ I catalyst was employed and the reactions stirred for 20-22
hours at room temperature in dry dichloromethane under an inert atmosphere with
removal of ethene. The reactions were monitored by thin layer chromatography and
interestingly both reaction mixtures developed a green colouration. Workup of these
reactions was smooth requiring only a few purification steps.

Filtration of the

reaction mixture followed by flash chromatography using dichloromethane afforded
the expected dihydropyrrole derivatives 113 and 114 in good yield of 73 % and 80 %
for respectively. It was predicted that the new compounds may be both photo- and air
sensitive and consequently they were stored at low temperature under nitrogen and in
the dark. Full spectroscopic characterization was obtained. In the 1H-NMR of 113
and 114 the olefinic protons were assigned to signals at 4.31 and 4.48 ppm (2x CH2)
with the corresponding signals at 5.79 and 5.93 ppm (2x CH). In the

13

C-NMR

signals at δ 161.7 were assigned to the amide carbonyl groups in 113 and 114
respectively.

N

S

X

(Homogeneous or polymer bound)
Grubbs' catalyst,112a
Dry DCM

X

O

N

S
O

78 X = Cl

113 X = Cl

79 X = Br

114 X = Br

Scheme 3.16- Ring closing metathesis of a diallyl benzo[b]thiophene compound to
the corresponding dihydropyrroles.
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Polymer bound Grubbs’ I catalyst122 has also been widely used in ring closing
metathesis reactions with a profound effect on the purity and yield of cyclised
products124. This catalyst had several advantages over its homogeneous counterpart in
that it was reusable up to three times without adversely affecting yield. The ring
closing metathesis reaction using 78 as a substrate was attempted with the use of the
polymer bound Grubbs’ I catalyst under the same conditions used with the
homogeneous catalyst (Scheme 3.16).
Filtration of the reaction mixture after 22 hours gave a colourless solution
containing the product. Evaporation of the dichloromethane gave colourless oil that
solidified on standing. The product 113, was purified by flash chromatography to
remove trace ruthenium contaminants. A comparison between the two forms of the
catalyst showed that the polymer bound variety gave a better yield of 85 % versus 73
% of 113 and a much cleaner product and, importantly, the catalyst was recovered.
The higher yield of 113 with the use of a polymer supported ruthenium
catalyst could be attributed to the greater stability of the polymer supported catalyst,
compared to the homogeneous variety that is susceptible to decomposition under
normal atmospheric conditions.

Comparisons of reaction residues derived from

polymer bound catalyst versus those from the homogeneous catalyst were
informative, with those from the homogeneous catalyst being highly coloured and
hence requiring purification by silica chromatography, while the polymer supported
product solution was almost colourless after filtration.

Ring closing metathesis of molecules containing a tetrahydroisoquinoline
motif
The successful synthesis of the above mentioned new benzo[b]thiophene
compounds with dihydropyrrole moieties paved the way for the synthesis of
89

benzo[b]thiophene systems with larger rings. The initial goal was to attempt the
synthesis of a 9-membered ring compound (of type E as mentioned in Chapter 1
under project aims) via ring closing metathesis reaction. The cyclisation precursor
under investigation needed allyl groups at the C3 position of the benzo[b]thiophene
ring and at the C1 position of the 1,2,3,4-tetrahydroisoquinoline ring moiety in the
amide. It was therefore necessary to synthesize a benzo[b]thiophene acid with an allyl
group at the C3 position that could then be coupled to 32 to give the cyclisation
precursor

2-(3-allylbenzo[b]thiophen-2-oyl)-1-allyl-1,2,3,4-tetrahydroisoquinoline

(118) (Scheme 3.17). A literature search indicated that no previous work had been
conducted on allylation of the C3 position of the benzo[b]thiophene ring system.
The allylation of the C3 position of the benzo[b]thiophene ring was attempted
using a Stille coupling method. The conditions used were adapted from a literature
method for the reported synthesis of new dibenzothiophene amino acid and
cyclophane derivatives125, which involved an allyl-aryl intermediate. The starting
point for these reactions was the bromination of 20 to afford 25 (Scheme 2.3) which
was then converted to its methyl ester to protect the carboxylic acid functionality.
The substitution of the C3 bromine with an allyl group to give methyl 3allylbenzo[b]thiophene-2-carboxylate (116) was attempted using a Stille coupling
method in dimethylformamide with 1 mole equivalent of 115 and allyl tributyltin and
a half mole equivalent of palladium(II) chloride in the presence of triphenylphosphine
(Scheme 3.17).
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Scheme 3.17- Synthesis of precursors 118 and 119 for the 9-membered ring
compounds through ring closing metathesis.

The reaction was carried out under an inert atmosphere at 110 oC in a sealed
tube. These conditions were maintained for one and a half days while the progress of
the reaction was monitored using thin layer chromatography (Scheme 3.17). This
reaction gave a crude residue which was difficult to workup due to the formation of
triphenylphosphine oxide and the presence of tin by-products. Simple filtration was
insufficient to eliminate the tin by-products.

After a series of chromatographic
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purification steps the desired product, methyl 3-allylbenzo[b]thiophene-2-carboxylate
(116), was isolated as an oily product in moderate yield (50 %). A trace amount of the
starting material was also detected. The structure of 116 was confirmed using
spectroscopic techniques. The 1H-NMR showed the presence of characteristic signals
for the allylic protons at 4.15 (d, J = 4.2 Hz, -CH2), 5.04-5.13 (m, 2H, = CH2) and
5.97-6.06 (m, CH), as well as the expected relative integral for signals in the aromatic
region. The methyl and methylene protons were confirmed using a DEPT spectrum.
+

The m/z value for the MH ion in the high-resolution mass spectrum was consistent
with the molecular formula for 116.
The methyl 3-allylbenzo[b]thiophen-2-carboxylate (116) was then hydrolysed
to the corresponding acid 117 in high yield (93 %) by heating at reflux in 2 % LiOH
solution in tetrahydrofuran, followed by acidification (Scheme 3.17). Evidence for the
hydrolysis was apparent in the 1H-NMR spectrum of 117 with the loss of the signal
for the methyl ester protons. The other peaks remained similar for both the product
and the substrate except for a broad singlet resonating downfield at 11.0 ppm
consistent with the carboxylic acid proton.
The final step in the synthesis of the cyclisation precursor 118 was the DCC/
HOBt mediated coupling of 3-allylbenzo[b]thiophene-2-carboxylic acid (117) with
the 1-allyltetrahydroisoquinoline 32 (Scheme 3.17). The tetrahydroisoquinoline 118
was obtained in 50 % yield. The 1H-NMR spectrum of 118 was complicated owing to
the presence of amide rotamers. Amongst the characteristic proton signals for 118 was
the signal associated with the H1 proton at 4.85 ppm and the signals for the H3 and
H4 methylene protons on the tetrahydroisoquinoline ring at 3.50ppm and 3.66 ppm
respectively. The allyl groups gave overlapping signals but the relative integration
was consistent for two such groups. The DEPT NMR spectrum confirmed the
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expected number of methylene and methine groups. The

13

C-NMR gave a signal

ascribed to the carbonyl carbon at 165 ppm.
A simple molecular modelling study performed on 118 using AM196 as the
minimiser suggested that the two allyl groups were disposed geometrically in a
manner that would facilitate the ring closing metathesis.

Figure 3.2- Orientation of the allyl groups on the cyclisation precursor 118 showing
their closeness in space, indicating their ease to ring close leading to the
9-membered product 120.

Excellent orbital overlap could be achieved using simple allyl aliphatic bond rotation
from a descent appropriate local minimum (Figure 3.2).
For the final step, the precursor 118 was taken up in dry dichloromethane
together with 10 mol % of polymer supported Grubbs’ I ruthenium catalyst. The
reaction was carried out under argon at room temperature for a period of 15 hours
(Scheme 3.18). Workup was relatively easy involving the recovery of the catalyst by
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filtration and thin layer chromatographic analysis of the filtrate indicated a single
major product (Rf 0.4) was formed. This product was isolated chromatographically
and shown to be the novel fused 9-membered ring compound 120. The compound was
obtained in 78 % yield.

R
N

S

118 R = H
119 R = OMe

O

R
Grubbs' I catalyst (polymer bound),
DCM, r.t

7

6

4

3

2

15
14

N

S

13

R

R

1

O

120 R = H
121 R = OMe
Scheme 3.18- Formation of a 9-membered ring system through ring closing
metathesis.

+

The mass spectrum of 120 showed a peak at m/z 346 (MH ) consistent with the
expected cyclised compound 5,8,16,17-tetrahydroazonino[3,4-b]benzo[b]thieno[3,2a]isoquinolin-14(4bH)-one (120). The

1

H-NMR spectrum of 120 was not as

complicated as the corresponding spectrum of its precursor due in part to the absence
of lactam rotamers in the ring-closed product. The olefinic protons in the 9-membered
ring was 5.99 ppm (H7) and 6.17 ppm (H6), consistent with a cis double bond; no
evidence of the trans isomer was seen. Preliminary computational studies using
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AM196 minimisation suggested that the cis arrangement of the olefinic double bond in
the ring was about 5 kcal mol-1 more stable than its trans-counterpart (Figure 3.3).

A

B

C

D

Figure 3.3- 3D representations of local AM196 minima found for the cis (A, B) and
trans (C, D) isomers for compound 120.

This appears to be in part due to the steric strain induced on the tertiary carbon
adjacent to the amide nitrogen. In the case of the trans conformer there is a larger
deviation from a tetrahedral geometry for this carbon than there is in the same carbon
for the cis isomer. Furthermore, there is considerable orbital overlap involved in the

95

C-N amide bond and the trans olefinic bond with the centroid-centroid distance
between the bonds being only 2.60 Å, as opposed to the analogous distance in the cis
isomer of 3.7 Å.
The compound 120 was recrystallised from ethanol to give colourless rhombic
crystals which were submitted for X-ray crystallographic analysis by Professor A.H.
White, University of Western Australia. The X-ray data confirmed the cis double
bond at C(13) and C(14) as shown in Figure 3.4. The compound 120, which is
representative of a new heterocyclic system, was tested for biological activity as an
antimalarial agent, a topic that is discussed in more detail in Chapter 4.

Figure 3.4- The single crystal X-ray structure of 120 confirming the cis nature of the
olefinic double bond C(13) and C(14). Note: The X-ray crystallographic
numbering is different from the systematic numbering.
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In order to assess substituent effects on biological activity, the synthesis of the
dimethoxy analogue of 120 was also investigated. The benzo[b]thiophene-based
precursor 119 for the ring closing metathesis reaction was prepared from 117 (Scheme
3.17) and the 6,7-dimethoxytetrahydroisoquinoline 34. In the initial synthesis of the
amine 34, (Scheme 2.7) the commercially acquired 33 was converted in good yield
(75 %) to the corresponding 6,7-dimethoxy-3,4-dihydroisoquinoline 37 using NBS.
However, the allylation of the imine 37 using the allyl bromide/ zinc approach was
low yielding (42 %). Alternative reagents were thus investigated for the allyl group
addition to 37 (Scheme 3.19). Allyltributyltin has been reported to react readily with
aldimines to give homoallyl amines in good yield with Lewis acid catalysis126,127.
Thus initial studies in the current work focussed on the use of boron trifluoride
etherate as the Lewis acid for the addition of allyltributyltin to 37.

MeO

MeO
NBS, DCM

NH

MeO

N

MeO

33

37
Sn3Bu3
SnBu3

BF3.Et2O,
DCM, -78 oC

BF3.Et2O, Zn,
DCM, -78 oC

MeO

MeO
NH

MeO

34

NH

MeO

34

Scheme 3.19- The boron trifluoride etherate / allyltributyltin approach to compound
34.
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Boron trifluoride etherate was added to the imine 37 in dry dichloromethane at
low temperature (-78 oC), followed by brief warming of the reaction mixture to near
room temperature and then re-cooling to -78

o

C before the addition of the

allyltributyltin was commenced (Scheme 3.19). However, none of the 1-allyl-6,7dimethoxy-tetrahydroisoquinoline (34) was formed in this reaction. Interestingly,
when activated zinc powder was added to the reaction mixture including boron
trifluoride etherate, the desired product 34, was obtained in good yield (80 %).
It is possible that, diallylzinc may have been generated in situ from the
allyltributyltin and it was this reagent that was responsible for the addition of the allyl
group to the BF3-complexed imine moiety as shown in Scheme 3.20. Trace amounts
of the amine 33 were also observed, and the formation of this compound may have
been due to the reduction of the imine 37 by the elemental zinc. The combination of
zinc, allyltributyltin and boron trifluoride etherate does not appear to have been
reported previously for allyl additions to imines and is worthy of further investigation
to ascertain its wider synthetic utility.

+ Zn

2 Bu3Sn

Zn

2

+ Bu3Sn-SnBu3

MeO

Zn

OMe

+
2

MeO

N

HN

OMe

BF3

34
Scheme 3.20- The proposed formation of 34 where, diallylzinc generated in situ from
allyltributyltin adds the allyl functionality to the BF3-complexed imine.
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The DCC/ HOBt coupling of 3-allylbenzo[b]thiophene-2-carboxylic acid 117
with 34 afforded the diallyl amide 2-(3-allylbenzo[b]thiophen-2-oyl)-1-allyl-6,7dimethoxy-1,2,3,4-tetrahydroisoquinoline (119) in 57 % yield (Scheme 3.17). The
cyclisation of 119 using polymer-supported Grubbs’ I catalyst then gave 121 in good
yield (Scheme 3.18), and the presence of the cis double bond in the cyclised product
was confirmed by 1H-NMR spectroscopic analysis.
The synthesis of 8-membered ring benzo[b]thiophene-fused analogues of 120
compounds was also considered. One approach to achieve this was to incorporate a
vinyl group at the C1 position of the tetrahydroisoquinoline ring portion of the amide
precursor for the ring closing metathesis. The synthesis of this isoquinoline precursor
for the 8-membered compound was attempted in a one pot reaction. This involved the
reaction of 3,4-dihydroisoquinoline with vinylmagnesium bromide in diethyl ether at
low temperature, followed by the addition methyl 3-allyl-benzo[b]thiophene
carboxylate (116) (Scheme 3.21).

BrMg
Dry ether

NMgBr

N
OCH3

S
O

36

Dry ether

N

S

122

O

Scheme 3.21- The attempted synthesis of the vinyl substituted derivative 122.

99

The

expected

product

2-(3-allylbenzo[b]thiophen-2-oyl)-1-vinyl-1,2,3,4-

tetrahydroisoquinoline (122) was not isolated after workup of this reaction however
only trace amounts of the starting material were observed. Due to time constraints, the
reaction using this pathway was only attempted once and was not pursued further.
In summary, the ring closing metathesis reaction was demonstrated to be a
feasible method for the synthesis of compounds with 9-membered ring annulation to
the benzo[b]thiophene nucleus.

3.2.5. Palladium-Catalysed Cyclisations
Cyclisation reactions mediated by palladium are widely used in synthetic
organic chemistry, including the synthesis of heterocyclic systems128.
Apart from the major role played by palladium in hydrogenation and oxidation
reactions, it also acts as a catalyst for numerous C-C bond formation reactions. There
are three key areas where palladium is used efficiently; the reaction of palladium
cation complexes with nucleophiles127, the cross coupling129 of organometallic
reagents (such as organotin, organoboron and organozinc reagents) with organic
halides130-133 (e.g. Stille coupling; Scheme 3.22), and the reaction of organic halides
(usually aryl/ alkenyl halides) with olefins134.
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Scheme 3.22- Proposed mechanism for the palladium catalysed C-C bond formation
reaction following the Stille coupling133,135.

The catalyst in these reactions is usually a Pd(0) species. However, this is usually
generated in situ from a Pd(II) salt by reduction with the organometallic reagent,
solvent or some other species in the reaction mixture. The oxidative addition of aryl
halides and triflates to a Pd(0) species inverts the relative activities of aryl and alkyl
halide systems, i.e. in nucleophilic displacement reactions it is expected that the alkyl
halide would be more reactive, but in the palladium catalysed reactions the alkyl
halides are unreactive.
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3.2.6. Palladium-promoted ring closure
Palladium-catalysed cyclisation through C-C bond formation was also
investigated in this project because it opened up a way to the preparation of novel
fused-derivatives with a benzo[b]thiophene framework.
In recent years, polycyclic compounds bearing an indole ring within their
motif have been of immense interest to medicinal chemists. Many of these polycyclic
compounds have been successfully synthesised by intramolecular dehydrogenation of
aroylindoles with palladium(II) acetate136-140. A similar approach was attempted in
this project where highly constrained and planer molecules of benzo[b]thiophene were
required (molecules of type (D); as mentioned in Chapter 1 under project aims). The
specific target was the new heterocyclic derivative 126 (Scheme 3.23).
The acid chlorides 26 and 27 required for these reactions were synthesised
from their precursor benzo[b]thiophene carboxylic acids 20 and 25 as explained in
chapter two (Scheme 2.4). The acid chlorides were achieved in good yield and were
used immediately due to their tendency to hydrolyse.
The coupling of benzo[b]thiophene-2-carbonyl chloride (26) and 3bromobenzo[b]thiophene-2-carbonyl chloride (27) with indole 123 was performed
after the indolic proton was removed with sodium hydride at low temperature; this
afforded the (benzo[b]thiophen-2-oyl)(1H-indol-1-yl)methanone (124) and (3bromobenzo[b]thiophen-2-yl)(1H-indol-1-yl)methanone (125) cyclisation precursors
respectively (Scheme 3.23). Cyclisation reactions with palladium(II) acetate were
investigated first with the C3-unsubstituted benzo[b]thiophene derivatives.

102

X

X

SO2Cl, Pyd.
Toluene, reflux

OH

S

20 X = H O
25 X = Br
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Scheme 3.23- The intramolecular ring closure of 124 and 125 by palladium acetate.

The reaction of 26 with indole 123 in dry dimethylformamide and sodium
hydride afforded the N-acylated indole 124 in good yield (71 %) after flash column
chromatography (Scheme 3.23). The 1H-NMR of 124 had characteristic doublet
signals at 7.28 ppm and 6.71 ppm for the indolic H2 and H3 protons respectively and
a singlet at 7.90 ppm ascribed to the benzo[b]thiophene H3 proton.
The aromatic protons for the benzo[b]thiophene appeared further downfield
than those of the indole; however the peak integration for the total number of aromatic
protons expected was consistent with the proposed structure 124. The

13

C-NMR

signals were consistent with the number of carbons expected and the presence of an
amide carbonyl carbon peak at 164.3 ppm was also noted.
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Figure 3.5- Two views of a ball and stick representation of an AM196 local
minimum conformation of 126.

The oxidative cyclisation of 124 was achieved using 1 mol. equivalent of
palladium(II) acetate in glacial acetic acid at reflux for 2 days. The workup was
difficult owing to the presence of metallic palladium in the reaction mixture; however,
upon purification using column chromatography and preparative TLC, an intense
orange product (14 % yield) was isolated whose structure was assigned as 126. The
intense colour was consistent with the extensively conjugated π-electron system in
126. An AM196 local minimum-derived molecular model showed that 126 was highly
planar (Figure 3.5). An analysis of the mass spectrum showed the presence of a peak
+

at m/z 276 (CI+), consistent with the MH

ion peak expected for 11H-

benzo[b]thieno[2,3-c]pyrrolo[2,3-a]indol-11-one (126).
Further structural confirmation of the isolated cyclised product 126 was
established by 1H-NMR in which the H5 proton appeared as a sharp singlet at 6.57
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ppm. The

13

C-NMR spectrum of 126 lacked signals which could be assigned to the

C2 and C3 methine peaks formerly associated with the indole ring as well as the C3
methine in the benzo[b]thiophene moiety. A new methine carbon signal was apparent
at 102.1 and this was ascribed to the C5 carbon. High-resolution mass spectrometry
supported the molecular formula for 126. The UV-visible absorption spectrum of 126
showed a moderate absorption band at λmax 264 nm together with stronger bands at

λmax 278 nm and 283 nm as might be expected for π Æ π∗ excitations. A weak and
broad peak at λmax 369 nm was also observed possibly due to an n Æ π∗ excitation.

Figure 3.6- UV/Visible absorbance spectrum for 126 in absolute ethanol.

The fore mentioned reaction sequence (Scheme 3.23) was repeated under the
same conditions but using the 3-bromo substituted acid chloride 27 as the starting
material. The synthesis of the 3-bromobenzo[b]thiophene-2-carbonyl chloride (27)
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was achieved in good yield (67 %) and the acid chloride was used immediately after
isolation due to its tendency to hydrolyse. The coupling of 27 with 123 followed a
similar route as that mentioned previously (Scheme 3.23), however the cyclisation
precursor,

3-bromobenzo[b]thiophen-2-yl)(1H-indol-1-yl)methanone

(125)

was

isolated in only 20 % yield after flash column chromatography. Steric hindrance
associated with the bromo- substituent may account for the lower yield in this case.
The structural elucidation of 125 was achieved by comparison of the 1H-NMR
spectrum with that of 124 where the indolic C2 and C3 proton signals appeared as a
doublet at 7.2 ppm and a doublet of doublets at 6.5 ppm respectively. The 13C-NMR
spectrum indicated the relevant number of carbons expected for 125, and a key signal
at δ 164.3 ascribed to the carbonyl group. The peaks observed at 125.5 ppm and 102.7
ppm were assigned to the C2 and C3 indolic carbons respectively. The mass
+

spectrometric data (CI ) revealed a molecular ion peak at m/z 356 (MH+) with
characteristic isotopic peaks for the presence of one bromine. A fragmentation peak
at m/z 276 associated with the loss of the bromine was also seen. Finally, the
molecular formula was determined via high resolution mass spectroscopy and this
was consistent with 125 (Scheme 3.23).
The precursor 125 was cyclized in the presence of palladium(II) acetate in
boiling glacial acetic acid to give 11H-benzo[b]thieno[2,3-c]pyrrolo[2,3-a]indol-11one (126) in 23 % yield. From these two approaches to the palladium catalysed
benzo[b]thiophene/ indole derivative 126 it was clear that the use of the C3
unsubstituted compound gave better yields of the cyclised product, probably due to a
slower attack by the 6-arylpalladium(II) complex intermediate on the hindered
benzo[b]thiophene C3 position in the case where X = Br (Scheme 3.23).
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Scheme 3.24- The proposed pathway for the cyclisation to 126, showing possible
intermediates.

The low yield observed with the synthesis of the cyclised compound 126 led
to further optimisation studies. It had been demonstrated previously by others that
these palladium(II)-mediated oxidative cyclisation reactions become catalytic in
palladium with the re-oxidation of Pd(0) to Pd(II) with addition of an oxidising agent
such as copper(II) acetate138,139.

107

SO2Cl, Pyd.
Toluene, reflux

OH

S

Cl

S

20 O

25

O

N
H

NaH, DMF

123
Pd(OAc)2,
Cu(OAc)2

N

S

CH3COOH/
(CH3CO)2O

O

126

N

S
O

124

Scheme 3.25- The attempted synthesis of 126 in the presence of Cu(II) ions with aim
to re-oxidise Pd(0) to Pd(II) and hence favor the forward reaction.

The palladium-mediated cyclisation of (benzo[b]thiophen-2-yl)(1H-indol-1yl)methanone (124) was thus attempted (Scheme 3.25) with a catalytic amount of
palladium(II) acetate and 2.5 equivalents of copper(II) acetate in a mixture of glacial
acetic acid/ acetic anhydride. The reaction mixture was heated at reflux for 24 hours
but no product was isolated. Thin layer chromatographic analysis of the reaction
mixture showed only the presence of the starting material, and this was confirmed by
mass spectrometric analysis. Even after extended periods of time, there was no
indication of product formation (Scheme 3.25).
In summary, the palladium(II) oxidative coupling reactions involving the
benzo[b]thiophene skeleton afforded a pathway to a novel heterocyclic system,
however, further study is required to improve the yields.
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Chapter 4 Biological Testing
The mind-boggling number of compounds with characteristics of drug-like molecules that
can be synthesized means that many tools are needed to select those compounds of
greatest biological benefit.
•Sophie Petit-Zeman

Introduction
Biological testing of the benzo[b]thiophene amides synthesised as discussed in
Chapters 2 and Chapter 3 was undertaken to determine antimalarial activity and to a
lesser extent, antibacterial activity. The in vitro antimalarial studies were carried out by
Dr Sumalee Kamchongwongpaisan at the BIOTEC, NSTDA research laboratories in
Thailand, while the antibacterial studies were undertaken through Dr. J. Deadman,
Avexa Ltd, Melbourne (formally Amrad).
The antimalarial activities are reported as IC50 values in micrograms per
millilitre (µg/ mL) and as micro-molar (µM) values. The IC50 value is a measure of the
concentration required to kill 50 % of the microbes being tested, in this case the
Plasmodium falciparum protozoan. The range of benzo[b]thiophene derivatives
synthesised during the course of this study exhibited a wide range of biological activity
data which in turn provided valuable information on the essential structural
requirements for greater activity. This led to the design and synthesis of new molecules
which provided further information regarding structure activity relationships.

4.2 Antimalarial testing
4.2.1. Test procedures
Although a study of the synthesis of the compounds presented in this project is
in itself of value, the primary purpose for their preparation, in this case, was to
investigate their activity as antimicrobial, and in particular, antimalarial agents.
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The novel benzo[b]thiophene amide derivatives were tested for in vitro activity
against two particular strains of the protozoan Plasmodium falciparum. These strains
were the double mutant K1 CB1, which is a multidrug resistant/ antifolate resistant
strain, and the wild type TM4/8.2, an antifolate sensitive strain. In this chapter the two
parasite strains will be referred to as K1 and TM4 respectively.

4.2.2. In vitro antimalarial activity of non-fused benzo[b]thiophene
amides
The non-fused benzo[b]thiophene amides were synthesized with a framework
(Figure 4.1) incorporating a Cl, Br, H or allyl group in the C3 position (X in Figure 4.1)
of the benzo[b]thiophene moiety and a ring structure limited largely to a 6-membered
ring moiety.
Varied
substituents
X
3

S

N

2

Varied ring and
substituents

1

O

Figure 4.1- The generic benzo[b]thiophene amide structure.

The lead molecule 30 showed encouraging in vitro activity against both strains
of P. falciparum (Table 4.1; structures are shown in the following fold out sheet and
they are arranged in decreasing order of activity) leading to the development of a
strategy to discover and identify a second generation of non-fused benzo[b]thiophene
amide derivatives which retained the desirable attributes of the lead but with improved
potency.
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Table 4.1- Antimalarial activities of the non-fused benzo[b]thiophene amide analogues

N

S

N

S

O

Compound
Number.

K1
30
29
67
81
80
61
63
85
60
54
76
53
59
70
62
50
52
51
71
84
55
82
56
66
72
73
75

µM
13.00
13.70
16.77
17.90
18.20
18.30
18.39
19.1
20.00
22.70
23.20
23.50
28.89
37.10
43.06
46.92
51.10
54.13
58.10
58.71
65.97
71.3
74.40
135.89
> 50
> 50
> 20

µg/ mL
4.84
4.49
40.38
8.40
7.73
9.18
7.82
8.55
10.03
7.56
11.34
9.69
13.20
14.51
16.40
18.2
18.8
23.4
25.31
23.60
24.2
28.96
30.60
50.40
-

µM
0.30
18.8
14.3
16.5
18.9
17.2
22.3
15.4
28.95
> 50.0
26.2
16.5
> 50.0
> 50.0
66.12
> 50
> 50
> 50
> 20

HN

Cl

N

S

N

S

61

80

81
O

Br

Br
N

N

N

S

N

S

60

85

63

O

Br

Cl
N

N

S

O

N

S

O

O

76

53

Cl

Cl

O

Cl

Cl

N
N

S

N

N

N

S
O

59

O

70

Cl
N

62

Cl

OMe

Br

N

S

OMe

OMe

O

52

50

OMe
N

S

O

O

O

N

S

O

S

N

S

O

54

N

O

O

O

NO2

Br

Cl

O

N

N

O

O

O

51

Cl
Cl

Br
N
N

S

Cl

Cl
N

N

S

O

OH

Cl

N
H

O

55

84

71

N

S

O

Cl

Br

N

Cl

N

S

N

S

82

56

N

N

N

Br
N

N

N
N

S

O

66

Br

Cl

N

S

N
H

O

O

N

S

72

73

Cl

Note: For clarity purposes, the standard deviation figures for the IC50 values are not indicated here;

N

S

75

Br

N

N

S

O

O

these values are given in the Appendix.

O

Cl

N

S

67

O

Br

S

µg/ mL
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The synthesis of benzo[b]thiophene amides with methoxy substituents on the
tetrahydroisoquinoline moiety at the C6 and C7 positions (amides, 51 and 50) did not
seem to improve activity relative to the non-methoxylated parent which showed an
activity greater than 20 µM against the K1 strain of the parasite.
The allyl substituted compounds 52 and 53 had weak activity but the bromosubstituted amide 53 exhibited double the activity of the chloro- substituted analogue
52. For comparison purposes, the amide 54 which had no halogen at the C3 position
was tested and it showed mild activity against the K1 and the TM4 strains and exhibited
similar IC50 values as those for 53 (22.70 µM and 23.50 µM respectively) (Table 4.1).
The presence of a bulky group in the nitrogen containing moiety seemed to
increase biological activity as seen in the case of compounds 80 and 81; this group is
hydrophobic and hence could increase membrane permeability. Even though the activity
for these benzo[b]thiophene amides was not high, a few differences in results were
observed, and it is noticeable that while the activities for amides 80 and 81 against the
K1 strain have a similar IC50 range, the chloro- substituted derivative 80 showed higher
potency (14.3 µM) in activity against the TM4 strain.
The incorporation of an N-benzyl substituent in the piperazine based amide 67
slightly improved the activity (16.77 µM) relative to the parent molecule 63 containing
the bulkier group (18.39 µM). Further attempts to improve potency in the piperazine
derivatives by attaching substituted aromatic rings (p-chlorophenyl) as in amides 70 and
71 dramatically decreased the activity. The fmoc-protected piperazine 76, which
contains a bulky hydrophobic substituent, showed better activity against the TM4
parasite (15.4 µM) than against the K1 strain (23.3 µM).
The much more conformationally constrained bicyclic amide 85 was of interest
in this class of piperazines; however, amide 85 had a similar potency (19.1 µM) to that
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observed for the boc protected amides. It might thus be deduced that steric constraints
were affecting activity in these amides. The activity of the piperidine derivative 82,
which lacked a nitrogen at position 4 in the 6-membered ring but had a hydrophilic
hydroxyl group at this position, was not promising. The IC50 value against the two
Plasmodium strains for this amide increased to values greater than 50 µM.
The tetrahydrocarbazole-based amides 55 and 56 were also tested and had
similar activities. As mentioned in Chapter 2, the indolic proton was substituted with a
benzyl moiety giving amides 59 and 60, and preliminary testing indicated a large
improvement in activity from IC50 values of 65.97 µM to 28.39 µM for the chlorosubstituted amide and 74.40 µM to 20.00 µM for the bromo- substituted derivative.
The improvement in activity indicated that an electron rich substituent was vital
for activity for these amide derivatives. Researchers at GlaxoSmithKline reported141,142
the

synthesis

of

some

structurally

analogous

2,9-disubstituted

1,2,3,4-

tetrahydropyrido[3,4-b]indoles (A and B in Figure 4.2) as inhibitors of bacterial enoyl
acyl carrier protein reductase (FabI)141,142. However, no antimalarial activity was
reported for these compounds.
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Figure 4.2- Compounds A and B were reported141,142 by Burgess and Miller as
inhibitors of FABI, and bear a partial resemblance to compounds C which
were synthesised during this project.

Even though the substituents on the benzyl moiety of the compounds vary, their
partial resemblance to those synthesised during this project suggested that the
benzo[b]thiophene amides also acted on the same biological target. A further
substitution of the benzyl functionality in compound 59 with a nitro group at the ortho
position to give 61 saw a 10 fold improvement in activity from 28.89 µM to 18.30 µM,
but an overall large improvement compared to the parent compound 55 (65.97 µM) to
61 (18.30 µM) in the case of the K1 strain. The change in activity value ranged
similarly for the TM4 strain when compared with the K1 strain.
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The novel dihydropyrrole amides 113 and 114 (Scheme 3.14), only exhibited
weak activity against both strains of Plasmodium falciparum (> 50 µM).
From the biological test results (Table 4.1) it is clear that the benzo[b]thiophene
derivatives of the bromo-substituted series generally exhibited a slightly better
antimalarial activity profile compared to their chloro-substituted counterparts. The
increased hydrophobicity of the bromo substituent may enable increased membrane
permeability. This is highlighted by the difference in activity observed between amides
66 and 67 where the bromo- substituted derivative (67) is 9 times more potent than the
analogous chloro- substituted derivative (66) against the K1 strain parasite.

Possible mode of action
The mode of action for the non-fused benzo[b]thiophene amides that exhibited
in vitro activity against the two strains of P. falciparum remains unclear. It is possible
however that some of these compounds may be acting as inhibitors of fatty acid
biosynthesis by blocking the enoyl acyl carrier protein reductase (FabI)27,69, based on
their partial resemblance to some known inhibitors of this bacterial enzyme.
The enoyl acyl carrier protein reductase enzyme is almost exclusively found in
bacteria and is crucial in catalysing the ultimate and rate-limiting step of fatty acid
synthesis69,141. The Plasmodium parasite also possesses this enzyme in the apicoplast
and it is possible that some of the benzo[b]thiophene compounds for example those with
tetrahydrocarbazole functionality could selectively act against the Plasmodium
malarial parasite through inhibition of this enzyme. The crystal structure of the enoyl
acyl carrier protein reductase complexed to the antimalarial triclosan has been
reported27,69 (Figure 1.3). Time constraints prevented further assessment of molecular
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modelling studies to the tetrahydro-β-carboline amides and docking in this structure in
the context of enzyme inhibition studies.

Figure 4.3- Crystal structure of Plasmodium falciparum enoyl-ACP reductase (pfENR)
complexed with an antimalarial inhibitor (triclosan- a known FabI
inhibitor)69.
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4.2.3. In vitro antimalarial activity for the fused benzo[b]thiophene
amides
Ring formation

N

S

Cyclic or
non cyclic

O

Figure 4.4- The generic structure for the fused benzo[b]thiophene amide derivatives.

As mentioned previously in Chapter 3, the underlying principle behind the
synthesis of the fused benzo[b]thiophene amide derivatives was to assess the effects of
increased conformational restriction on biological activity. The ring-fused derivatives
were based on the generic structure shown above (Figure 4.4).
Table 4.2- Antimalarial activities of the fused-ring benzo[b]thiophene amides.

Compound
Number.

Antimalarial activity against the two strains of P.
falciparum. (IC50) values reported in µM and µg/ mL.
K1

TM4

µM
3.63

µg/ mL
2.01

µM
3.32

µg/ mL
1.84

92

3.90

1.00

3.70

0.95

106

14.20

3.08

> 20.00

-

120

> 20.00

-

> 20.00

-

96

> 100.00

-

> 100.00

-

105

Note: For clarity purposes, the standard deviation figures for the IC50 values are not
indicated here; these values are given in the Appendix.

117

OMe
N

S

N

S

O

105

NH

S

O

O

92

106

OH
N

S
O

N

OH

96

S
O

120

The fused benzo[b]thienopyridone 92 showed very promising antimalarial
activity against the two strains of Plasmodium falciparum (IC50 3.90 µM, 3.70 µM
respectively). Compound 92 was only tested as a racemate. It is possible that one of the
enantiomers may be more potent than the other. However due to time constraints the
enantiomers were not prepared and tested.
The allyl group in compound 92 offered a point for further functionalisation with
the potential to substitute with hydrophobic (benzyl and substituted benzyl) moieties as
well as hydrophilic groups through either de-allylation, N-substitution or asymmetric
dihydroxylation. When 92 was transformed to 105, there was an overall improvement
in potency (Table 4.2). The methoxy group in 105 may serve as a H-bond acceptor
group at the ether oxygen or as a hydrophobic group. The compound 105 was identified
in this project as the most potent antimalarial (K1; 3.63 µM and TM4; 3.32 µM) against
both strains of Plasmodium falciparum.
The unsubstituted benzyl derivative 104, although synthesised, was not tested
due to time constraints. The removal of the hydrophobic allyl group in compound 92 led
to a loss of potency (compound 106, K1; 14.20 µM and TM4; > 20 µM). When
hydroxylic groups were introduced in 92, to give the corresponding diol 96, a drastic
reduction in activity was observed. This decrease in potency indicated that hydrophilic
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groups on 96 were unfavourable, through a reduction in membrane permeability or
through steric interactions that are unfavourable for appropriate drug-target interaction.
Unfortunately when the benzo[b]thiophene amide moiety was constrained in a 9membered ring, as in 120, the antimalarial activity was greatly diminished with IC50
values greater than 100 µM against both strains of the test protozoan.

4.2.4. Potential benzo[b]thiophene compounds for future drug
development

Some of the benzo[b]thiophene amides discussed above exhibited very
promising in vitro activity against the two strains of Plasmodium falciparum. Table 4.3
(fold out; pg 120) identifies benzo[b]thiophene compounds with IC50 values of 20 µM
or less.
Compounds 105 and 92 had the greatest potency of all these benzo[b]thiophene
derivatives (Table 4.3) and they are of particular interest because further chemistry to
include different functional groups which could improve their potency, is still possible.
These two compounds provide the basis for new antimalarial lead compounds.
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Table 4.3- Antimalarial IC50 values with a cut off value at < 20µM for the fused and non-fused benzo[b]thiophene amide derivatives.

Compound
Number

Molecular
Weight

Antimalarial activity against two strains of P.
falciparum (IC50) values reported in µM and in
µg/ mL.

Br

OMe
N

S

N

S

O

µM
105

554.72

3.63

TM4 strain

µg/ mL
2.01

µM
3.32
13.70

1.84

3.90

1.00

30

372.20

13.00

4.84

-

-

29

327.82

13.70

4.49

1.22

4.00

106

217.29

14.20

3.08

67

415.34

16.77

40.38

N

N

S

17.90

8.40

18.8

8.82

80

424.99

18.20

7.73

14.3

6.07

61

501.98

18.30

9.18

16.5

8.03

63

425.34

18.39

7.82

18.9

8.03

85

447.77

19.1

8.55

17.2

7.70

60

501.43

20.00

10.03

-

76

488.99

23.20

11.34

15.4

7.53

50

387.88

46.92

18.2

16.5

6.40

HN

O

67
O
Cl

Cl

Br

-

469.44

O

106
HN

N

S

N

S

O

O

81

80

N

S

O

29

-

NH

S

O

0.95

81

N

S

N

O

61
NO2

O
Br

Br
N

85

60
Cl

Cl
N
O

N

O

O
N

N

S
O

63

76

Br

N

N

S

O

-

Cl

O

N

S

S

Note: For clarity purposes, the standard deviation figures for the IC50 values are not

Br

µg/ mL

257.35

-

30

Cl

92

> 20.0

O

O

92

105
K1 strain

N

S

O

OMe
N

S

OMe

O

50

indicated here; these values are given in the Appendix.
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The substitution of 29 on the tetrahydroisoquinoline ring with methoxy groups at
the C6 and C7 positions to give amide 50 saw a marked reduction in potency. However,
other substituent groups at these positions with different electronic activity should still
be investigated. The halogen on the C3 position on the non-fused amides played a vital
role depending on the ring type and the substitution on the ring system, but generally the
bromo-substituted derivatives exhibited better potency.
A difference in potency for the benzo[b]thiophene amides against the K1 strain
and the TM4 strain was apparent with some amides. For example compounds 50 (IC50
K1; 46.92 µM, TM4; 16.5 µM , 76 IC50 K1; 23.20 µM, TM4 15.4 µM) were both more
potent against the TM4 strain, while 106 (K1; 14.20 µM, TM4; >20µM) was more
active against the K1 strain. Compounds 50 and 76 belong to the class of non-fused
benzo[b]thiophene ring system and probably act as antifolates whereas 106 which is a
fused analogue, may bind differently to the drug target.

4.3 Antibacterial testing
4.3.1. Test procedures

The benzo[b]thiophene antibacterial assay studies were carried out on seven
amides against the Staphylococcus aureus and four strains of Enterococcus faecium;
two of these strains were vancomycin resistant (VRE # 449 and VRE # 820) and two
were sensitive to vancomycin although still designated as VRE (VRE # 243 and VRE #
987). The amides were made up in dimethyl sulfoxide (DMSO) and the first test control
was at 2.5 %. The similar tests were also carried out on vancomycin against the same
bacterial cultures, and the results used as a reference. The activities are reported as
Minimum Inhibitory Concentration (MIC) values, in micrograms per millilitre (µg/ mL).
The MIC value is a standard measure of the lowest concentration of the antibiotic that
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results in the inhibition of visible bacteria growth under standard conditions staff at
Avexa Ltd (formally AMRAD, Melbourne) carried out the antibacterial assays. The
results are summarized in Table 4.4 where some of the compounds showing
antibacterial activity are highlighted in colour.
The assay results shown in Table 4.4 indicate that the conformationally
restricted amide 92 was weakly active against Staphylococcus aureus. This amide was
of interest as it had been shown to also have good potency when tested as an
antimalarial (Table 4.2). The conformationally restricted 9-membered derivative 120
showed weak activity against VRE # 820 even though the MIC cut-off point was 125
µg/ mL. The boc-protected amide 63 also showed weak activity against the same culture
(VRE # 820) and perhaps further investigations should be conducted.

Table 4.4- Antibacterial assay results for some selected benzo[b]thiophene amides
against cultures of vancomycin resistant S. aureus and E. faecium.

Antibacterial assay: MIC (µg/ mL)

Compound
number:

E. faecium

S. aureus

29

> 125

VRE # 243 VRE # 449
> 125
> 125

61

> 125

> 125

> 125

> 125

> 125

> 125

> 125

> 125

> 125

92

62.5

VRE # 820
> 125

VRE # 987
> 125

120

> 125

> 125

> 125

> 125, 125

> 125

60

> 125

> 125

> 125

> 125

> 125

30

> 125

> 125

> 125

> 125

> 125

63

> 125

> 125

> 125

125

> 125

Vancomycin

2.5

< 0.98

62.5

> 125

0.98
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Chapter 5 Conclusions and recommendations
Conclusions

A wide range of benzo[b]thiophene amide derivatives were synthesised and
characterised during the course of this project. These derivatives included two
categories based on their molecular framework, the fused benzo[b]thiophenes and the
non-fused benzo[b]thiophene derivatives.
The project was set to design analogues based on the lead molecule 29, and then
to develop a structure-activity relationships with a view to optimising antimicrobial
activity, particularly antimalarial activity. Benzo[b]thiophene analogues based on 29
were then systematically varied to include hydrophobic, aromatic, hydrogen-bond donor
and ionisable groups. Conformationally restricted derivatives were also made. A range
of compounds was then tested for antimalarial activity and a more limited number for
antibacterial activity.
Two categories of benzo[b]thiophene amide analogues were synthesised: the
first was the non-fused category which incorporated different ring systems such as
isoquinoline, tetrahydro-β-carboline, piperazine, piperidine and bridged ring systems in
the nitrogen component of the benzo[b]thiophene amide framework, and the fused-ring
system category which included annulations of the benzo[b]thiophene moiety.

5.2 Non-fused benzo[b]thiophene amides
The non-fused amides were synthesised by coupling reactions involving an acid
or an acid chloride with appropriate amines, giving chloro substituted and bromosubstituted analogues. The bromo-substituted analogues required the use of the coupling
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reagents DCC/ HOBt under specified appropriate conditions to yield the desired amides.
An array of benzo[b]thiophene amides were synthesised this way.
The in vitro antimalarial (Plasmodium falciparum) testing of the non-fused
benzo[b]thiophene derivatives revealed some active compounds (Chapter 4, Table 4.1)
which were further modified and their potency improved. For example, the amide 55,
was transformed to 59 then to 61 with a remarkable improvement in potency. The most
potent

antimalarial

amide

found

was

2-(4-methoxybenzyl)-4-methyl-1,2,3,4-

tetrahydrobenzo[4,5]thieno[2,3-c]pyridin-1-one (105).

5.2.1. Future directions for the non-fused benzo[b]thiophene amides
The future work for the non-fused benzo[b]thiophene amides (Chapter 2) should
ensure the synthesis of analogues with a wider range of substituent groups. Substitution
with appropriate groups that would potentially offer better drug/ target interactions and
hence improved anti-malarial activity should be probed.
Further chemistry on compounds substituted with a benzyl moiety (49, 59, 60,
61, 66 and 67) need to be explored to include other lipophilic groups since the test
results suggested this functionality could be a key pharmacophoric element for these
amides, especially on compounds exhibiting good antimalarial activity (61 and 67).
The allylation of aldimines (Chapter 2, Scheme 2.7) was a challenge during this
project, especially upon substitution of the C6 and C7 positions with methoxy groups,
hence other alternative pathways towards synthesising substituted 1-allyl-1,2,3,4tetrahydroisoquinoline intermediates should be investigated.
The use of Group 4 metal triflates as Lewis acids in the allylation of aldimines
has been reported with exceptionally good yields. Even though a related reaction was
attempted for the synthesis of 34 during the course of the project, (Chapter 3, Scheme
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3.18) there is a need to look into triflates such as those of hafnium, zirconium and
scandium with the use of appropriate allyltributylstannanes in order to improve yield for
these intermediates.
The synthesis of amides with substitution on the benzo[b]thiophene ring system
should also be investigated further since, during this project only a single amide (58) of
this nature was synthesised due to time constraints. Other derivatives bearing
functionalities such as methoxy, o-, m-, p-nitro- and/or hydroxyl groups should be
investigated.
The synthesis of bromo- substituted amide derivatives using DCC/ HOBt
coupling methods gave moderate yields but, alternate reagents such as polymer
supported HOBt or even the more beneficial 7-aza-1-hydroxybenzotriazole (HOAt)
which are commercially available could be employed to improve yield and purity of
these amides.
Finally, future work on other chiral benzo[b]thiophene derivatives such as 84
and 85 containing bridged ring systems should also be investigated to allow the
assessment of in vitro studies as antimalarials.

5.3 Fused benzo[b]thiophene amides.
The ring fused amides involved the synthesis of conformationally restricted
heterocyclic molecules (Chapter 3) with the intention of affording better specificity in
their biological potency. To attain these fused ring derivatives, free radical reactions
involving tributyltin hydride and AIBN, palladium-mediated reactions, and ring closing
metathesis reactions using Grubbs’ I catalyst were pursued.
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A new approach to the 1,2,3,4-tetrahydrobenzo[b]thieno[2,3-c]pyridine-1-one
system via free radical cyclisation was established. The application of this radical
cyclisation synthesis to 79 and 53 produced the new compounds 92 and 112
respectively which were crucial to the project (Scheme 3.4 and 3.11).
Benzylated derivatives 104 and 105 were isolated in good yields from 92 and the
IC50 value for 105 was significantly enhanced making it the most biologically active
benzo[b]thiophene derivative. Compound 92 was deallylated to afford 106. This latter
compound is of particular importance because it offers a reactive site where further
substituents can be attached with ease, compound 106 was also found to be moderately
active against the K1 strain of the Plasmodium falciparum parasite (14.20 µM).
Attempts to further modify 92 to the corresponding diol 96 using Sharpless
chemistry initially failed, however an alternative pathway towards a racemic diol using
the osmium tetroxide/ NMO reagent combinations was successful. Compound 96 was,
however, found to be inactive IC50 >100 µM against both strains of the protozoan
Plasmodium falciparum. However, this data remains useful for analysing the structure
activity relationships.
Palladium assisted intramolecular ring closure of benzo[b]thien-2-yl)(1H-indol1-yl)methanone intermediates 124 and 125 gave the novel derivative 126, a highly
strained and planar molecule (Scheme 3.21).
The ring-closing metathesis reaction using Grubbs` I catalyst was used to cyclise
benzo[b]thiophene derivatives with multiple olefinic groups such as 118, 78 and 79.
The use of polymer supported Grubbs’ I ruthenium catalyst improved the yield and
purity of the derivatives and was hence preferred over the homogeneous catalyst.
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The ring closure of compound 118 via metathesis gave the novel 9-membered
benzo[b]thiophene ring system derivative 120. The successful synthesis of 120 was
seen as a new approach towards synthesising conformationally restricted and larger ring
heterocyclic systems. Lactam 120 retains an olefinic double bond which can be further
functionalised. The tetrahydroisoquinoline ring remains open for functionalisation and
in fact, attempts to model the compound to include methoxy groups at the C6 and C7
positions was attempted, however due to time constraints the substituted 9-membered
precursor 119 was not cyclised to its final derivative 121. The compound 120 was found
to have antimalarial IC50 values > 20 µM.

5.3.1. Future directions for the fused benzo[b]thiophene amides
Free radical cyclisation approach marked the synthesis of the most biologically
active fused benzo[b]thiophene derivatives; this important discovery should be pursued
further to investigate possible modifications of the derivatives, in order to enhance
potency. Analogues of 105, the most active derivative should be investigated where
different functional groups could be substituted on the benzyl ring to potentially
enhance activity. The same approach could be applied to 92 where the allyl group
remains available for functionalisation. In vitro antimalarial studies for 105 were
performed on an unresolved sample, hence the enantiomers of 105 should be isolated
and tested to probe enatiomeric potency differences.
Synthetic routes towards the deallylated derivative 106 should also be
investigated further to increase yields of this compound.
The chemistry of products related to 126 acquired through palladium assisted
reactions should also be extended to include derivatives with substituents on either the
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benzo[b]thiophene and/ or the indolic motif. The in vitro antimalarial studies on such
planar molecules should also be investigated.
Ring closing metathesis towards the fused 9-membered compounds and their
derivatives was not fully completed and further research is warranted. The attempt to
synthesise the precursor 122 which could then give access to an 8-membered ring
derivative failed (Scheme 3.21), and this should be investigated further. The synthetic
method depicted under Scheme 3.21 for the synthesis of 122 requires further assessment
where alternative reagents and methods could be used.

5.4 Future work on in vitro studies
The in vitro antimalarial studies were carried out on a number of the
benzo[b]thiophene derivatives mentioned in this thesis. The results were varied but had
a consistent trend and several compounds showed their potential as future leads as
antimalarial drugs (Table 4.3).
The biological activity for these compounds was carried out against the K1 CB1
and TM4 8/2 strains of the Plasmodium falciparum parasite (Chapter 4). The mode of
action for these compounds remains unclear hence a detailed assessment on the mode of
action should be undertaken.
From the wide range of benzo[b]thiophene amides synthesised and tested during
this project, a training set for molecular modelling studies could be generated and a
pharmacophore developed in order to offer a greater understanding for lead
modification with the purpose of improving drug/ target interactions.
The crystal structure of one proposed drug target (FabI, Chapter 4, Figure 4.3)
for these amides is now well documented, hence docking studies should be carried out
to provide an insight on the nature and behaviour of the discussed benzo[b]thiophene
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derivatives. Finally, human cell toxicity testing of the active amides should also be
assessed.
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Chapter 6 Experimental
General
6.1.1. Solvents and Reagents
Reagents were purchased from Sigma-Aldrich Pty Ltd, Lancaster or Merck
and were used as supplied except for those compounds purchased as their acid salts
which were converted into their free base before use in the procedure described
below.
Tetrahydrofuran and diethyl ether were distilled from sodium in the presence
of benzophenone.

Toluene was distilled from anhydrous calcium hydride.

Dichloromethane and hexanes were distilled and stored over molecular sieves (4 Å).
When dry dichloromethane was required it was distilled over anhydrous calcium
chloride. Anhydrous dimethylformamide was purchased from Sigma-Aldrich Pty Ltd
in a Sure-seal® bottle and was stored under an inert atmosphere and used as supplied.
Petroleum ether refers to hexanes with a boiling range between 60 oC and 80 oC while
ether refers to diethyl ether. All other solvents were used as supplied.

Generation of free bases.
The purchased salt was dissolved in water (20 mL), placed on an ice bath and
basified with ammonia solution to pH 11. The free base was then extracted with
dichloromethane, dried over anhydrous sodium sulfate and the solvent was evaporated
to afford the free base.
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6.1.2. Nuclear Magnetic Resonance Spectroscopy
1

H-NMR spectra.
Unless otherwise stated, proton NMR spectra were acquired on a Varian Unity

300 NMR spectrometer running at 299.5 MHz at 298 K. Chemical shifts are quoted
in δ values in ppm shift relative to TMS in CDCl3, D2O, CD3COCD3 or d6-DMSO.
Some spectra (stated in the text) were acquired on a Varian Innova (500.6 MHz).
Coupling constants (J) are reported in Hertz, with signal multiplicity designated as
singlet (s), doublet (d), doublet of doublets (dd), triplet (t), quartet (q), quintet (qn),
sextet (sx), multiplet (m) and broad (b). The order in which the signal is described in
the text is d, multiplicity, coupling constant(s), assignment and number of protons
(integral). For example – 7.34 (d, J = 3 Hz, H-a, 2H). The samples were prepared by
dissolving approximately 5-6 mg of the products in CDCl3, D2O, CD3COCD3, or d6DMSO.
13

C-NMR spectra
Unless otherwise stated,

13

C-NMR spectra were acquired on a Varian Unity

300 NMR spectrometer running at 74.99 MHz at 298 K. Some spectra (stated in the
text) were acquired on a Varian Innova (125.1 MHz). Completely proton decoupled
spectra were recorded. Chemical shifts are quoted in δ values in ppm shift relative to
TMS in CDCl3, D2O, CD3COCD3 or d6-DMSO.

Mass spectrometry
Low-resolution chemical ionization (isobutane, CI+) mass spectroscopy
(LRMS) were obtained on a Shimadzu CC-17A gas chromatograph equipped with a
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QP-5000 mass spectrometer and CI-50 chemical ionization controller. The direct
probe insertion method was used to acquire data.
High-resolution mass spectra (HRMS) (methane CI+ and EI+) were determined on a
VG Autospec spectrometer using PFK (Perfluorokerosene) as the reference.

UV spectrometry
UV spectra (solvent corrected) were recorded on a Shimadzu 2401-PC UVVIS spectrophotometer.

Melting points
The melting point (Mp.) determinations were recorded on a Reichert melting
point apparatus and are reported uncorrected.

6.1.3. Miscellaneous

The term routine workup refers to the extraction of crude products into organic
solvent several times from water, combining the organic fractions, drying over
anhydrous sodium sulfate followed by gravity filtration and evaporation under
reduced pressure (in vacuo) using a Büchi rotary evaporator.

Crystal growth
After column chromatography fractions containing the amide derivative were
pooled and concentrated in vacuo. The product was then dissolved in minimal volume
of absolute alcohol (unless otherwise stated) and warmed on hot water bath till
completely dissolved, the resulting solution was left to cool slowly overnight. Crystals
were collected via vacuum filtration on a sintered funnel, washed at least twice with
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minimal cold distilled hexane and dried under vacuum. The X-ray crystallography
was undertaken by Prof. A.H. White at the University of Western Australia.

6.1.4. Chromatography
Column chromatography was performed using silica gel 60 (230-400 mesh,
Merck) or neutral alumina (activated Brockmann 1, standard grade ~150 mesh, 58 Å,
Aldrich) Reactions were monitored with thin layer chromatography (0.25 mm
aluminium backed silica gel plates) using analytical grade solvents. Chromatographic
solvent mixtures are quoted as volume ratios.

Column chromatography was

performed with the indicated solvents freshly distilled over molecular sieves (4 Å).

Preparative plate
Pre-made silica plates with aluminium backing (0.2 mm thickness) supplied
by Merck were used for separating smaller quantities of isolates. Visualization of the
separated bands on preparative TLC plates was done using short and long wave UV
light.

6.1.5. Biological testing
Antimalarial activity
In-vitro

biological

tests

were

undertaken

by,

Dr.

Sumalee

Kamchonwongpaisan, National Centre for Genetic Engineering and Biotechnology
(BIOTEC) and the National Science and Technology Development Agency
(NSTDA), Bangkok. These tests were carried out against the double mutant K1 CB1
strain, which is a multidrug resistant/ antifolate resistant Plasmodium falciparum, and
a wild type antifolate sensitive strain TM4/ 8.2 of Plasmodium falciparum.
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The activity was recorded as an IC50 value in µM: on the concentration of a compound
required to kill 50 % of the malarial parasites.

Antibacterial activity
The antibacterial testing was carried out against the Staphylococcus aureus
and four strains of Enterococcus faecium. Two on these strains were vancomycin
resistant and the other two sensitive too vancomycin although designated as VRE.
The staff at Avexa Ltd (formally-Amrad, Melbourne) carried out the antibacterial
assays through Dr. J. Deadman. The test samples were made up in dimethyl sulfoxide
(DMSO) and the first test control carried out at 2.5 % and referenced against
vancomycin as the control. The activities are reported in Minimum Inhibitory
Concentration (MIC) values, in micrograms per millilitre (µg/ mL). The MIC value is
a standard measure of the lowest concentration of the antibiotic that results in the
inhibition of visible bacteria growth under standard conditions.
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6.2 Synthetic Procedures
6.2.1. Experimental for Chapter 2: The synthesis of non-fused
benzo[b]thiophene amides.

Synthesis of 3-chlorobenzo[b]thiophene-2-carbonyl chloride (23)143,144.

Cl

Thionyl chloride (5.0 mL, 67.56 mmol) was added to a
solution of (E)-cinnamic acid (2.0 g, 1.35 mmol), in pyridine

S

COCl

(0.3 mL, 1.8 mmol) and toluene (22.2 mL, 20.92 mmol). The

stirred reaction mixture was heated at reflux under nitrogen for 60h after which, it was
quenched in ice water.

The acid chloride was extracted with distilled

dichloromethane (2x 25 mL, 2x 10 mL) and the combined organic extracts washed
with distilled water (2x 20 mL) and dried. The solvent was evaporated under reduced
pressure yielding a crude yellow residue which was purified using flash silica gel
chromatography with dichloromethane and recrystallised from dichloromethane:
hexane to afford colourless needles of 23 (1.35 g, 43 %). Mp. 115-116 oC, (Lit.143 Mp:
114-116 oC). Mass spectrum (CI+), m/z 231 [MH+1,

35

Cl]. 1H-NMR (CDCl3, 300

MHz): 7.46 (m, 2H), 7.73 (d, J = 6 Hz, 1H), 7.89 (d, J = 6 Hz, 1H). 13C-NMR: 134.6
(C2), 129.65 (C3), 125.62 (C4), 126.59 (C5), 126.73 (C6), 122.91 (C7) and 157.88
(C=O).
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Synthesis of 3-chloro-5-methoxybenzo[b]thiophene-2-carbonyl chloride
(24)143.
MeO

Thionyl chloride (10.0 mL, 136 mmol) was added to a

Cl

solution of 5-methoxy-(E)-cinnamic acid (4.8 g, 26.96
S

COCl

mmol), in pyridine (0.3 mL, 1.8 mmol) and toluene

(50 mL, 47.11 mmol). The stirred reaction mixture was refluxed under nitrogen for 48
h after which it was quenched in ice water and toluene evaporated in vacuo. The acid
chloride was extracted with distilled dichloromethane (2x 25 mL, 2x 10 mL) and the
combined organic extracts washed with distilled water (2x 20 mL) and dried. The
solvent was evaporated under reduced pressure yielding a crude yellow residue which
was purified using flash silica gel chromatography with dichloromethane to afford 24
(2.62 g, 50 %) as yellow needles. Mp. 141-143 oC, (Lit.143 Mp: 143-144 oC). Mass
spectrum (CI+), m/z 261 [MH+1, 35Cl].
1

H-NMR (CDCl3, 300 MHz): 4.01 (s, -OCH3), 7.26 (qn, J = 2.85 Hz, 1H), 7.38

(bs, 1H), 7.7 (d, J = 8.7 Hz, 1H), 13C-NMR: 56.0 (OCH3), 104.6 (C4), 122.1 (C6),
123.9 (C7) and158.9 (C=O).

Synthesis of 3-bromobenzo[b]thiophene-2-carboxylic acid (25).
Br

Bromine (2.48 g, 31.4 mmol) was added drop wise to a
solution of commercially acquired benzo[b]thiophene-2-

S

COOH

carboxylic acid (20) (1.0 g, 5.61 mmol), and anhydrous

sodium acetate (1.0 g, 12.1 mmol) in glacial acetic acid (35 mL). The reaction mixture
was stirred at 55 oC under a reflux condenser in a nitrogen atmosphere over 24h. The
mixture was poured in ice water and the resulting precipitate filtered under reduced
pressure and then washed with distilled water (3x 25 mL) followed by cold ethanol
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(25 mL) to afford a colourless solid. The product was then oven-dried for 10 minutes
and recrystallised from hot acetone to afford 25 (0.70 g, 49 %) as colourless needles.
Mp. 280-283 oC. Mass spectrum (CI+), m/z 257 [MH+1, 79Br]. 1H-NMR (CD3COCD3,
300 MHz): 7.58-7.67 (m, 2H, Ar-H5 and H6), 7.99-8.05 (m, 2H, ArH4 and H7).
13

C-NMR: 115.2 (C3), 122.8 (C7), 125.5 (C5), 125.8 (C6), 128.3 (C2), 138.7 (C3a),

139.4 (C7) and 161.9 (C=O).

Synthesis of benzo[b]thiophene-2-carbonyl chloride (26).

Thionyl chloride (0.81 mL, 11.1 mmol) was added to a
Cl

S
O

solution of the commercially available benzo[b]thiophene2-carboxylic acid (20) (0.4 g, 2.24 mmol), in pyridine (0.3

mL, 1.8 mmol) and toluene (15 mL, 14.1 mmol) at reflux. The reaction mixture was
quenched in ice water and the toluene evaporated in vacuo. The acid chloride was
extracted with distilled dichloromethane (2x 25 mL, 2x 10 mL) and the combined
organic extracts washed with distilled water (2x 20 mL) and dried over anhydrous
sodium sulfate. The solvent was evaporated under reduced pressure to a brown
residue of which was purified using flash chromatography with dichloromethane to
yield 26 (0.27 g, 61 %) as a colourless solid. Mass spectrum (CI+), m/z 196 [MH+1,
35

Cl]. 1H-NMR (CDCl3, 300 MHz): 7.50 (m, 2H), 7.91 (m, 2H), 8.27 (s, 1H).

13

C-

NMR: 123.1 (C3), 125.9 (C7), 126.9 (C4), 128.9 (C5 and C6), 136.1 (C2), 138.3
(C3a), 144.3 (C7) and 161.9 (C=O).
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Synthesis of 3-bromobenzo[b]thiophene-2-carbonyl chloride (27).
4
3a

5

3

In the same manner as that reported for 26, reaction of 25

Br

(0.60 g, 2.33 mmol) yielded 27 after chromatography (DCM)

7a

6
7

S

2

COCl

1

as a colourless solid (0.43 g, 67 %). Mass spectrum (CI+),

m/z 276 [MH+1, 35Cl 79Br]. 1H-NMR (CDCl3, 300 MHz): 7.58-7.67 (m, 2H, ArH- H5
and H6), 7.99-8.05 (m, 2H, ArH- H4 and H7).

13

C-NMR: 115.2 (C3), 122.8 (C7),

125.5 (C5), 125.8 (C6), 128.3 (C2), 138.7 (C3a), 139.4 (C7), and161.9 (C=O).

Attempted synthesis of 3-bromobenzo[b]thiophene-2-carbonyl bromide (28).
Thionyl bromide (4.0 mL, 51.00 mmol) was added to a

Br

Br

S
O

solution of (E)-cinnamic acid (1.0 g, 0.675 mmol), in
pyridine (0.3 mL, 1.8 mmol) and toluene (22.2 mL, 20.92

mmol). The stirred reaction mixture was heated at reflux under nitrogen for 60h after
and then quenched in ice water. The crude residue was extracted with distilled
dichloromethane (2x 25 mL, 2x 10 mL) and the combined organic extracts washed
with distilled water (2x 20 mL) and dried. The solvent was evaporated under reduced
pressure yielding a crude dark brown residue (Rf 0.8, 3 % ethyl acetate: hexane)
which was purified using flash silica gel chromatography with dichloromethane to
afford dark brown solid (0.56 g, 27 %). However, the data collected on the isolated
product was not consistent with that of the expected product. Mp. 113-114 oC. Mass
spectrum (CI+), m/z 289, expected: 318 [MH+1], m/z 257, 203, 178 and 160. 1H-NMR
(CDCl3, 300 MHz): 1. 25 (t), 1.6 (bs), 3.73 (q, J = 7 Hz), 5.25 (s) and 7.26 (s).
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Synthesis of 3,4-dihydroisoquinoline (36)145,146.
1,2,3,4-tetrahydroisoquinoline (31) (3.0 g, 22.55 mmol) was
dissolved in dichloromethane (50 mL) under nitrogen. To this
N

stirred solution, N-bromosuccinimide (4.41 g, 24.82 mmol) was

gradually added over 20 minutes. The mixture was stirred at room temperature for one
and half-hours. Sodium hydroxide solution (15 mL, 30 %) was added and stirring
continued for one hour. Distilled water (20 mL) was added to the mixture, and stirred
for a further 15 minutes. The two phases were separated and the aqueous phase
washed with dichloromethane (20 mL). Combined organic phases were washed with
water (25 mL) and extracted with 2 M hydrochloric acid (2x 30 mL, 15 mL).
Combined aqueous extracts were washed with dichloromethane (25 mL) and basified
to pH 11 with concentrated ammonia solution, this afforded a yellow oil which was
back extracted with dichloromethane (20 mL, 2x 15 mL), dried and the solvent
evaporated under reduced pressure. The yellow oil was distilled under reduced
pressure on a kugelrohr distillation apparatus and 36 (2.32 g, 79 %) was collected at
140 oC between 50-70 mbar as a clear oil which turned light yellow on standing. Mass
spectrum (CI+), m/z 132 [MH+1]. 1H-NMR (CDCl3, 300 MHz): 2.71 (t, J = 7.8 Hz,
2H, H4), 3.74 (t, J = 6.6 Hz, 2H, H3), 7.12 (d, J = 7.5 Hz, 1H, H8), 7.21-7.34 (m, 3H,
H5, H6 and H7) and 8.31 (s, 1H, H1).

13

C-NMR: 25.2 (C4), 47.5 (C3), 127.2 (C7),

127.3 (C5), 128.6 (C8), 131.2 (C6), 136.4 (C8a) and 160.4 (C1).
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Basification of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride
(33)147,148.
The

hydrochloride

salt

of

6,7-dimethoxy-1,2,3,4-

MeO

tetrahydroisoquinoline hydrochloride (33) (3.0 g, 13.1
MeO

NH

mmol), obtained from Sigma-Aldrich, was dissolved in

water (20 mL) and placed on an ice bath and basified with ammonia solution to pH
11. The product was extracted with dichloromethane (2x 30 mL, 15 mL), washed
once with water (20 mL) and dried over anhydrous sodium sulfate. Pooled organic
solvents were evaporated to dryness on the rotary evaporator to afford a clear oil. The
oil was further dried in vacuo to afford a white solid of the free-base 33 (2.50 g, 98
%). Mp. 82-84 oC. Mass spectrum (CI+), m/z 194 [MH+1]. 1H-NMR (CDCl3, 300
MHz): 2.75 (t, J = 7.8 Hz, 2H, H4), 3.15 (t, J = 6.6 Hz, 2H, H3), 3.83 (s, 6H, 2x
CH3), 3.97 (s, 1H, H1), 6.51 (s, 1H, ArH- H5), 6.58 (s, 1H, ArH- H8).

13

C-NMR:

25.0 (C4), 47.5 (C3), 56.3 (2x O-CH3), 111.2 (C7), 128.6 (C8), 130.3 (C4a), 147.5
(C5) and 151.0 (C6).

Synthesis of 6,7-dimethoxy-3,4-dihydroisoquinoline (37)149.
The amine 33 (1.0 g, 1.58 mmol) was dissolved in

MeO

MeO

N

dichloromethane (50 mL) under nitrogen. To this stirred
solution, N-bromosuccinimide (1.0 g, 5.64 mmol) was

gradually added over 20 minutes. The mixture was stirred at room temperature for one
and half-hours. Sodium hydroxide solution (15 mL, 30 %) was added and stirring
continued for one hour. Distilled water (20 mL) was added to the mixture, and stirred
for a further 15 minutes. The two phases were separated and the aqueous phase
washed with dichloromethane (20 mL). Combined organic phases were washed with
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water (25 mL) and extracted with 2 M HCL (2x 30 mL, 15 mL). Combined aqueous
extracts were washed with dichloromethane (25 mL) and basified to pH 11 with
concentrated ammonia solution, this afforded a yellow oil which was back extracted
with dichloromethane (20 mL, 2x 15 mL), dried over anhydrous sodium sulfate and
the solvent evaporated under reduced pressure to afford 37 (0.74 g, 75 %) as an oil.
Mass spectrum (CI+), m/z 192 [MH+1]. 1H-NMR (CDCl3, 300 MHz): 2.67 (t, J = 7.8
Hz, 2H, H4), 3.70 (t, J = 6.6 Hz, 2H, H3), 3.90 (s, 6H, 2x CH3), 6.67 (s, 1H, ArHH5), 6.81 (s, 1H, ArH- H8), 8.23 (s, 1H, H1).

13

C-NMR: 24.9 (C4), 47.5 (C3), 56.2

(2x O-CH3), 110.5 (C7), 128.3 (C8), 130.0 (C4a), 147.9 (C5), 151.3 (C6) and 159.8
(C1).

Synthesis of 1-allyl-1,2,3,4-tetrahydroisoquinoline (32)150,151.
Allyl bromide (1.83 g, 15.25 mmol) was added to a stirred

4

5
6

4a
8a

7

3

NH 2

1

8
2'

3'

1'

suspension of zinc powder (1.00 g, 15.38 mmol) in dry
tetrahydrofuran (20 mL) under nitrogen. The mixture was
cooled to 0

o

C where 36 (2.00 g, 15.03 mmol) in dry

tetrahydrofuran (30 mL) was added gradually and stirring

maintained for two days. Saturated sodium bicarbonate solution (25 mL) was added
and the mixture stirred for 15 minutes before being filtered through celite. Organic
solvent was removed under reduced pressure and the resulting aqueous mixture
extracted with dichloromethane (25 mL, 10 mL). The combined organic mixtures
were extracted with 2 M hydrochloric acid, (2x 25 mL). Combined aqueous portions
were washed with dichloromethane (25 mL), basified with ammonia solution to pH
11 on an ice bath, and then back extracted with dichloromethane (2x 25 mL, 15 mL).
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Combined organic phases were dried, and solvent evaporated under reduced pressure
to afford 32 (1.55 g, 59 %) as pale yellow oil. Mass spectrum (CI+), m/z 174 [MH+1].
1

H-NMR (CDCl3, 300 MHz): 2.63; 2.49 (m, 2H, H1`), 2.69 (qn, J = 1.72 Hz, 2H,

H4), 2.93 (qn, J = 4.05 Hz, 2H, H3), 5.15 (m, 2H, H3`), 5.81 (m, 1H, H2`), 4.03 (t, J
= 4.5 Hz, 1H, H1), 7.05-7.16 (m, H5, H6, H7 and H8).

13

C-NMR: 30.2 (C4), 40.9

(C3), 41.3 (C2`), 55.3 (C1), 118.1 (C3`), 126.0 (C7), 126.2 (C5), 129.5 (C5 and C8),
135.6 (C1`), 135.9 (C8a), and 138.9 (C4a).

Synthesis of 1-allyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (34)150.
MeO

MeO

Allyl bromide (0.42 g, 3.57 mmol) was added to a stirred

4

5
6

3

NH 2

1

7
8

suspension of zinc powder (0.24 g, 3.76 mmol) in dry
tetrahydrofuran (20 mL) under nitrogen. The mixture was

2'

3'

1'

cooled to 0 oC where 37 (0.73 g, 3.78 mmol) in dry
tetrahydrofuran (30 mL) was added gradually and stirring

maintained for 3 days. Saturated sodium bicarbonate solution (25 mL) was added and
the mixture stirred for 15 minutes before being filtered through celite. Organic solvent
was removed in vacuo and the resulting aqueous mixture extracted with
dichloromethane (30 mL, 10 mL). The combined organic mixtures were extracted
with 2 M hydrochloric acid, (2x 25 mL). Combined aqueous portions were washed
with dichloromethane (25 mL), basified with ammonia solution to pH 11 on an ice
bath, and then back extracted with dichloromethane (2x 25 mL, 2x 15 mL). Combined
organic phases were dried and solvent evaporated to dryness to afford 34 (0.38 g, 42
%) as a dark oil. Mass spectrum (EI), m/z 233. 1H-NMR (CDCl3, 300 MHz): 2.412.68 (m, 2H, H1`), 2.87 (m, 2H, H4), 3.14 (m, 2H, H3), 3.64 (t, J = 7.95 Hz, 1H, H1),
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3.76 (bs, 6H, CH3), 5.08 (t, J = 12 Hz, 2H, H3`), 5.76 (m, 1H, H2`), 6.49 (s, 1H, ArHH5), 6.57 (s, 1H, ArH- H8), 8.23 (s, 1H, H1). 13C-NMR: 26.9 (C4), 38.8 (C1`), 38.6
(C3), 44.8 (C1), 53.5 (CH3), 108.0 (C5), 109.4 (C8), 115.5 (C3`), 127.9 (C8a), 133.1
(C2`), 144.8 (C7) and 145.0 (C6).

Boron trifluoride etherate/ allyltributyltin approach to 1-allyl-6,7-dimethoxy1,2,3,4-tetrahydroisoquinoline (34).
Boron trifluoride etherate (0.30 mL, 2.12 mmol) was added to a stirred suspension of
the amine 37 (0.41 g, 2.13 mmol) and zinc powder (0.13 g, 2.00 mmol) in anhydrous
dichloromethane at minus 78 oC (liquid nitrogen: chloroform) under nitrogen. The
suspension was then warmed to 10 oC over a period of 20 minutes and then re-cooled
to minus 78 oC. Allyltributyltin (0.7 mL, 2.11 mmol) was slowly added to the
suspension and the mixture warmed to room temperature with continued stirring
overnight. Saturated sodium bicarbonate solution (20 mL) was added and the mixture
stirred for 15 minutes before being vacuum filtered through celite. Organic solvent
was removed in vacuo and the resulting aqueous mixture extracted with
dichloromethane (30 mL, 10 mL). The pooled organic mixtures were extracted with 2
M hydrochloric acid, (2x 25 mL). Combined aqueous portions were washed with
dichloromethane (25 mL), basified with ammonia solution to pH 11 on an ice bath,
and back extracted with dichloromethane (2x 25 mL, 2x 15 mL). Combined organic
phases were dried and solvent evaporated to under reduced pressure to give 34 (0.39
g, 80 %) as an oil. Mass spectrum (EI), m/z 233 [MH+1].

1

H-NMR (CDCl3, 300

MHz): 2.40-2.65 (m, 2H, H1`), 2.85 (m, 2H, H4), 3.14 (m, 2H, H3), 3.64 (t, J = 7.9
Hz, 1H, H1), 3.76 (bs, 6H, CH3), 5.08 (t, J = 12 Hz, 2H, H3`), 5.76 (m, 1H, H2`), 6.49
(s, 1H, ArH- H5), 6.57 (s, 1H, ArH- H8), 8.23 (s, 1H, H1).

13

C-NMR: 26.9 (C4),
144

38.8 (C1`), 38.6 (C3), 44.8 (C1), 53.5 (CH3), 108.0 (C5), 109.4 (C8), 115.5 (C3`),
127.7 (C8a), 133.3 (C2`), 145.0 (C7) and 145.0 (C6).

Synthesis of 1-benzyl-1,2,3,4-tetrahydroisoquinoline (35)150,152.
Benzyl bromide (0.43 g, 2.52 mmol) was added to a stirred
NH

suspension of zinc powder (0.14 g, 2.14 mmol) in dry
tetrahydrofuran (15 mL) under nitrogen. The temperature was
adjusted to 0oC after which freshly prepared 36 (0.30 g, 2.29 mmol)

in dry tetrahydrofuran (30 mL) was added gradually. The mixture was warmed to
room temperature and stirring continued for two days. Saturated sodium bicarbonate
solution (25 mL) was added and the mixture stirred for 15 minutes before being
filtered through celite. Organic solvent was removed under reduced pressure and the
resulting aqueous mixture extracted with dichloromethane (25 mL, 10 mL). The
combined organic mixtures were extracted with 2 M hydrochloric acid, (2x 20 mL).
Combined aqueous portions were washed with dichloromethane (20 mL), basified
with ammonia solution to pH 11 on an ice bath, and then back extracted with
dichloromethane (2x 25 mL, 15 mL). Combined organic phases were dried, and
solvent evaporated under reduced pressure to give compound 35 (0.14 g, 29 %) as an
oil. Mass spectrum (CI+), m/z 224 [MH+1]. 1H-NMR (CDCl3, 300 MHz): 2.69 (qn, J
= 1.72 Hz, 2H, H4), 2.93 (qn, J = 4.05 Hz, 2H, H3), 4.03 (t, J = 4.5 Hz, 1H, H1), 5.31
(s, 2H, CH2-benzyl), 7.05-7.16 (m, H5, H6, H7 and H8), 7.28-7.35 (m, 5H, benzyl).
13

C-NMR: 30.2 (C4), 40.9 (C3), 55.3 (C1), 58.5 (CH2, benzyl), 126.0 (C7), 126.2

(C5), 129.5 (C5 and C8), 130.1 (C4”) 132.2 (C2”, C3”, C5” and C6”), 135.9 (C8a),
and 138.9 (C4a).
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Synthesis of 2-(3-chlorobenzo[b]thien-2-oyl)-1,2,3,4-tetrahydroisoquinoline
(29).
1,2,3,4-tetrahydroisoquionoline (31) (0.5 g, 4.48

Cl

mmol), was slowly added to the acid chloride 23 (1.0

N

S

g, 4.34 mmol) and anhydrous potassium carbonate

O

(1.0 g, 7.24 mmol), in dry tetrahydrofuran (30 mL). The mixture was heated at reflux
under nitrogen for two and half-hours. The mixture was cooled, filtered to remove
unreacted potassium carbonate, and solvent evaporated in vacuo to give an oil, which
was recrystallised from hot ethanol to yield 29 (0.84 g, 59 %). Mp. 120-121 oC. Mass
spectrum (CI+), 328 [MH+1,

35

Cl]. HRMS (CI+): Found: 328.0571; required:

328.0577 for C18H1435ClNOS. 1H-NMR (CDCl3, 300 MHz): 2.93 (bs, 2H, -CH2)
4.04; 3.70 (bs 2H, N-CH2), 4.96; 4.64 (bs, 2H, N-CH2), 7.20 (bs, 4H, ArH), 7.47 (m,
2H, H5 and H6), 7.83 (m, 2H, H4 and H7). 13C-NMR: 28.3, 30.0, 41.5 (CH2); 119.2,
122.6, 122.8, 125.5, 126.4, 128.2, 132.2 (Ar-CH); 135.8 (C2), 137.8 (C3) and 163.1
(C=O).

Synthesis of 2-(3-bromobenzo[b]thien-2-oyl)-1,2,3,4-tetrahydroisoquinoline
(30).
The isoquinoline 31 (0.26 g, 1.95 mmol) was added

Br

N

S
O

to a mixture of 25 (0.5 g, 1.95 mmol), 1,3dicyclohexylcarbodiimide (0.40 g, 1.94 mmol), and

1-hydroxybenzotriazole (0.32 g, 2.37 mmol) in dry DMF (20 mL). The mixture was
stirred at room temperature under nitrogen within 24h. The precipitated
dicyclohexylurea was removed by vacuum filtration. Solvent was then evaporated
under reduced pressure to give an oily residue, which was then taken up in ethyl
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acetate (30 mL), and traces of the urea removed by filtration. The filtrate was then
washed with distilled water (50 mL), dried and the solvent evaporated to give a
yellow oil. Re-crystallisation from absolute alcohol afforded white crystals of 30
(0.59 g, 82 %). Mp.101-103 oC. Mass spectrum (CI+), 372 [MH+1,81Br]. HRMS (EI)
Found: 372.9959 (4.8 ppm), required: 372.9941 for C18H14

81

BrNOS. 1H-NMR

(CDCl3, 300 MHz): 2.98 (bs, 2H, CH2), 4.09; 3.73 (bs 2H, N-CH2), 4.96; 4.60 (bs,
2H, N-CH2), 7.21 (bs, 4H, ArH), 7.85 (m, 2H, H4 and H7), 7.49 (m, 2H, H5 and H6).
13

C-NMR: 28.3, 30.0, 41.5 (CH2); 119.2, 122.6, 122.8, 125.5, 126.4, 128.2, 132.2

(Ar-CH); 135.8 (C2), 137.8 (C3) and 164.1 (C=O).

Synthesis of 1-benzyl- 2-(3-bromobenzo[b]thien-2-oyl)-1,2,3,4-tetrahydro
isoquinoline (49).
Following the method used to synthesize 30, 49
Br

(0.48g 55 %) was prepared from the acid 30 (0.40g,
N

S

1.55 mmol) and 1-benzyl-1,2,3,4-tetrahydroisoO

quinoline (35) (0.35 g, 1.55 mmol) as a colourless
oil after chromatography (30 % ethyl acetate:
hexane). Mass spectrum (CI+), 462 [MH+1,81Br]. HRMS (EI) Found: 461.4014 (1.8
ppm), required: 461.4020 for C25H20 81BrNOS. 1H-NMR (CDCl3, 300 MHz): 2.69
(qn, J = 1.72 Hz, 2H, H4), 2.93 (qn, J = 4.05 Hz, 2H, H3), 4.03 (t, J = 4.5 Hz, 1H,
H1), 5.31 (s, 2H, CH2-benzyl), 7.05-7.16 (m, H5`, H6`, H7` and H8`), 7.28-7.35 (m,
5H, benzyl), 7.85 (m, 2H, H4 and H7), 7.49 (m, 2H, H5 and H6).

13

C-NMR: 30.2

(C4`), 40.9 (C3`), 55.3 (C1`), 58.5 (CH2, benzyl),126.0 (C7`), 115.2 (C3), 122.8 (C7),
125.5 (C5), 125.8 (C6), 126.2 (C5`), 128.3 (C2), 129.5 (C5` and C8`), 130.1 (C4”)
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32.2 (C2”, C3”, C5” and C6”), 135.9 (C8a`), 138.7 (C3a), 139.4 (C7), and162.1
(C=O).

Synthesis of 2-(3-chlorobenzo[b]thien-2-oyl)-6,7-dimethoxy-1,2,3,4tetrahydroisoquinoline (50).
Cl

4
3

5
6
7

S

4'

5'

3'

7'

N 2'

2

1'

O

OMe

Dry tetrahydrofuran (30 mL) was added to a

6'

8'

OMe

mixture of 33 (0.89 g, 4.61 mmol), 23 (1.05
g, 4.56 mmol), and anhydrous potassium

carbonate (1.0 g, 7.24 mmol) after which the mixture was heated at reflux under
nitrogen for two and a half-hours. The mixture was then cooled to room temperature
before being filtered to remove unreacted potassium carbonate. The solvent was
evaporated under reduced pressure to give a light yellow oil which was
chromatographed (30 % ethyl acetate: hexane) and recrystallised from hot ethanol to
give white crystals of 50 (1.44 g, 86 %). Mp. 148-150 oC. Mass spectrum (CI+), m/z
388 [MH+1,

35

Cl]; HRMS (EI) Found: 390.0745 (1.7 ppm) required: 390.0738 for

C20H1937ClNO3S. 1H-NMR (CDCl3, 300 MHz): 2.63 (bs, 2H, CH2). 3.48 (bs 2H,
NCH2), 3.62 (s, 6H, OMe), 4.64*; 4.37* (bs, 2H, NCH2), 6.40 (bs, 2H, H5` and H8`),
7.26 (m, 2H, H5 and H6), 7.62 (m, 2H, H4 and H7).

13

C-NMR: 28.3, 30.0, 41.5

(CH2), 53.1 (-OMe), 116.2, 118.6, 120.8, 125.5, 126.4, 128.2, 130.2 (Ar); 135.8 (C2),
145.1 (C3), 158, 156.5 (C6`, C7`) and 162.1 (C=O).
Note: The signals marked here as “*” refer to amide rotamers.
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Synthesis of 2-(3-bromobenzo[b]thien-2-oyl)-6,7-dimethoxy-1,2,3,4tetrahydroisoquinoline (51).
Br

OMe

2.07 mmol), 25 (0.51 g, 1.99 mmol), DCC

N

S

To a cooled mixture (ice bath) of 33 (0.40 g,

OMe

(0.47 g, 2.28 mmol), and HOBt (0.30 g, 2.22

O

mmol) was added dry DMF (35 mL). The mixture was stirred for 24h at room
temperature under nitrogen. The reaction mixture was filtered and solvent evaporated
under reduced pressure to give yellow oil. This residue was taken up in ethyl acetate
(30 mL), washed with saturated sodium bicarbonate solution (3x 25 mL) and distilled
water (25 mL) to remove traces of unreacted acid. The organic portion was dried and
the solvent evaporated under reduced pressure to give a yellow oil which was
chromatographed (30 % ethyl acetate: hexane) and recrystallised from hot ethanol to
afford 51 (0.26 g, 30 %) as a white solid. Mp.165-167 oC; Mass spectrum (CI+), m/z
432 [MH+1,

79

.

Br], 192 (C11H14NO2 ); HRMS (EI) Found: 434.0249 (3.6 ppm),

required: 434.0233 for C20H19 81BrNO3S.

1

H-NMR (CDCl3, 300 MHz): 2.63 (bs,

2H, CH2), 3.48 (bs 2H, N-CH2), 3.62 (s, 6H, -OMe), 4.64*; 4.37* (bs, 2H, NCH2),
6.40 (bs, 2H, H5` and H8`), 7.26 (m, 2H, H5 and H6), 7.62 (m, 2H, H4 and H7).
13

C-NMR: 28.3, 30.0, 41.5 (CH2), 53.1 (-OMe), 116.2, 118.6, 120.8, 125.5, 126.4,

128.2, 130.2 (Ar); 135.8 (C2), 145.1 (C3), 158, 156.5 (C6`, C7`) and 162.1 (C=O).

Synthesis of 2-(3-chlorobenzo[b]thien-2-oyl)-1-(2-propenyl)-1,2,3,4tetrahydroisoquinoline (52).
Cl

4

4'
3'

5
6
7

6'

N

S

50, 52 (0.31 g, 47 %) was prepared from 32 (0.3

7'
8'

O

Following the method used for the synthesis of

5'

1"

g, 1.73 mmol) and 23 (0.5 g, 2.2 mmol) as a

2"

3"
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white crystalline solid (hot ethanol) after column chromatography using 30 % ethyl
acetate: hexane. Mp.116-117 oC. Mass spectrum (CI+), m/z 368 [MH+1, 35Cl], m/z 326
.

[C3H5 ]; HRMS (EI) Found: 368.0876 (3.3 ppm), required: 368.0877 for
C21H1935ClNO. 1H-NMR (CDCl3, 300 MHz): 2.65 (m, 2H, H1”), 2.73 (m, Hz, 2H,
H4’), 3.37 (m, 2H, H3`), 4.94 (t, J = 4.5 Hz, 1H, H1`), 5.15 (m, 2H, H3”), 5.81 (m,
1H, H2”), 7.20 (m, 4H, ArH), 7.47 (m, 2H, H5 and H6), 7.83 (m, 2H, H4 and H7).
13

C-NMR: 26.0 (C4`); 42.1 (C3`, C1”), 52.8 (C1`), 119.2 (C3”), 122.6, 124.2x 2,

125.5, 126.4x 2, 128.2, 132.2 (Ar-CH); 134.8 (C2”), 135.5 (C7a), 138.1 (C4a) and
162.5 (C=O).

Indium metal approach to 2-(3-chlorobenzo[b]thien-2-oyl)-1-(2-propenyl)1,2,3,4-tetrahydroisoquinoline (52).
To a stirred and cooled mixture (ice bath) of the acid chloride 23 (0.40 g, 1.72 mmol)
and the dihydroisoquinoline 36 (0.25 g, 1.90 mmol) was added dry tetrahydrofuran
(15 mL) under nitrogen. To this mixture was then added allyl bromide (0.62 g, 5.16
mmol) and stirring continued for a further 10 minutes before indium powder (0.60 g,
3.84 mmol) was added. The reaction was then warmed to room temperature and
stirred over 12h. The reaction was stopped with the addition of 1 M HCL (10 mL) and
then extracted with diethyl ether (2x 20 mL). The organic portion was washed with
distilled water (2x 15 mL) and dried. Solvent was then evaporated to afford a yellow
oil (0.4 g). A TLC spotting (30 % ethyl acetate: hexane) of the oil against an authentic
sample of 52 indicated a very minute spot corresponding to the desired product, a
minor spot which had the same Rf as 2-(3-chlorobenzo[b]thien-2-oyl)-1,2,3,4tetrahydroisoquinoline (29) was evident and a major spot (Rf 0.4) was also present.
Mass spectrum (CI+), m/z 368 [MH+1, 35Cl], m/z 326 and m/z 344. A preparative TLC
was used to isolate the components for further identification. A mass spectrum of the
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minor component had an MH+1 peak at m/z 326 which was consistent with the amide
2-(3-chlorobenzo[b]thien-2-oyl)-1,2,3,4-tetrahydroisoquinoline (29) probably formed
from reduction of the 3,4-dihydroisoquinoline (36) to 1,2,3,4-tetrahydroisoquinoline
(31), while the peak at m/z 368 was that of the desired product 52 (less than 15 %
overall). The MH+1 peak at m/z 344 was assigned to the major product of the reaction,
N-(2-(hydroxymethyl)phenyl)-3-chlorobenzo[b]thiophene-2-carboxamide (89) (0.30
g). 1H-NMR (CDCl3, 300 MHz): 3.43 (t, J = 7.2 Hz, 2H, -CH2-phenyl), 3.81 (q, J =
6.6 Hz, 2H, CH2-NH), 4.13 (s, 2H, CH2-OH), 7.17-7.39 (m, 4H, ArH) and 7.47 (m,
2H, H5 and H6, BTP), 7.83 (m, 2H, H4 and H7, BTP).

Synthesis of 2-(3-bromobenzo[b]thien-2-oyl)-1-(2-propenyl)-1,2,3,4tetrahydro isoquinoline (53).
Br

4

4'
3'

5
6
7

6'

N 2'

S

7'
8'

O

The isoquinoline 32 (1.0 g, 5.78 mmol) was

5'

1"

added to a mixture acid 25 (1.5 g, 5.83 mmol),
1,3-dicyclohexylcarbodiimide

(1.23

g,

5.97

2"

mmol), and 1-hydroxybenzotriazole (0.79 g,
3"

5.85 mmol) in dry DMF (70 mL), on an ice bath. The reaction mixture was then
stirred at room temperature under nitrogen overnight. After all the substrate had
reacted (via TLC), the precipitated dicyclohexylurea was filtered and organic solvent
concentrated under reduced pressure to yellow oil. This residue was taken up in ethyl
acetate (25 mL) and traces of the precipitate that crushed out were filtered again. The
organic layer was washed with distilled water (50 mL) and dried (anhydrous sodium
sulfate) and finally evaporated in vacuo to afford a yellow oil which was
recrystallised from hot ethanol to give colourless crystals of 53 (1.02 g, 43 %).
Mp.125-127 oC. Mass spectrum (CI+), m/z 412 [MH+1,79Br]. HRMS (EI) Found:
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414.0350 (-1.2 ppm), required: 414.0355 for C21H1981BrNOS.

1

H-NMR (CDCl3,

300 MHz): 2.68 (m, 2H, H1”), 2.70 (m, 2H, H4’), 3.39 (m, 2H, H3`), 4.95 (t, J = 4.5
Hz, 1H, H1’), 5.15 (m, 2H, H3”), 5.81 (m, 1H, H2”), 7.22 (m, 4H, ArH), 7.47 (m, 2H,
H5 and H6), 7.83 (m, 2H, H4 and H7).

13

C-NMR: 26.0 (C4`); 42.1 (C3`, C1”), 52.8

(C1`), 119.2 (C3”), 122.6, 124.2x 2, 125.5, 126.4x 2, 128.2, 132.2 (Ar-CH); 134.8
(C2”), 135.2 (C7a), 138.3 (C4a) and 164.5 (C=O).

Synthesis of 2-(benzothien-2-oyl)-1-(2-propenyl)-1,2,3,4-tetrahydroisoquinoline (54).
Following a similar approach as for the synthesis
N

S
O

of 53, amide 54 (0.10 g, 11 %) was prepared from
the coupling of amine 32 (0.6, 3.40 mmol) and the

acid 20 (0.5 g, 2.81 mmol). After the usual work up procedure, and column
chromatography (20 % ethyl acetate: hexane), 54 was obtained as clear oil. Mass
.

spectrum (CI+), m/z 334 [MH+1], GC-MS (EI+) 292 (C18H14NOS , 35 %), 161
.

(C9H5NOS , 100 %). HRMS (ES) Found: 334.0755, required: 334.0777 for
C21H20NOS.

1

H-NMR (CDCl3, 300 MHz): 2.71 (bs, 2H, H1”), 2.73 (bs, 2H, H4’),

3.37 (bs 2H, H3`), 5.09 (t, J = 4.5 Hz, 1H, H1’), 5.14 (m, 2H, H3”), 5.81 (bs, 1H,
H2”), 7.36-7.80 (m, 8H, ArH) and 7.85 (s, 1H, H3). 13C-NMR: 26.0 (C4`); 42.1 (C3`,
C1”), 52.8 (C1`), 119.2 (C3”), 120.8 (C3), 122.6, 124.2x 2, 125.5, 126.4x 2, 128.2,
132.2 (Ar-CH); 134.8 (C2”), 135.5 (C7a), 138.1 (C4a) and 162.5 (C=O).
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Synthesis of 2-(3-chlorobenzo[b]thien-2-oyl)-1,2,3,4-tetrahydro-9H-pyrido
[3,4-b] indole (55).
4
5

Cl
3a

3

Dry

4'
4a'

3'

7

S

1'

1

(55

mL)

was

syringed onto a flask containing a

N

6

tetrahydrofuran

N
H

O

mixture 23 (1.10 g, 4.78 mmol), 1,2,3,4-

tetrahydro[b]carboline (40) (0.77 g, 4.43 mmol), and anhydrous potassium carbonate
(1.0 g, 5.61 mmol). The mixture was heated at reflux under nitrogen for two and halfhours. The cooled solution was filtered to remove unreacted potassium carbonate.
Solvent was removed in vacuo to give a yellow oil which was crystallised from hot
ethanol to give 55 (1.41 g, 81 %) as colourless crystals. Mp.202-205 oC. Mass
spectrum (CI+), m/z 367 [MH+1,35Cl]; HRMS (CI) Found: 367.0671, (3.3 ppm),
required: 367.0659 C20H1635ClN2OS. 1H-NMR (CD3COCD3, 300 MHz): 2.06 (d, J
= 6.6 Hz, 2H, H4`), 2.86 (d, J = 10.2 Hz, 2H, H3`), 3.84; 4.14 (bs, 2H, H1`), 7.05 (m,
2H, ArH5` and ArH8`), 7.6 (qn, J = 7.58 Hz, 4H, ArH- H5, H6, H6` and H7`), 7.89
(d, J = 7.5 Hz, 1H, ArH4), 8.09 (d, J = 7.8 Hz, 1H, ArH7). 13C-NMR: (δ): 22.4 (C2`),
46.1 (C1`), 47.2 (C3`), 109.6 (C4a`), 118.3-126.0 (Ar-CH), 130.8 (C12a`), 137.4
(C8a`) and 165.4 (C=O).

Synthesis of 2-(3-bromobenzo[b]thien-2-oyl)-1,2,3,4-tetrahydro-9H-pyrido
[3,4-b] indole (56).
Dry N,N-dimethylformamide (30 mL)

Br

was added to a mixture of 25 (0.40 g,

N
S

N
H

1.56 mmol), 40 (0.26 g, 1.51 mmol),

O

DCC (0.32 g, 1.55 mmol), and HOBt (0.21 g, 1.55 mmol) on an ice bath. The mixture
was stirred under nitrogen overnight at room temperature. The precipitated
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dicyclohexylurea was filtered and DMF evaporated under reduced pressure. To the
oily residue was added dichloromethane (25 mL), and the organic layer was then
washed with sodium bicarbonate solution (3x 25 mL) and then distilled water (25
mL). Pooled organic solvents were dried and the solvent evaporated to afford a yellow
oil which was chromatographed (DCM) and recrystallised from hot ethyl alcohol to
give 56 (0.22 g, 36 %) as a colourless crystalline solid. Mp. 217-220 oC. Mass
spectrum (CI+), m/z 411 [MH+1,79Br]. HRMS (CI) Found: 412.0007, (-5.3 ppm)
required: 412.0029 for C20H1579BrNO2S. 1H-NMR (CD3COCD3, 300 MHz): 2.09 (d,
J = 6.6 Hz, 2H, H4`), 2.88 (d, J = 10.2 Hz, 2H, H3`), 3.82; 4.14 (bs, 2H, H1`), 7.08
(sp, J = 7.31 Hz, 2H, ArH5` and ArH8`), 7.6 (qn, J = 7.56 Hz, 4H, ArH- H5, H6, H6`
and H7`), 7.89 (d, J = 7.5 Hz, 1H, ArH4), 8.09 (d, J = 7.8 Hz, 1H, ArH7). 13C-NMR:
22.4 (C2`), 46.2 (C1`), 47.3 (C3`), 109.6 (C4a`), 118.4-126.0 (Ar-CH), 130.8 (C12a`),
137.4 (C8a`) and 165.4 (C=O).

Synthesis of 2-(3-chlorobenzo[b]thien-2-oyl)-5-methoxy-1,2,3,4-tetrahydro9H-pyrido[3,4-b]indole (57).
Anhydrous tetrahydrofuran (15 mL)

Cl

MeO

was added to a mixture of 24 (0.50

N
S

N
H
O

g,

1.92

mmol),

40

(0.33

g,

1.91mmol), and anhydrous potassium carbonate (0.22 g, 1.59 mmol). The reaction
mixture was heated at reflux under nitrogen for two and half-hours. The cooled
solution was filtered to remove unreacted potassium carbonate and the solvent
evaporated under reduced pressure to give oil. The oil was taken up in DCM (15 mL)
and washed with saturated sodium bicarbonate solution (2x 15mL) to remove
unreacted 24 (via TLC). Pooled organic layers were washed with distilled water (30
154

mL) and solvent removed under reduced pressure to give an oil which was
chromatographed (30 % ethyl acetate: hexane) and crystallised from hot ethanol to
give yellow crystals of 57 (0.7 g, 92 %). Mp. 148-150 oC. Mass spectrum (CI+), m/z
397 [MH+1, 35Cl]; 1H-NMR (CD3COCD3, 300 MHz): 1.70 (d, J = 6.6 Hz, 2H, H4`),
2.88 (d, J = 10.2 Hz, 2H, H3`), 3.85 (s, 3H, CH3), 5.10 (s, 2H, H3`), 7.92-7.65 (m,
7H, ArH- H4, H6, H7, H5`, H6`-H8`). 13C-NMR: 22.5 (C4`), 40.7(C1`), 46.9 (C3`),
55.9 (CH3), 104.3 (C4), 109.6 (C4a`), 119.8-126.5 (Ar-C6, C7, C6`-C8`), 130.8
(C12a`), 137.4 (C8a`), 158.2 (C5) and 165.4 (C=O).

Synthesis of 2-(3-chlorobenzo[b]thien-2-oyl)-5-methoxy-1,2,3,4-tetrahydro-9benzyl-pyrido[3,4-b]indole (58).
4

MeO

3

Cl

5

5'

4'

mmol) was dissolved in dry DMF

N 2'

S

N

1'

1

O

5"
4"

Sodium hydride (0.051 g, 2.12

4a`

3'

1"
2"

8'

(15 mL) under nitrogen. The
mixture was then cooled in ice to 5
o

C after which 57 (0.40 g, 10.10

mmol), in dry DMF (15 mL) was added and mixture stirred at room temperature for
45 minutes. The reaction mixture was then cooled to minus 60 oC on a dry ice/
acetone bath. Benzyl bromide (0.2 g, 1.17 mmol) dissolved in dry DMF (15 mL) was
added and the mixture stirred overnight at room temperature under nitrogen. Solvent
was evaporated under reduced pressure to give a crude gummy solid. Distilled water
(50 mL) was added to the solid and the mixture stirred vigorously for one hour. The
solid was extracted in dichloromethane (25 mL) and the organic phase washed with
distilled water (30 mL). The organic solvent was concentrated in vacuo to afford a
semi solid yellow product which was chromatographed (40 % ethyl acetate: hexane)
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to give a clear oil which was then recrystallised from hot ethanol to give 58 (0.12 g,
24 %) as a colourless crystalline solid. Mp. 153-155 oC. Mass spectrum (CI+), m/z 487
[MH+1,
35

35

Cl]; HRMS (CI) Found: 487.1139, required:

487.1130 for C28H24

ClN2O2S. 1H-NMR (CDCl3, 300 MHz): 2.32 (bs, 2H, H4`,-CH2), 2.96 (bs, 2H,

H3`,-CH2), 3.93 (s, 3H, -CH3), 4.91(s, 2H, H1`, CH2-N), 5.30 (s, 2H, CH2-benzyl),
7.12-7.68 (m, 12H, ArH). 13C-NMR: 22.5 (C4`), 40.7 (C1`), 45.9 (C3`), 47.1 (CH2benzyl), 55.9 (-CH3), 104.3 (C4), 109.6 (C4a`), 117.7-123.7 (Ar-C6, C7, C6`-C8`),
126.5-129.1 (C2”-C6” benzyl),130.8 (C12a`), 137.4 (C1”), 137.4 (C8a`), 158.2 (C5)
and 165.4 (C=O).

Synthesis of 9-benzyl- 2-(3-chlorobenzo[b]thien-2-oyl)-1,2,3,4-tetrahydro9H-pyrido[3,4-b]indole (59).
Sodium hydride (0.06 g, 2.50 mmol) was

Cl

N

S
O

dissolved in dry N,N-dimethylformamide
N

(10 mL) under nitrogen and the mixture
cooled to 5 oC on an ice bath. The amide

55, (0.4 g, 1.73 mmol), in dry N,N-dimethylformamide (15 mL) was then added and
mixture allowed to warm to room temperature while stirring for 45 minutes. The flask
containing the reaction mixture was then cooled to -60 oC using a dry ice/ acetone
bath before benzyl bromide (0.3 g, 1.76 mmol) dissolved in dry N,Ndimethylformamide (10 mL) was added. The mixture was then stirred at room
temperature over 24h after which the substrate had reacted (TLC analysis). DMF was
removed under reduced pressure to afford a gummy solid. Distilled water (50 mL)
was added to the crude product and then stirred vigorously for 1h. Dichloromethane
(25 mL) was poured onto the mixture, separated, and the organic layer washed with
distilled water (2x 20 mL) and then dried. Upon evaporation of the DCM, a yellow
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semi solid product was obtained which was then chromatographed (40 % ethyl
acetate: hexane) to give a clear oil. The oil was crystallised from absolute ethanol to
give 59 (0.30 g, 38 %) as a colourless solid. Mp.143-145 oC. Mass spectrum (CI+),
m/z 457 [MH+1,35Cl], HRMS (CI) Found: 457.1141, (0.9 ppm), required: 457.1137
for C27H2235ClN2OS. 1H-NMR (CDCl3, 300 MHz): 2.94 (bs, 2H, H4`,-CH2), 3.81
(bs, 2H, H3`,-CH2), 4.90(s, 2H, H1`, CH2-N), 5.31 (s, 2H, CH2-benzyl), 7.12-7.68 (m,
12H, ArH).

13

C-NMR: 22.5 (C4`), 30.5 (C1`), 46.1 (C3`), 47.2 (-CH2-benzyl), 104.3

(C4), 109.6 (C4a` or C7`), 118.4-126.8 (Ar-C6, C7, C6`-C8`), 127.7-129.1 (C2”-C6”
benzyl),130.8 (C12a`), 137.4 (C1”), 137.4 (C8a`) and 164.0 (C=O).

Synthesis of 9-benzyl-2-(3-bromobenzo[b]thien-2-oyl)-1,2,3,4-tetrahydro-9Hpyrido[3,4-b]indole (60).
In a nitrogen atmosphere a solution of

Br

sodium hydride (0.055 g, 2.2 mmol) in
N

S
O

N

dry DMF (5 mL) was cooled to 5 oC on
an ice bath, and 56 (0.4 g, 0.97 mmol) in
anhydrous DMF (10 mL) was slowly

added. Stirring was continued at room temperature for 1h. The reaction mixture was
then cooled to -60 oC in a dry ice/ acetone bath. Benzyl bromide (0.16 g, 0.94 mmol)
dissolved in dry N,N-dimethylformamide (5 mL) was slowly added via syringe into
the mixture and stirring continued overnight at room temperature. The solvent was
evaporated under reduced pressure to give an oil. Distilled water (50 mL) was added
to this oil and a gummy solid was formed immediately. Vigorous stirring of the
gummy product was continued for one and half hours before the solid was extracted
with dichloromethane (25 mL). Organic solvent was dried and concentrated to give a
yellow oily product which was then chromatographed (30 % ethyl acetate: hexane) to
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a clear oil. The oil was finally recrystallised from absolute ethanol to give 60 (0.23 g,
48 %) as a colourless crystalline solid. Mp. 138-140 oC. Mass spectrum (CI+), m/z 501
[MH+1,79Br]; HRMS (EI) Found: 502.0537 (0.1 ppm), required: 502.0537 for
C27H2181BrN2OS. 1H-NMR (CDCl3, 300 MHz): 2.94 (bs, 2H, H4`,-CH2), 3.81 (bs,
2H, H3`,-CH2), 4.90(s, 2H, H1`, CH2-N), 5.31 (s, 2H, CH2-benzyl), 7.12-7.68 (m,
12H, ArH). 13C-NMR: 22.5 (C4`), 30.5 (C1`), 46.1 (C3`), 47.2 (CH2-benzyl), 104.3
(C4), 109.6 (C4a` or C7`), 118.4-126.8 (Ar-C6, C7, C6`-C8`), 127.8-129.1 (C2”-C6”
benzyl),130.8 (C12a`), 137.4 (C1”), 137.4 (C8a`) and 164.0 (C=O).

Synthesis of 2-(3-chlorobenzo[b]thien-2-oyl)-9-o-nitrobenzyl-9H-1,2,3,4tetrahydro-pyrido[3,4-b]indole (61).
Following the method used for the

Cl

synthesis of 60, 61 (C27H21ClN3O3S)
N

S

N

O

(0.34 g, 50 %) was prepared by reacting
55

NO2

(0.5

g,

1.36

mmol),

with

o-

nitrobenzylbromide (0.46 g, 2.1 mmol) as

yellow oil after flash chromatography (40 % ethyl acetate: hexane). The oil was
recrystallised from hot absolute ethanol to give 61 as a yellow crystalline solid.
Mp.191-193 oC. Mass spectrum (CI+), m/z 502 [MH+1,35Cl]; HRMS (CI) Found:
502.0992 (1.2 ppm), required: 502.0983 for C27H2135ClN3O3S. 1H-NMR (CDCl3, 300
MHz): 3.00 (bs, 2H, H4`, CH2), 3.86 (bs, 2H, H3`, CH2), 4.87(s, 2H, H1`, CH2-N),
5.83 (s, 2H, CH2-benzyl), 7.14-7.82 (m, 11H, ArH), 8.24(bs, 1H, H3”).

13

C-NMR:

21.4 (C4`), 22.6 (C1`), 40.5 (C3`), 44.9 (CH2-benzyl), 104.3 (C4), 109.5 (C4a` or
C7`), 118.4-126.8 (Ar-C6, C7, C6`-C8`), 127.8-129.1 (C2”-C6” benzyl),130.8
(C12a`), 137.4 (C1”), 137.4 (C8a`) 147.1 (C-NO2) and 162.5 (C=O).
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Synthesis of 4-tert-butyloxycarbonyl-1-(3-chlorobenzo[b]thien-2-oyl)piperazine (62).
Anhydrous tetrahydrofuran (35 mL), was
O

added to a mixture of 23, (0.69 g, 3.0

Cl

4
5

N

6
7

O

mmol), amine 44 (0.46 g, 2.20 mmol) and

N

S

anhydrous potassium carbonate (0.34 g,

O

2.46 mmol). The mixture was then heated at reflux for 3h under nitrogen. After the
reaction was complete (via TLC), the cooled solution was filtered to remove unreacted
potassium carbonate and the solvent evaporated to give a yellow oil that solidified
rapidly. The product was chromatographed (30 % ethyl acetate: hexane) and then
recrystallised from hot ethanol to give 62 (1.09 g, 97 %) as a white crystalline solid. Mp.
124-126 oC. Mass spectrum (CI+) m/z 381 [MH+1,35Cl]; HRMS (CI) Found: 380.096,
(0.1 ppm), required: 380.0961 for C18H2135ClN2O3S. 1H-NMR (CDCl3, 300 MHz): 1.40
(s, 3H, CH3), 3.52 (s, 8H, CH2), 7.49 (m, 2H, Ar-H5 and H6), 7.84 (m, 2H, Ar-H4 and
H7). 13C-NMR: 28.7 (3C, CH3), 42.3 (4C, CH2), 80.7 (C-CH3), 122.8 (C7), 122.9 (C4),
125.7, 126.9 (C5 and C6), 130.0 (C3), 135.8 (C3a), 154.1 (C=O, boc), 162.2 (C=O,
amide).

Synthesis of 4-tert-butyloxycarbonyl-1-(3-bromobenzo[b]thien-2-oyl)piperazine (63).
Anhydrous DMF (15 mL) was syringed

O
Br
N
N

S
O

O

into a flask containing a mixture of 25
(0.41 g, 1.59 mmol), 44 (0.30 g, 1.6
mmol), HOBt (0.21 g, 1.55 mmol) and

DCC (0.32 g, 1.55 mmol) placed on an ice bath. The mixture was stirred at room
temperature overnight under nitrogen. The reaction mixture was vacuum filtered to
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remove the precipitated by-product dicyclohexylurea and solvent evaporated to give
an oily residue which was taken up in ethyl acetate (25 mL) and re-filtered to remove
traces of remaining urea. The organic portion was then washed with distilled water
(50 mL) and dried. Solvent was evaporated to afford a clear oil which was flash
chromatographed (30 % ethyl acetate: hexane) and recrystallised from hot ethanol to
give white crystals of 63 (0.57 g, 85 %). Mp. 90-93 oC. Mass spectrum, (CI+) m/z 425
[MH+1,79Br]; HRMS (EI) Found: 426.0435 (4.8 ppm), required: 426.0415 for
C18H2181BrN2O3S.

1

H-NMR (CDCl3, 300 MHz): 1.40 (s, 3H, CH3), 3.52 (s, 8H,

CH2), 7.49 (m, 2H, Ar-H5 and H6), 7.84 (m, 2H, Ar-H4 and H7). 13C-NMR: 28.7 (3x
CH3), 42.3 (4C, CH2), 80.7 (C-CH3), 122.8 (C7), 122.9 (C4), 125.7, 126.8 (C5; C6),
130.0 (C3), 135.8 (C3a), 154.5 (C=O, boc) and 162.5 (C=O, amide).

Synthesis of (3-chlorobenzo[b]thien-2-yl)(piperazine-1-yl)methanone (64).
Trifluoroacetic acid (3.0 mL, 38.95 mmol) was

Cl
NH
N

S
O

slowly added into a solution 61 (0.71 g, 1.89 mmol)
in dry dichloromethane (30 mL) under nitrogen. The

mixture was stirred for one and half-hours at room temperature. Solvent was
evaporated under reduced pressure to afford a clear oil which was dissolved in
dichloromethane (25 mL), washed with saturated sodium bicarbonate solution (2x 25
mL) and distilled water (50 mL). Combined organic portions were dried and the
solvent evaporated to afford 64 (0.52 g, 99 %) as a colourless oil. Mass spectrum
(CI+) m/z 281 [MH+1,37Cl]. HRMS (EI) Found: 280.2335, (1.8 ppm), required:
280.2375 for C13H1335ClN2OS. 1H-NMR (CDCl3, 300 MHz): 1.96 (NH), 2.93 (bs,
2H, H3` and H5`), 3.48, 3.79 (bs, 2H, H2` and H6`), 7.49 (m, 2H, Ar-H5 and H6),
7.84 (m, 2H, Ar-H4 and H7).

13

C-NMR: 46.6 (C3` and C5`), 49.0 (C2` and C6`),
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122.7 (C7), 122.9 (C4), 125.6 (C6), 126.7 (C5), 129.9 (C3), 137.6 (C3a) and 161.7
(C=O).

Synthesis of (3-bromobenzo[b]thien-2-yl)(piperazine-1-yl)methanone (65).
Following the same method used to deprotect

Br
NH

amide 64, compound 65 (0.38 g, 83 %) was

N
S

prepared from 62 (0.61 g, 1.42 mmol) as a clear oil.

O

Mass spectrum (CI+) m/z 325 [MH+1, 35Cl]; HRMS (EI) Found: 324.1255, (1.3 ppm),
required: 324.1258 for C13H1381BrN2OS. 1H-NMR (CDCl3, 300 MHz): 1.96 (NH),
2.93 (bs, 2H, H3` and H5`), 3.48, 3.79 (bs, 2H, H2` and H6`), 7.49 (m, 2H, Ar-H5 and
H6), 7.84 (m, 2H, Ar-H4 and H7).

13

C-NMR: 46.6 (C3` and C5`), 49.0 (C2` and

C6`), 122.7 (C7), 122.9 (C4), 125.6 (C6), 126.7 (C5), 130.0 (C3), 137.6 (C3a) and
161.7 (C=O).

Synthesis of (3-chlorobenzo[b]thien-2-yl)(4-benzylpiperazine-1-yl) (66).
Benzyl bromide (0.5 mL, 4.11 mmol)

Cl
N
N

S
O

was syringed to a mixture 65 (0.42 g,
0.129 mmol) and anhydrous potassium

carbonate (0.15 g, 1.08 mmol) in dry tetrahydrofuran (15 mL). The stirring was
continued overnight at room temperature under nitrogen. The reaction mixture was
filtered to remove unreacted potassium carbonate, and the solvent concentrated under
reduced pressure to give a yellow oil which was chromatographed (30 % ethyl
acetate: hexane) to give 66 (0.24 g, 44 %) as a clear oil. Mass spectrum (CI+) m/z 371

161

[MH+1 35Cl]; HRMS (EI) Found: 370.0235, required: 370.0229 for C20H2035ClN2OS.
1

H-NMR (CDCl3, 300 MHz): 2.51 (bs, 2H, H3` and H5`), 3.54, (bs, 2H, H2` and

H6`), 3.82 (bs, 2H, CH2 benzyl) 7.22-7.32 (m, 5H, benzyl) 7.44-7.48 (m, 2H, Ar-H5
and H6), 7.84 (m, 2H, Ar-H4 and H7).

13

C-NMR: 46.6 (C3` and C5`), 49.0 (C2` and

C6`), 60.1 (CH2 benzyl), 122.7 (C7), 122.9 (C4), 125.6 (C6), 126.7 (C5), 127-129.1 (
C2”-C6”, benzyl) 131.9 (C3), 137.6 (C3a) and 162.7 (C=O).

Synthesis of (3-bromobenzo[b]thien-2-yl)(4-benzylpiperazine-1-yl) (67).
To a cooled mixture (ice bath) of 25

Br
N
N

S
O

(0.40 g, 1.55 mmol), 1-benzylpiperazine
(0.30 mL, 1.73 mmol), HOBt (0.19 g,

1.40 mmol) and DCC (0.34 g, 1.65 mmol) was added dry DMF (15 mL). The mixture
was then stirred at room temperature overnight under argon after which it was filtered
to remove the precipitated urea by-product. DMF was concentrated under reduced
pressure and the oily residue taken up in ethyl acetate (25 mL) and re-filtered again to
remove traces of the crushed out urea. The organic portion was washed once with
distilled water (50 mL) and dried. Solvent was evaporated to afford an oil which was
purified via chromatography (30 % ethyl acetate: hexane) to give a colourless oil of
67 (0.47 g, 73 %). Mass spectrum, (CI+) m/z 415 [MH+1,

81

Br]; 337

.

(C14H1479BrN2OS ); HRMS (EI) Found: 414.0415, required: 414.0419 for
C20H2081BrN2OS. 1H-NMR (CDCl3, 300 MHz): 2.55 (bs, 2H, H3` and H5`), 3.55,
(bs, 2H, H2` and H6`), 3.89 (bs, 2H, CH2 benzyl) 7.25-7.35 (m, 5H, benzyl) 7.44-7.49
(m, 2H, Ar-H5 and H6), 7.85 (dd, J = 5.4 Hz, 2H, Ar-H4 and H7).

13

C-NMR: 46.2

(C3` and C5`), 49.2 (C2` and C6`), 60.1 (CH2, benzyl), 122.8 (C7), 123.0 (C4), 125.7
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(C6), 126.4 (C5), 127-129.1 ( C2”-C6”, benzyl) 131.9 (C3), 137.7 (C3a) and 163.0
(C=O).

Synthesis of 1-(3-chlorobenzo[b]thien-2-oyl)-4-phenacyl piperazine (68).
Anhydrous THF (15 mL) was

2"
4
3a

7

3

Cl

3'
2'

N 1'

S

1"

4'

N

5"

added to a mixture of 64 (0.30 g,

6"

O

1

O

1.0 mmol), 2-bromoacetophenone
(0.21

g,

1.04

mmol)

and

anhydrous potassium carbonate (0.15 g, 1.08 mmol).The reaction mixture was heated
at reflux for 3h at room temperature under nitrogen. The cooled solution of the
reaction mixture was then filtered to remove excess potassium carbonate. The solvent
was evaporated to give an orange coloured oil which was column chromatographed to
afford 68 (0.17 g, 40 %) as a clear oil. Mass spectrum (CI+) m/z 399, [MH+1

35

Cl];

HRMS (EI) Found: 398.0555, (2.8 ppm); required: 398.0545 for C21H2035ClN2O2S.
1

H-NMR (CDCl3, 300 MHz): 2.71 (bs, 4H, CH2-NCH2), 3.60 (s, 2H, CH2, OCH2),

3.90 (bs, 2H, NCH2), 7.43-7.51 (m, 5H, ArH- H5, H6, H3”, H4” and H5”) and 7.787.98 (m, 4H, ArH-H4, H7, H2” and H6”). 13C-NMR: 46.6 (C3` and C5`), 49.0 (C2`
and C6`), 64.18 ( CH2, phenacyl), 119.5 (C3), 122.7-126.7 (C4, C5, C6, C7), 128.2
(C3” and C5”), 128.8 (C2” and C6”), 133.6 (C4”) 135.9 (C1”), 137.6 (C4a), 161.7
(C=O, amide) and 195.8 (C=O, ketone).
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Synthesis of 1- (3-bromobenzo[b]thien-2-oyl)-4-phenacyl piperazine (69).
Following the same method used to
Br

synthesise 68, 69 (C21H19BrN2O2S)

N
N

S

O

(0.12 g, 38 %) was synthesised by

O

reacting 65 (0.24 g, 0.73 mmol), with

2-bromoacetophenone (0.15 g, 0.72 mmol) and anhydrous potassium carbonate (0.1 g,
0.72 mmol) as a colourless oil after column chromatography. Mass spectrum (CI+)
m/z 442 [MH+1,

81

.

.

Br], 365 (C15H14BrN2O2S ), 337 (C14H14BrN2OS ); HRMS (EI)

Found: 441.0435, (4.8 ppm); required: 441.0415 for C21H2081BrN2O2S. 1H-NMR
(CDCl3, 300 MHz): 2.71 (bs, 4H, CH2-NCH2), 3.60 (s, 2H, CH2, OCH2), 3.90 (bs,
2H, NCH2), 7.43-7.51 (m, 5H, ArH- H5, H6, H3”, H4” and H5”) and 7.78-7.98 (m,
4H, ArH-H4, H7, H2” and H6”).

13

C-NMR: 46.6 (C3` and C5`), 49.0 (C2` and C6`),

64.18 ( CH2, phenacyl), 119.5 (C3), 122.7-126.7 (C4, C5, C6 and C7), 128.2 (C3” and
C5”), 128.8 (C2” and C6”), 133.6 (C4”) 135.9 (C1”), 137.6 (C4a), 161.7 (C=O,
amide) and 195.8 (C=O, ketone).

Synthesis of (3-chlorobenzo[b]thien-2-yl)(4-(4-chlorophenyl)piperazine-1-yl)
methanone (70).
Cl

Following the method used to synthesise
62, 70 (0.35 g, 52 %) was prepared by

Cl
N
N

S
O

reacting 23 (0.40 g, 1.73 mmol), and 42
(0.40 g, 1.71 mmol) as a colourless solid

after flash chromatography (DCM) and crystallisation from absolute alcohol. Mp.
143-145 oC. Mass spectrum (CI+) m/z 391 [MH+1,

35

Cl]; HRMS (CI) Found:

164

391.0438, required: 391.0410 for C19H16Cl2N2OS.

1

H-NMR (CDCl3, 300 MHz):

3.19 (bs, 4H), 3.91, 3.66 (bs, 4H), 6.88 (d, J = 22.8 Hz, 2H, ArH), 7.23 (d, J = 6 Hz,
2H, ArH), 7.48 (m, 2H, ArH) and 7.82 (m, 2H, ArH).

13

C-NMR: 47.4 (C2`, C6`),

118.2 (C2”, C6”), 122.8 (C7), 123.9 (C7, C4”), 125.9 (C5, C6), 129.3 (C3, C3”and
C5”), 138.0 (C3a), 149.5 (C1”) and 161.5 (C=O).

Synthesis of (3-chlorobenzo[b]thien-2-yl)(4-(4-chlorophenyl)piperazine-1-yl)
methanone (71).
Cl

was added into a mixture of 25 (0.40 g,

Br
N
N

S

Dry N,N-dimethylformamide (15 mL)

1.55 mmol), 42 (0.40 mL, 1.73 mmol),
HOBt (0.21 g, 1.55 mmol) and DCC

O

(0.34 g, 1.65 mmol) placed on an ice bath. The mixture was then stirred at room
temperature overnight under nitrogen. After the reaction came to completion (via
TLC) the reaction mixture was filtered to remove precipitated dicyclohexylurea byproduct. The DMF was concentrated on the rotary evaporator to give a crude oily
residue which was taken up in ethyl acetate (25 mL) and re-filtered to ensure
complete removal of the urea. The solvent was washed once with distilled water (50
mL) and dried. Solvent was then evaporated to afford a clear oil which was column
chromatographed (DCM) and crystallised from hot ethanol to give 71 (0.65 g, 96 %)
as a colourless crystalline solid. Mp.148-150 oC. Mass spectrum (CI+) m/z 435 [MH+1,
35

Cl81Br]; HRMS (CI) Found: 433.9858 (0.1 ppm), required: 433.9854 for

C19H1635Cl81BrN2OS.

1

H-NMR (CDCl3, 300 MHz): 3.18 (bs, 4H), 3.61, 3.92 (bs,

4H), 6.83 (d, J = 22.8 Hz, 2H, ArH), 7.23 (d, J = 6 Hz, 2H, ArH), 7.48 (m, 2H, ArH)
and 7.80 (m, 2H, ArH).

13

C-NMR: 47.4 (C2`, C6`), 118.2 (C2”, C6”), 122.8 (C7),

123.9 (C7, C4”), 125.9 (C5, C6), 129.3 (C3, C3”, C5”), 138.0 (C3a), 149.5 (C1”) and
161.5 (C=O).
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Synthesis of (3-chlorobenzo[b]thiophen-2-yl)(4- (pyridin-2-yl) piperazine-1yl) methanone (72).
3"
4"

N
Cl

4
3a

7

3

3'
2'

4'

1"

N

6"

N 1'

S

5"

Following the same method used to
synthesise 62, 72 (0.30 g, 63 %), was
prepared by 23 (0.31 g, 1.30 mmol) and the
amine 38 (0.21 g, 1.28 mmol) as a

O

colourless crystalline solid after flash chromatography (30 % ethyl acetate: hexane)
and re-crystallisation from hot ethanol. Mp.132-134 oC. Mass spectrum (CI+) m/z 358
[MH+1, 35Cl]; HRMS (CI) Found: 357.0702 (-1.4 ppm) required: 357.0707 for C18H16
35

ClN3OS.

1

H-NMR (CDCl3, 300 MHz): 3.65, 3.92 (bs, 8H, -CH2, H2`,H3`,H5`,

H6`), 6.67 (q, J = 4.2 Hz, 2H, H4”, H6”), 7.44-7.52 (m, H5, H6, H5”), 7.84 (dd, J =
2.5 Hz, 2H, H4 and H7), 8.20 (s, 1H, H3”).

13

C-NMR: 45.7 (C2`, C6`), 47.5 (C3`,

C5`), 107.6 (C6”), 114.2 (C4”), 122.9 (C7), 125.7 (C5), 126.8 (C6), 129.7 (C3), 137.6
(C3a), 137.8 (C5”), 148.1 (C3”), 159.1 (C1”) and 161.8 (C=O).

Synthesis of (3-chlorobenzo[b]thien-2-yl)(4-(pyridin-2-yl)piperazine-1-yl)
methanone (73).
In the same manner as that used to prepare
N
Br
N
N

S
O

71, 73 (C18H1681BrN3OS) (0.30 g, 48 %) was
synthesised by reacting 25 (0.40 g, 1.55
mmol), and 38 (0.25 g, 1.53 mmol), to afford
a clear oil after chromatography. The oil was

then re-crystallised from hot ethanol to give 73 as a colourless highly crystalline solid.
Mp.154-155 oC. Mass spectrum, (CI+) m/z 402 [MH+1,

81

.

Br], 324 (C18H16N3OS );

HRMS (CI) Found: 401.0197 (8.8 ppm), required: 401.0162 for C18H16 81BrN3OS.
1

H-NMR (CDCl3, 300 MHz): 3.65, 3.94 (bs, 8H, -CH2, H2`,H3`,H5`, H6`), 6.65 (q, J
166

= 4.2 Hz, 2H, H4”, H6”), 7.46-7.53 (m, H5, H6, H5”), 7.84 (dd, J = 2.5, 6 Hz, 2H, H4
and H7), 8.18 (s, 1H, H3”). 13C-NMR: 45.7 (C2`, C6`), 47.5 (C3`, C5`), 107.6 (C6”),
114.2 (C4”), 122.9 (C7), 125.7 (C5), 126.8 (C6), 129.7 (C3), 137.6 (C3a), 137.8
(C5”), 148.1 (C3”), 159.1 (C1”) and 161.8 (C=O).

Synthesis of (benzo[b]thien-2-yl)(4- (pyridin-2-yl) piperazine-1-yl)
methanone (74).
In the same manner used to prepare 73, 74
N

(C18H17N3OS),

(0.72

g,

67

%)

was

N
N

S
O

synthesised by reacting the acid 20 (0.60 g,
3.3 mmol), and the amine 38 (0.54 g, 3.3

mmol), to afford a yellow solid after column chromatography (30 % ethyl acetate:
hexane) which was then re-crystallised from absolute ethanol. Mp.123-125 oC. Mass
spectrum, (CI+) m/z 324 [MH+1]; HRMS (CI) Found: 323.0207 (6.8 ppm), required:
323.0172 for C18H18N3OS. 1H-NMR (CDCl3, 300 MHz): 3.63 (s, 4H, CH2, H2`,
H6`), 3.89 (s, 4H, -CH2, H3`, H5`), 6.67 (q, J = 4.2 Hz, 2H, H4”, H6”), 7.46-7.52 (m,
H5, H6, H5”), 7.54 (s, 1H, H3), 7.85 (m, 2H, H4 and H7), 8.19 (s, 1H, H3”).

13

C-

NMR: 45.5 (C2`, C6`), 47.5 (C3`, C5`), 107.6 (C6”), 114.2 (C4”), 122.6 (C3), 124.9
(C7), 125.0 (C5), 126.8 (C6), 138.8 (C5”), 140 (C3a), 148.2 (C3”), 159.2 (C1”) and
164.2 (C=O).
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Synthesis of (3-bromobenzo[b]thien-2-yl)(4-(pyrimidin-2-yl) piperazine-1-yl)
methanone (75).
In the same manner used to prepare 73, 75

3"
4"

N
Br

4
3a

7

3

S

3'
2'

4'

1"

N

N

N 1'

2

5"

(C17H15N4OS)

(0.50

g,

50

%)

was

synthesised by reacting the acid 25 (0.70 g,
2.72 mmol), and the amine 39 (0.44 g, 2.64

O

mmol), to afford a colourless solid after column chromatography (30 % ethyl acetate:
hexane) which was then re-crystallised from hot ethanol. Mp.188-190 oC. Mass
spectrum, (EI+) m/z 404 [MH+,

81

.

Br], 323 (C17H15N4OS ); HRMS (CI) Found:

403.0228 (-1.0 ppm), required: 403.0232 for C17H16

81

BrN4OS. 1H-NMR (CDCl3,

300 MHz): 3.94 (bs, 8H, -CH2, H2`, H6` H3`, H5`), 6.54 (t, J = 4.95 Hz, 1H, H4”),
7.47 (m, 2H, H5 and H6), 7.84 (dd, J = 4.35, 7.35 Hz, 2H, H4 and H7), 8.32 (d, J =
4.8 Hz, 2H, H3” and H5”). 13C-NMR: 45.5 (C2`, C6`), 47.5 (C3`, C5`), 110.8 (C4”),
122.8 (C7), 125.0 (C5), 126.7 (C6), 137.4 (C3a), 138.1 (C2) 158.0 (C3” and C5”),
161.5 (C1”), and 162.6 (C=O).

Synthesis of 9H-9-fluorenylmethyl 4-(3-chlorobenzo[b]thien-2-oyl)-1piperazinecarboxylate (76).
Dry THF (15 mL) was added to
O

a mixture of 64 (0.20 g, 0.86

Cl
N
N

S
O

O

mmol), 46 (0.20 g, 0.77 mmol)
and

anhydrous

potassium

carbonate (0.15 g, 1.08 mmol).

The mixture was heated at reflux for 3h under nitrogen. After the reaction came to
completion (TLC analysis), the cooled reaction mixture was vacuum filtered to
remove unreacted potassium carbonate and the organic solvent evaporated under

168

reduced pressure on a rotary evaporator to give a yellow oil. The oil was purified by
column chromatography to a afford clear oil, which was then recrystallised from hot
ethanol to give colourless crystals of 76 (0.30 g, 69 %). Mp. 88-90 oC. Mass spectrum
(CI+) m/z 503 [MH+1,

35

Cl]; HRMS (CI) Found: 503.1196 (1.1 ppm), required:

503.1190 for C28H24 35ClN2O3S.

1

H-NMR (CDCl3, 300 MHz): 3.50 (bs, 8H, CH2,

piperazine), 4.26 (t, J = 11.4 Hz, 1H, CH, H1”), 4.52 (d, J = 6.3 Hz, 2H, OCH2), 7.257.42 (m, 6H, ArH- H5, H6, H3”, H4”, H7” and H8”), 7.46-7.56 (m, 2H, ArH- H2”
and H8”), 7.74-7.88 (m, 4H, ArH- H4, H7, H5” and H6”). 13C-NMR: 47.7 (C2` and
C6`), 122.8 (C7), 122.9 (C4), 127.3 (C4” and C7”), 128.0 (C2”, C5”, C6” and C8”),
141.5 (C6a” and C6b”), 143.9 (C1a” and C9a”), 156.3 (C=O) and 162.5 (C=O).

Synthesis of 9H-9-fluorenylmethyl 4-(3-bromobenzo[b]thien-2-oyl)-1piperazinecarboxylate (77).
Following the same procedure
O

used

Br
N

O

N

S

to

prepare

71,

77

(C28H23BrN2O3S) (0.19 g, 32
%), was prepared by reacting 65

O

(0.35 g, 1.07 mmol) and 46 (0.31 g, 1.25 mmol) to give 77 as a solid after
chromatography and re-crystallisation from hot ethanol. Mp 98-102 oC. Mass
spectrum, (CI+) m/z 547 [MH+1,

81

Br]; HRMS (CI) Found: 546.3121 (1.5 ppm),

required: 546.2590 for C28H2481BrN2O3S. 1H-NMR (CDCl3, 300 MHz): 3.53 (bs, 8H,
CH2, piperazine), 4.25 (t, J = 11.4 Hz, 1H, CH, H1”), 4.52 (d, J = 6.3 Hz, 2H, OCH2),
7.26-7.42 (m, 6H, ArH- H5, H6, H3”, H4”, H7” and H8”), 7.46-7.57 (m, 2H, ArHH2” and H8”), 7.73-7.88 (m, 4H, ArH- H4, H7, H5” and H6”).

13

C-NMR: 47.7 (C2`
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and C6`), 122.8 (C7), 122.9 (C4), 127.3 (C4” and C7”), 128.0 (C2”, C5”, C6” and
C8”), 142.0 (C6a” and C6b”), 143.9 (C1a” and C9a”), 158.2 (C=O) and 163.1 (C=O).

Synthesis of N,N-diallyl-3-chlorobenzo[b]thiophen-2-carboxamide (78).
Diallylamine (0.266 mL, 2.16 mmol) dissolved in dry
Cl

tetrahydrofuran (5 mL) was added to a mixture of 23
N

S
O

(0.5 g, 2.17 mmol) and anhydrous potassium carbonate
(0.5 g, 3.62 mmol) in dry THF (15 mL). The mixture

was heated at reflux for 3h under nitrogen. The reaction mixture was cooled to room
temperature and then filtered to remove the unreacted potassium carbonate. Organic
solvent was evaporated under reduced pressure to give a yellow oil which was
purified via column chromatography (30 % ethyl acetate: hexane). Compound 78
(0.60 g, 95 %) was isolated as a clear oil. Mass spectrum (CI+), m/z 292 [MH+1, 35Cl];
HRMS (CI) Found: 291.0176 (1.1 ppm), required: 291.0170 for C15H15
1

35

ClNOS.

H-NMR (CDCl3, 300 MHz): 3.92, 4.19 (bd, 4H, 2x NCH2), 5.24 (sx, J = 13.0 Hz,

4H, CH2), 5.74, 5.81 (bd, J = 36.9 Hz, 2H, 2x CH), 7.45 (qn, J = 7.28 Hz, 2H, ArH,
H5 and H6), 7.8 (m, 2H, ArH, H4 and H7). 13C-NMR: 47.1, 51.1 (C2`), 118.2, 118.8
(C4`), 122.6 (C7), 122.9 (C4), 125.6, 126.6 (C5 and C6), 129.9 (C3), 132.2, 132.9
(C3`), 137.4 (C3a) and 163.1 (C=O).

Synthesis of N,N-diallyl-3-bromobenzo[b]thiophen-2-carboxamide (79).
In the same manner used to synthesise 73, 79 (0.35 g,
Br

95 %) was prepared by the reaction of 25 (0.28 g, 1.09
N

S

mmol) and 47 (0.14 mL, 1.09 mmol) to give a yellow

O
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oil which was then flash chromatographed to afford 79 as a clear oil. Mass spectrum
(CI+), m/z 337 [MH+1,

81

Br]; HRMS (CI) Found: 336.3171, required: 336.3170 for

C15H15 81BrNOS. 1H-NMR (CDCl3, 300 MHz): 3.92, 4.19 (bd, 4H, 2x NCH2), 5.24
(sx, J = 13.08 Hz, 4H, CH2), 5.74, 5.81 (bd, J = 36.9 Hz, 2H, 2x CH), 7.45 (qn, J =
7.28 Hz, 2H, ArH, H5 and H6), 7.8 (m, 2H, ArH, H4 and H7). 13C-NMR: 47.1, 51.1
(C2`), 118.2, 118.8 (C4`), 122.6 (C7), 122.9 (C4), 125.6, 126.6 (C5 and C6), 129.9
(C3), 132.2, 132.9 (C3`), 137.4 (C3a) and 163.1 (C=O).

Synthesis of N-4-(tert-butyl)-(4S)-2-(3-chlorobenzo[b]thien-2-oyl)-1,2,3,4tetrahydro-4-isoquinolinecarboxamide(80).
Following the same method as that used to
HN

O

Cl

by reacting 23 (0.45 g, 1.95 mmol) and 45
N

S

synthesise 76, 80 (0.75 g, 90 %) was prepared

O

(0.45 g, 1.93 mmol). Compound 80 was
obtained

as

colourless

crystals

after

purification by chromatography and re-crystallisation from ethanol. Mp 162-164 oC.
Mass spectrum (CI+) m/z 427 [MH+1,

35

.

Cl], 391 (C23H23N2O2S ). HRMS (EI) Mass

Found: 426.1168 (7.5 ppm), required: 426.1136 for C23H2335ClN2O2S.

1

H-NMR

(CDCl3, 300 MHz): 1.31 (s, 9H, 3x CH3), 3.14; 3.48 (dd, 2H, H3`), 4.62 (s, 2H, H1`),
5.28 (bs, 1H, H4`), 6.93-7.48 (m, 4H, ArH- H5`, H6`, H7` and H8`),7.53 (m, 2H,
ArH, H5 and H6), 7.88 (m, 2H, ArH- H4 and H7).

13

C-NMR: 29.0 (3x CH3), 47.7

(C4`), 51.8 (C1` and C-CH3), 54.6 (C3`), 122.9 (C7), 124.0 (C5), 125.7 (C6), 126.7;
127.0 (C6`or C7`), 128.0; 128.5 (C3, C4), 134.1 (C4a`), 137.2 (C3a), 164.3 (C=O)
and 168.5 (C=O-NH).
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Synthesis of N-4-(tert-butyl)-(4S)-2-(3-bromobenzo[b]thien-2-oyl)-1,2,3,4tetrahydro-4-isoquinolinecarboxamide (81).
Dry N,N-dimethylformamide (20 mL) was
HN
Br

4
3

7

added to an ice-cooled mixture of 25 (0.42 g,

O

3'

4'

N

S

7'
1'

O

6'

1.63 mmol), 45 (0.35 g, 1.56 mmol), HOBt
(0.21 g, 1.55 mmol) and DCC (0.35 g, 1.69
mmol). The mixture was then warmed to room

temperature and stirring continued overnight under nitrogen. The mixture was filtered
to remove the precipitated urea. The filtrate was then evaporated to give an oil which
was dissolved in ethyl acetate (25 mL) and re-filtered. The organic portion was
washed once with distilled water (50 mL) and dried. Solvent was evaporated to afford
a clear oil which solidified rapidly. The solid was then chromatographed (30 % ethyl
acetate: hexane) and re-crystallised from dichloromethane: hexane to give 81 (0.45 g,
60 %) as a colourless crystalline solid. Mp 148-150 oC. Mass spectrum (CI+) m/z 471
[MH+1, 81Br]; HRMS (EI) Found: 472.0643 (1.2 ppm), required: 472.0637 for C23H23
81

BrN2O2S. 1H-NMR (CDCl3, 300 MHz): 1.31 (s, 9H, 3x CH3), 3.14; 3.46 (dd, 2H,

H3`), 4.62 (s, 2H, H1`), 5.28 (bs, 1H, H4`), 6.93-7.48 (m, 4H, ArH- H5`, H6`, H7`
and H8`),7.53 (m, 2H, ArH- H5 and H6), 7.88 (m, 2H, ArH, H4 and H7). 13C-NMR:
29.0 (3x CH3), 47.7 (C4`), 51.8 (C1` and C-CH3), 54.6 (C3`), 122.9 (C7), 124.0 (C5),
125.7 (C6), 126.7; 127.0 (C6`or C7`), 128.0; 128.5 (C3, C4), 134.1 (C4a`), 137.2
(C3a), 164.3 (C=O) and 168.5 (C=O-NH).
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Synthesis of 1-(3-chlorobenzo[b]thien-2-oyl)-4-(4-chlorophenyl)-4-hydroxypiperidine (82).

Cl

N

S

Following the same method as that

OH

Cl

used to synthesise 76, 82 (0.40 g, 45
%) was synthesised by reacting 23

O

(0.5 g, 2.17 mmol) and 48 (0.45 g,

2.13 mmol) to give a clear oil after chromatography. Mass spectrum (CI+) m/z 406
[MH+1,

35

Cl]; HRMS (EI) Found: 406.3254 (1.2 ppm), required: 406.0357 for

C20H17Cl2NO2S. 1H-NMR (CDCl3, 300 MHz): 1.73-1.87 (bs, 4H, 2x CH2), 2.06 (s,
1H, OH), 3.36;3.63 (bs, 4H, 2x CH2), 7.3 (m, 4H, ArH, phenyl), 7.46 (m, 2H, ArH, H5
and H6), 7.82 (m, 2H, ArH, H4 and H7). 13C-NMR: 35.2 (2x N-CH2), 38.0 (2x CH2),
71.3 (C4`), 119.3 (C3), 122.7; 122.9 (C4, C7), 125.6 (C5, C6), 128.6 (C1”, C2” and
C5”), 129.9 (C4”), 137.5 (C3a, C1”), 146.3 (C7a) and 161.6 (C=O).

Synthesis of 1-(3-bromobenzo[b]thien-2-oyl)-4-(4-chlorophenyl)-4-hydroxypiperidine (83).

Cl

N

S

Following the same method as that

OH

Br

used to synthesise 81, 83 (0.71 g, 93
%) was prepared from 25 (0.37 g, 1.74

O

mmol) and 48 (0.37 g, 1.74 mmol) to

afford a clear oil after chromatography (30 % ethyl acetate: hexane). Mass spectrum
(CI+) m/z 449 [MH+,

81

Br]; HRMS (EI) Found: 448.7764 (3.2 ppm), required:

448.9851 for C20H1781Br35ClNO2S. 1H-NMR (CDCl3, 300 MHz): 1.73-1.87 (bs, 4H, 2x
CH2), 2.06 (s, 1H, OH), 3.36;3.63 (bs, 4H, 2x CH2), 7.3 (m, 4H, ArH, phenyl), 7.46 (m,
2H, ArH, H5 and H6), 7.82 (m, ArH, H4 and H7).

13

C-NMR: 35.2 (2x N-CH2), 38.0
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(2x CH2), 71.3 (C4`), 119.3 (C3), 122.7; 122.9 (C4, C7), 125.6 (C5, C6), 128.6 (C1”,
C2” and C5”), 129.9 (C4”), 137.5 (C3a, C1”), 146.3 (C7a) and 161.6 (C=O).

Synthesis of 2-(3-chlorobenzo[b]thien-2-yl)(5-(4-chlorophenyl)-2,5-diaza
bicyclo[2.2.1]heptan-2-yl)methanone (84).

5
6

7'

Cl

3a

3

2'
1'

S

2

O

3'

N

6'

The amine 43, (0.07 g, 0.33

2"
4'

Cl

1"

N

6"

5"

mmol) in its free base state was
reacted with 23 (0.07 g, 0.30
mmol), and anhydrous potassium

carbonate (0.06 g, 0.43 mmol) in anhydrous THF (15 mL). The mixture was heated at
reflux for 3h under nitrogen. The mixture was then cooled to room temperature and
vacuum filtered to remove unreacted base. The filtrate was evaporated under reduced
pressure to give light yellow oil, which was then purified via chromatography (30 %
ethyl acetate: hexane) to give a colourless solid of 84 (0.04 g, 33 %). Mp.114-120 oC.
Mass spectrum (CI+) m/z 403 [MH+1, 35Cl]; HRMS (CI) Found: 402.0356 (2.2 ppm),
required: 402.0360 for C20H1735Cl2N2OS. 1H-NMR (CDCl3, 300 MHz): 1.90; 2.08
(d, J = 9.5 Hz, 2H, H7`), 2.64 (t, J = 58.1 Hz, 1H, H3`), 3.33 (dd, J = 9.0, 5.02, Hz
2H, H5`), 4.52 (d, J = 9.3 Hz, 2H, H2`), 4.39 (q, J = 24.6 Hz, 1H, H6`), 6.42-6.90 (m,
2H, ArH-phenyl, H2”; H6”, 2H,), 7.13-7.20 (m, 2H, ArH-phenyl, H3”; H5”, 2H,),
7.46 (m, 2H, ArH- H5 and H6), 7.85 (m, 2H, ArH- H4 and H7).

13

C-NMR: 37.0

(C7`), 47.4 (C2`, C5`), 55.0 (C6`), 57.0 (C3`), 118.2 (C2”, C6”), 122.8 (C7), 123.9
(C7, C4”), 125.9 (C5, C6), 129.3 (C3, C3”, C5”), 138.0 (C3a), 150.0 (C1”) and 164.0
(C=O).
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Synthesis of 2- (3-bromobenzo[b]thien-2-yl)(5-(4-chlorophenyl)-2,5-diaza
bicyclo [2.2.1]heptan-2-yl)methanone (85).
Following the same method as that
Br

Cl

used to synthesise 81, 85 (0.20 g,

N
N

S

28 %) was prepared by reacting the

O

bromo- substituted acid 25 (0.40 g,

1.55 mmol) and the amine 44 (0.30 g, 1.40 mmol) in its free base form. Compound 85
was obtained as a colourless solid after chromatography and re-crystallisation from
ethanol. Mp.147-150

o

C. Mass spectrum, (CI+) m/z 449 [MH+1,

79

Br]; 369

.

(C20H16ClN2OS ). 1H-NMR (CDCl3, 300 MHz): 2.08 (d, J = 9.5 Hz, 2H, H7`), 2.66
(t, J = 58.1 Hz, 1H, H3`), 3.33 (dd, J = 9.0, 4.05 Hz, 2H, H5`), 4.49 (d, J = 9.3 Hz,
2H, H2`), 4.40 (q, J = 24.6 Hz, 1H, H6`), 6.40-6.91 (m, 2H, ArH-phenyl, H2”; H6”,
2H,), 7.13-7.22 (m, 2H, ArH-phenyl, H3”; H5”, 2H,), 7.47 (m, 2H, ArH- H5 and H6),
7.83 (m, 2H, ArH- H4 and H7).

13

C-NMR: 37.4 (C7`), 47.3 (C2`, C5`), 55.1 (C6`),

57.1 (C3`), 118.3 (C2”, C6”), 122.7 (C7), 123.9 (C7, C4”), 125.9 (C5, C6), 129.3 (C3,
C3”, C5”), 137.8 (C3a), 152.0 (C1”) and 164.0 (C=O).

Ethyl 3-chlorobenzo[b]thiophene-2-carboxylate (86).
Cl

To a solution of 23 (0.30 g, 1.30 mmol) in absolute
OCH2CH3

S
O

ethyl alcohol (5 mL) was added 2 drops of
concentrated sulfuric acid and the mixture heated at

reflux overnight. After all the substrate had reacted (via TLC), the mixture was cooled
to room temperature and solvent evaporated in vacuo to give a yellow oil which
solidified rapidly. The solid was purified by re-crystallisation from DCM: hexane to
give 86 (0.25 g, 81 %). Mass spectrum, (CI+) m/z 241 [MH+1,

35

Cl]. 1H-NMR
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(CDCl3, 300 MHz): 1.43 (t, J = 7.2 Hz, 3H, CH3), 4.43 (q, J = 7.1 Hz, 2H, CH2), 7.51
(m, 2H, H5 and H6), 7.81 (d, J = 5.7 Hz, 1H, H4), 7.98 (d, J = 6.9 Hz, 1H, H7). 13CNMR: 15.1 (CH3), 61.1 (CH2), 122.6 (C7), 122.9 (C4), 125.6, 126.6 (C5 and C6),
129.9 (C3), 137.4 (C3a) and 163.1 (C=O).
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6.2.2. Experimental for Chapter 3: The synthesis of fused
benzo[b]thiophene amides.

Synthesis of 2-allyl-4-methyl-1,2,3,4-tetrahydrobenzo[4,5]thieno[2,3-c]
pyridin-1-one (92).
To a solution of 79 (0.54 g, 1.61 mmol) heated at
reflux in dry toluene (20 mL) under argon was added
N

S
O

dropwise using an addition funnel a mixture of
tributyltin

hydride

(1.0

mL,

3.4

mmol)

and

azobis(isobutyronitrile) (0.28 g, 1.70 mmol) in dry toluene (35 mL) over a period of
one hour forty-five minutes. The mixture was heated at reflux for a further three and
half hours. The reaction mixture was then cooled to room temperature and the solvent
evaporated under reduced pressure which gave a yellow oil. The oil was then
dissolved in diethyl ether (25 mL) and a saturated solution of potassium fluoride (25
mL) added with continued stirring for a further 1h. The organic layer was then
separated, washed with distilled water (2x 25 mL) and dried. Organic solvent was
evaporated in vacuo to give a crude yellow oil which was purified via
chromatography (20 % ethyl acetate: hexane) to give 92 (0.20 g, 49 %) as colourless
.

oil. Mass spectrum (CI+) m/z 258 [MH+1], 242 (C14H12NOS ); HRMS (EI) Found:
257.0874 (4.5 ppm), required: 257.0862 for C15H15NOS. 1H-NMR (CDCl3, 300
MHz): 1.33 (d, J = 2.4 Hz, 3H, CH3), 3.33;3.87 (d and q Ja = 6 Hz, Jb = 6 Hz, 2H,
H3), 3.98 (d, J = 6.6 Hz, 2H, H1`), 4.36-4.38 (m, 1H, H4), 5.19-5.31 (m, 2H, H3`),
5.81-5.90 (m, 1H, H2`), 7.40 (m, 2H, ArH- H7 and H8), 7.85 (m, 2H, ArH- H6 and
H9). 13C-NMR: 18.6 (C5, CH3), 28.8 (C4), 49.2 (C1`), 53.0 (C3), 118.6 (C3`), 122.6
(C9), 122.9 (C6), 125.6, 126.6 (C7 and C8), 137.4 (C5a), 138.8 (C2`), 142.5 (C5b),
143.7 (C3a) and 161.4 (C=O).
177

Synthesis of N,N-diallyl-2-bromobenzamide (94).
3'
3

Br
2
1

1'

N

2'

o-Bromobenzoyl chloride (91) (4.0 g, 1.83 mmol) in THF (15
mL) was heated at reflux in 2 % LiOH (15 mL) for 1h after
which it was treated with 2 M HCl

to precipitate 2-

6

bromobenzoic acid (93) ( 3.7 g, 81 %) as a white solid. The

O

precipitate was washed with distilled water (20 mL) and dried in vacuo. Anhydrous
DMF (15 mL) was then added to a mixture of the acid 93 (2g, 10.0 mmol), HOBt
(1.35g, 10.0 mmol), DCC (2.06 g, 10.0 mmol) and diallylamine (47). The reaction
mixture was stirred overnight at room temperature under nitrogen after which it was
filtered to remove the precipitated dicyclohexyl urea. The filtrate was concentrated
under reduced pressure to give a dark oil which was dissolved in ethyl acetate and
filtered. The ethyl acetate was evaporated to give an oil which was purified via
column chromatography to afford 94 (1.9 g, 68 %) as a clear oil. Mass spectrum (CI+)
.

m/z 280 [MH+1], 200 (C13H14NO ). 1H-NMR (CDCl3, 300 MHz): 3.77 (bs, 4H, 2x
H1`), 5.03-5.30 (m, 4H, 2x H3`), 5.58; 5.85 9m, 2H, 2x H2`), 7.22 (t, J = 7.1 Hz, 2H,
ArH- H4 and H5), 7.49 (bs, 1H, H3), 7.71 (bs, 1H, H6). 13C-NMR: 49.1 (2x C1`),
118.4 (2x C3`), 119.1 (2x C3`), 125.4 (C5), 126.3 (C6), 127.6 (2x C2`), 130.4 (C3),
132.3 (C4), 137.9 (C1) and 169.3 (C=O).

Synthesis of 2-allyl-4-methyl-1,2,3,4-tetrahydro-1-isoquinolinone (95).
To a stirred solution of 94 (1.0 g, 3.58 mmol) heated at reflux
in dry toluene (20 mL) under argon was added dropwise using
N
O

an addition funnel, a mixture of tributyltin hydride (1.0 mL,
3.46 mmol) and AIBN (0.30 g, 1.73 mmol) in dry toluene (20

mL) over a period of one hour forty-five minutes. The mixture was further heated at
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reflux overnight. The reaction mixture was then cooled to room temperature and the
toluene evaporated under reduced pressure to give a yellow oil. The oil was then
dissolved in diethyl ether (20 mL) and to it a saturated solution of potassium fluoride
(25 mL) was added with stirring for 1h. The mixture was filtered and the organic layer
was separated, washed with distilled water (2x 25 mL) and dried. Organic solvent was
evaporated in vacuo to give an oil which was purified via chromatography (20 %
ethyl acetate: hexane) to give 95 (0.36 g, 50 %) as a clear oil. Mass spectrum (CI+)
m/z 202 [MH+1]; 1H-NMR (CDCl3, 300 MHz): 1.35 (d, J = 2.4 Hz, 3H, CH3),
3.35;3.87 (m, 2H, H3), 3.94 (d, J = 6.6 Hz, 2H, H1`), 4.34-4.38 (m, 1H, H4), 5.205.33 (m, 2H, H3`), 5.81-5.90 (m, 1H, H2`), 7.44 (m, 2H, ArH- H7 and H8), 7.82 (m,
2H, ArH- H6 and H9). 13C-NMR: 18.7 (C5, CH3), 32.3 (C4), 49.8 (C1`), 51.8 (C3),
118.3 (C3`), 122.7 (C6), 127.1 (C8), 127.8 (C9) 128.6 (C7), 133.0 (C2`), 133.2 (C9a),
143.2 (C5a) and 161.4 (C=O).

Attempted synthesis of the diol 96 using the Sharpless reagent (AD-mix α).
To a mixture of tert-butyl alcohol (3 mL) and distilled
OH

water (3 mL) was added AD-mix α followed by the

N
O

OH

addition of methyl sulfonamide (0.04 g, 0.42 mmol) and

the reaction stirred at room temperature until fully mixed (yellow solution). The
solution was then cooled to 0 oC (ice bath) and the olefin 95 (0.08 g, 0.39 mmol)
dissolved in minimal tert-butyl alcohol added. Stirring was continued with periodic
TLC monitoring. After 7h, no reaction of the starting material 95 was apparent. The
reaction mixture was then stirred at 0 oC (ice bath) for a further 5h; however, starting
material was still evident. The temperature was then raised to 10 oC and stirring

179

continued for 12h. TLC analysis (30 % ethyl acetate: hexane, visualisation: iodine
vapour) showed no reaction progress hence the reaction mixture was warmed to room
temperature and stirred overnight. The reaction was then quenched at low temperature
(0 oC) with the addition of sodium sulfite (0.1 g, 0.79 mmol) and stirring at room
temperature for 1h (clear solution). The solution was taken up in ethyl acetate (15
mL) and washed once with 2 M potassium hydroxide solution (10 mL) to remove any
methyl sulfonamide present and then once with distilled water (15 mL). The organic
portion was then dried and evaporated on the rotary evaporator to give a yellow oil
which on TLC and spectroscopic analysis was shown to be the starting material 95
(0.05 g).

Attempted synthesis of the model diol 98 from allyl bromide using the
Sharpless reagent AD-mix α.
OH

Following a similar method as that used to attempt the synthesis of
96, allyl bromide (97) (0.1 g, 0.83 mmol) was reacted with AD-mix

Br
OH

α. Workup of the reaction mixture after 10h indicated that the

expected diol was not formed, however the starting material 96 (0.07 g) was
recovered. Mass spectrum (CI+) m/z 121 [MH+1, 81Br]. 1H-NMR (CDCl3, 300 MHz):
3.15 (d, J = 4.8 Hz, 2H, H1), 5.25 (t, J = 7.0 Hz, 2H, H3), 5.84-5.90 (m, 1H, H2). 13CNMR: 53.6 (C1), 117.3 (C3) and 136.1 (C2).
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Synthesis of 2-(2,3-dihydroxypropyl)-4-methyl-1,2,3,4-tetrahydro-1isoquinolinone (96).
To a stirred solution of the olefin 95 (0.34 g, 1.69 mmol)
in a mixture of AR grade acetone (5 mL) and distilled

OH
N

water (2 mL) was added potassium osmate (0.034 g , 10

O

OH

%) and N-methylmorpholine-N-oxide (0.5g, 4.21mmol).

The reaction mixture was stirred at room temperature for 24h. The reaction was then
quenched by adding sodium sulfite (0.5 g, 3.52 mmol) and stirring continued for 1hr.
The mixture was extracted with ethyl acetate (2x 15 mL). The aqueous portion was
then washed with ethyl acetate (2x 10 mL) and the pooled organic solvents
concentrated under reduced pressure to give a dark oil (0.29 g, 74 %). The oil was
further purified by column chromatography (10 % methanol: DCM) to give 96 (0.12
g, 31 %) as a colourless oil. Mass spectrum (CI+) m/z 236 [MH+1]. 1H-NMR (CDCl3,
300 MHz): 1.35 (d, J = 2.4 Hz, 3H, CH3), 2.45 (bs, 2H, 2x OH), 3.31-3.92 (m, 8H,
H1`, H3`, H3, H4, H2`), 7.48 (m, 2H, ArH- H7 and H8), 7.82 (d, J = 6.0, Hz, 1H, H6)
and 8.03 (t, J = 3.5, Hz, 1H, H9). 13C-NMR: 18.7 (C5, CH3), 32.3 (C4), 51.0 (C1`),
55.4 (C3), 64.0 (C3`), 66.8 (C2`), 122.7 (C6), 127.1 (C8), 127.8 (C9) 128.6 (C7),
133.2 (C9a), 143.2 (C5a) and 162.4 (C=O).

Synthesis of 2-(2,3-dihydroxypropyl)-4-methyl-1,2,3,4-tetrahydrobenzo[4,5]
thieno[2,3-c]pyridin-1-one (99).
To a stirred solution of the olefin 92 (0.35 g, 1.36
OH

mmol) in a mixture of acetone (5 mL, AR grade)

N

S
O

and distilled water (2 mL) was added potassium
OH

osmate (0.04 g , 10 %) and N-methylmorpholine-

181

N-oxide (0.39 g, 3.36 mmol). The reaction mixture was stirred at room temperature
overnight. The reaction was then quenched by adding sodium sulfate (0.1g, 0.70
mmol) and stirring continued for 1hr. The mixture was extracted with ethyl acetate
(2x 15 mL). The aqueous portion was then washed with ethyl acetate (2x 10 mL) and
the pooled organic solvents concentrated under reduced pressure to give a dark oil
which was purified by column chromatography (10 % methanol: DCM) to give 99
(0.32 g, 82 %) as colourless oil. Mass spectrum (CI+) m/z 292 [MH+1]. 1H-NMR
(CDCl3, 300 MHz): 1.33 (d, J = 2.4 Hz, 3H, CH3), 2.44 (bs, 2H, 2x OH), 3.33-3.92
(m, 8H, H1`, H3`, H3, H4, H2`), 7.48 (m, 2H, ArH- H7 and H8), 7.85 (dd, J = 3.45,
5.2, Hz, 2H, ArH- H6 and H9).

13

C-NMR: 18.6 (C5, -CH3), 28.9 (C4), 50.2 (C1`),

56.1 (C3), 70.9 (C3`), 71.2 (C2`), 122.6 (C9), 122.9 (C6), 125.6, 126.6 (C7 and C8),
137.4 (C5a), 142.5 (C5b), 143.7 (C3a) and 161.6 (C=O).

Synthesis of N-benzyl-3-bromobenzo[b]thiophene-2-carboxamide (100).
To a cooled mixture (ice bath) of the 3-bromo

Br
H
N

S
O

substituted acid 25 (0.60 g. 2.33 mmol), benzyl
amine (0.24 g, 2.24 mmol), DCC (0.48 g, 2.33

mmol) and HOBt (0.31 g, 2.29) was added anhydrous DMF (15 mL). The reaction
mixture was then warmed to room temperature and stirred overnight under nitrogen
after which time all the substrate had reacted (via TLC). The reaction mixture was
vacuum filtered to remove precipitated urea by-product. The organic solvent was then
evaporated under reduced pressure to give a dark oil which was dissolved in ethyl
acetate (20 mL) and then re-filtered. The ethyl acetate was evaporated to afford an oil
which was chromatographed (30 % ethyl acetate: hexane). The product had a
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tendency to crystallise in the column and hence a short column was run under
pressure to give 100 (0.78 g, 98 %) as a colourless, highly crystalline solid. Mp. 115.

117 oC. Mass spectrum (CI+) m/z 346 [MH+1, 81Br]; 266 (C16H12NOS ). HRMS (CI)
Found: 344.9822 (-1.0 ppm), required: 344.9826 for C16H12

81

BrNOS. 1H-NMR

(CDCl3, 300 MHz): 4.72 (d, J = 5.7 Hz, 2H, CH2), 7.31-7.45 (m, 5H, ArH benzyl),
7.48 (m, 2H, ArH- H5 and H6), 7.83 (dd, J = 3.45, 5.3 Hz, 2H, ArH- H4 and H7).
13

C-NMR: 44.5 (CH2), 106.6 (C3), 122.9 (C7), 124.7 (C4), 125.8 (C5 and C6), 127.9

(C4`), 128.0 (C2`and C6`), 129.1 (C3` and C5`), 137.7 (C3a), 138.6 (C1`), 138.7
(C2), and 161.1 (C=O).

Synthesis of N-allyl-N-benzyl-3-bromobenzo[b]thiophene-2-carboxamide
(101).
To a cooled solution (5 oC, ice bath) of sodium

3'

Br

4
3

7

1'

N

S

3"

2'
1"

hydride (0.055 g, 2.29 mmol) in anhydrous DMF
(5 mL) was slowly added 100 (0.50 g, 1.44

6"

1

O

mmol) in dry DMF (15 mL). Stirring was

continued at room temperature for 1h. The reaction mixture was then cooled to -60 oC
( dry ice/ acetone bath) and allyl bromide (0.17 g, 1.41 mmol) dissolved in dry DMF
(10 mL) added slowly. The reaction was slowly warmed to room temperature and
stirring continued overnight. The solvent was evaporated under reduced pressure to
give an oil. Distilled water (50 mL) was added to the oil and a gummy solid was
rapidly formed. Vigorous stirring of the gummy product in water was continued for
one and half hours after which it was extracted with dichloromethane (25 mL). The
organic extract was dried and concentrated to give an oily residue which was then
chromatographed (30 % ethyl acetate: hexane). The amide 101 (0.50 g, 91 %) was
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.

obtained. Mass spectrum (EI+), m/z 385 [MH+1,81Br], 306 (C19H16NOS ), 238
.

(C9H4BrOS ). HRMS (EI) Found: 387.0115 (-1.9 ppm), required: 387.0122 for
C19H1681BrNOS. 1H-NMR (CDCl3, 300 MHz): 3.78 (t, J = 11.2 Hz, 2H, H2`), 4.12
(s, 2H, CH2-benzyl), 5.16-5.30 (m, 2H, H3`), 5.60-5.83 (bs, 1H, H2`), 7.31-7.36 (m,
5H, ArH benzyl), 7.44 (m, 2H, ArH- H5 and H6), 7.83 (dd, J = 3.45, 5.30 Hz, 2H,
ArH- H4 and H7). 13C-NMR: 46.8 (C1`), 50.5 (C-CH2, benzyl), 114.3 (C3`), 118.6
(C3), 122.8 (C7), 123.8 (C4), 125.8 (C5), 126.6 (C6), 130.1 (C4”), 132.0-132.2 (C2”,
C3”, C5” and C6”), 137 (C1”), 137.9 (C3a), 159.3 (C7a) and 164.1 (C=O).

Synthesis of N-(4-methoxybenzyl)-3-bromobenzo[b]thiophene-2-carboxamide
(102).
Following the same procedure as that
Br

OMe
H
N

S

used

to

synthesise

100,

102

(C17H14BrNO2S), (1.14 g, 91 %) was

O

synthesised from 25 (0.85 g, 3.30 mmol)

and 4-methoxybenzyl amine (0.43 mL, 3.12 mmol) and obtained as a highly
crystalline colourless solid after chromatography (30 % ethyl acetate: hexane). Mp.
123-124 oC. Mass spectrum (EI+) m/z 376 [MH+1,

81

Br]; HRMS (EI) Found:

374.9928 (-0.3 ppm), required: 374.9929 for C17H1481BrNO2S. 1H-NMR (CDCl3, 300
MHz): 3.80 (s, 3H, OMe), 4.65 (d, J = 5.7 Hz, 2H, CH2), 6.91 (m, 2H, H3` and H5`),
7.34 (m, 2H, H2`and H6`), 7.46 (m, 2H, ArH- H5 and H6), 7.83 (dd, J = 3.45, 5.28
Hz, 2H, ArH- H4 and H7).

13

C-NMR: 44.0 (CH2), 55.5 (CH3), 106.6 (C3), 114.4

C3`and C5`) 122.9 (C6), 124.7 (C5), 125.7 (C4), 129.4 (C2`and C6`), 135.1 (C1`),
138.7 (C3a), 159.4 (C-O) and 161.0 (C=O).
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Synthesis of N-allyl-N-(4-methoxybenzyl)- 3-bromobenzo[b]thiophene-2carboxamide (103).
Following the same method as that used
Br

OMe
N

S

to prepare 101, 103 (C20H18BrNO2S),
(0.34 g, 72 %) was synthesised from 102

O

(0.43 g, 1.14 mmol) and allylbromide

(0.13 g, 1.08 mmol) and obtained as a colourless oil after chromatography. Mass
spectrum (CI+) m/z 416 [MH+1,

81

Br]; HRMS (EI) Found: 418.0299 (-0.2 ppm),

required: 418.0300 for C20H19 81BrNO2S.

1

H-NMR (CDCl3, 300 MHz): 3.73 (bs,

3H, OMe), 4.07(bs, 2H, H1`), 4.48 (s, 2H, CH2-benzyl), 5.08-5.27 (m, 2H, H3`), 5.605.83 (bs, 1H, H2`), 6.87 (d, J = 1.95 Hz, 2H, H3” and H5”), 7.10 (d, J = 2.25, Hz, 2H,
H2”and H6”), 7.45 (m, 2H, ArH- H5 and H6), 7.78 (dd, J = 3.45, 5.30 Hz, 2H, ArHH4 and H7). 13C-NMR: 21.3 (CH3), 46.8 (C1`), 50.5 (C-CH2, benzyl), 114.3 (C3`),
118.6 (C3), 122.8 (C7), 123.8 (C4), 125.8 (C5), 126.6 (C6), 130.1 (C4”), 132.0-132.2
(C2”, C3”, C5” and C6”), 137 (C1”), 137.9 (C3a), 159.4 (C7a) and 164.2 (C=O).

Synthesis of 2-benzyl-4-methyl-1,2,3,4-tetrahydrobenzo[4,5]thieno[2,3-c]
pyridin-1-one (104).
Following the same method as that used to

5
6
5b

9

5a

S

prepare 92, 104 (C19H17NOS), (0.90 g, 80 %)

3
1

O

chromatography.

3'

4

N

1'

5'

was synthesised from 101 (0.90 g, 1.14 mmol)
and obtained as a straw yellow oil after

Mass spectrum (CI+) m/z 308 [MH+1]; HRMS (EI) Found:

307.1030 (1.0 ppm), required: 307.1027 for C19H17 NOS. 1H-NMR (CDCl3, 300
MHz): 1.33 (d, J = 2.4 Hz, 3H, CH3), 3.33;3.87 (d Ja = 6 Hz, Jb = 6 Hz, 2H, H3),
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4.36-4.38 (m, 1H, H4), 4.57 (s, 2H, CH2-benzyl), 7.31-7.36 (m, 5H, ArH benzyl),
7.40 (m, 2H, ArH- H7 and H8), 7.85 (dd, J = 3.45, 5.3 Hz, 2H, ArH- H6 and H9).
13

C-NMR: 18.6 (C5, CH3), 28.8 (C4), 50.5 (C-CH2, benzyl), 53.0 (C3) 122.6 (C9),

122.9 (C6), 125.6, 126.6 (C7 and C8), 130.1 (C4`) 132.2 (C2`, C3`, C5` and C6`),
137.1 (C1`), 137.4 (C5a), 142.5 (C5b), 143.7 (C3a) and 161.8 (C=O).

Synthesis of 2-(4-methoxybenzyl)-4-methyl-1,2,3,4-tetrahydrobenzo[4,5]
thieno[2,3-c] pyridine-1-one (105).
Following the same method as that used
OMe

to prepare 92, 105 (C20H19NO2S), (0.90
N

S

g, 80 %) was synthesised from 103 (0.90
O

g, 1.14 mmol) as an oil after chromatography. Mass spectrum (CI+) m/z 338 [MH+1];
HRMS (CI) Found: 338.1214 (1.8 ppm), required: 338.1208 for C20H20 NO2S. 1HNMR (CDCl3, 300 MHz): 1.36 (d, J = 2.4 Hz, 3H, CH3), 3.34;3.86 (d Ja = 6 Hz, Jb =
6 Hz, 2H, H3), 4.33-4.35 (m, 1H, H4), 4.55 (s, 2H, CH2-benzyl), 6.87 (d, J = 1.95 Hz,
2H, H3` and H5`), 7.10 (d, J = 2.25, Hz, 2H, H2`and H6`), 7.40 (m, 2H, ArH- H7 and
H8), 7.85 (dd, J = 3.45, 5.27 Hz, 2H, ArH- H6 and H9). 13C-NMR: 18.6 (C5, CH3),
28.8 (C4), 50.5 (C-CH2, benzyl), 53.0 (C3) 122.6 (C9), 122.9 (C6), 125.6, 126.6 (C7
and C8), 130.3 (C4`), 132.2 (C2`, C3`, C5` and C6`), 137.2 (C1`), 137.4 (C5a), 142.5
(C5b), 143.7 (C3a) and 161.4 (C=O).
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Synthesis of 4-methyl-1,2,3,4-tetrahydrobenzo[4,5]thieno[2,3-c]pyridin-1-one
(106).
To a mixture of 92, (0.24 g, 0.93 mmol), triphenylphosphine
(0.24 g, 0.91 mmol) and palladium(II) acetate (0.23 g, 1.02
NH

S
O

mmol) was added formic acid (10 mL) under nitrogen and the
mixture heated at reflux for 1h. The mixture was then cooled

to room temperature and then vacuum filtered. Solvent was evaporated under reduced
pressure to give a dark crude residue which was then chromatographed (40 % ethyl
acetate: hexane) to give 106 (0.17 g, 85 %) as a yellow oil; due to traces of impurities,
the oil was further purified by successive preparative plate chromatography (0.05 g,
.

25 %). Mass spectrum (EI+) m/z 217, 202 (C11H8NOS ). HRMS (CI) Found:
218.0639 (2.6 ppm), required: 218.0633 for C12H12 NO2S. 1H-NMR (CDCl3, 300
MHz): 1.38 (d, J = 2.4 Hz, 3H, CH3), 3.38-3.70 (m, 2H, H3), 3.92-3.98 (m, 1H, H4),
7.46 (m, 2H, ArH- H7 and H8), 7.91 (dd, J = 3.45, 5.3 Hz, 2H, ArH- H6 and H9).
13

C-NMR: 18.2 (CH3), 28.6 (C4), 47.8 (C3), 122.9 (C9), 123.7 (C5), 125.1 (C7; C8)

142.3 (C5b), 145.6 (C5a), and 164.7 (C=O).

Attempted allyl deprotection of (92) using rhodium chloride.
To a mixture of 2-allyl-4-methyl-1,2,3,4-tetrahydrobenzo[4,5]thieno[2,3-c] pyridin-1one (92) (0.2 g, 0.77 mmol) and rhodium(III) chloride (0.15 g, 0.72 mmol) under
nitrogen was added ethanol (15 mL). The mixture was then heated at reflux for 1hr,
after which time no 92 could be detected by TLC analysis. The reaction mixture was
then cooled to room temperature and vacuum filtered. The filtrate was evaporated
under reduced pressure to give a black residue which was further purified via
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chromatography to give a yellow oil (0.01g, 6 %). Mass spectrum (CI+) m/z 177
[MH+1], m/z 161, m/z 133. This product was not identified. The expected product 106
was not successfully synthesised through this method.

Synthesis of N-benzylprop-2-en-1-amine (107).
Anhydrous tetrahydrofuran (20 mL) was added to a
H
N

mixture of benzylamine (1.0 mL), allyl bromide (0.6 mL)

and an excess of potassium carbonate (1.5 g, 10.86 mmol) under nitrogen and the
reaction mixture heated at reflux for 1h. The reaction mixture was then cooled to
room temperature and vacuum filtered to remove unreacted potassium carbonate.
Solvent was then evaporated under reduced pressure to give 107 (1.05 g, 76 %) as a
yellow oil. Mass spectrum (CI+) m/z 148 [MH+1] (C10H13N, base peak), m/z 188
[MH+1] (C13H17N). The mass spectrum showed an [MH+1] peak at m/z 188 consistent
with the undesired tertiary amine N-allyl-N-benzylprop-2-en-1-amine (108). 1H-NMR
(CDCl3, 300 MHz): 3.15 (d, J = 4.8 Hz, 2H, H1`), 3.59 (s, 2H, CH2- benzyl), 5.25 (t,
J = 10.0 Hz, 2H, H3`), 5.84-5.90 (m, 1H, H2`), 7.20-7.34 (m, 6H, ArH). 13C-NMR:
53.6 (C1`), 55.8 (CH2- benzyl), 117.3 (C3`), 127.0 (C4), 126.1 (C3 and C5), 129.0
(C2 and C6), 136.1 (C2`) and 138.2 (C1).
Tertiary amine (108) (C13H17N): 3.08 (d, J = 4.8 Hz, 4H, H1`), 3.57 (s, 2H, CH2benzyl), 5.18 (t, J = 10.0 Hz, 4H, H3`), 5.83-5.91 (m, 2H, H2`), 7.20-7.34 (m, 6H,
ArH).

13

C-NMR: 56.6 (2x C1`), 57.8 (CH2- benzyl), 117.6 (2x C3`), 127.0 (C4),

126.4 (C3 and C5), 129.1 (C2 and C6), 136.1 (C2`) and 139.6 (C1).
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Synthesis of 2-(2-bromobenzoyl)-1-(prop-2-enyl)-1,2,3,4-tetrahydro
isoquinoline (109).
To a stirred solution of 32 (1.5 g, 8.87 mmol) in dry
5"

4

5

4"

3
1

N

3"
2"

8
2'

1'

O

Br

3'

dichloromethane

was

added

consecutively

triethylamine (5.0 mL, 36.25 mmol), DMAP (0.11 g,
0.90 mmol) and o-bromobenzoyl chloride (2.46 g,
11.23 mmol) in dry DCM under nitrogen. Stirring

was maintained for 5h after which time all the substrate had reacted (TLC analysis).
To the reaction mixture was then added distilled water (25 mL) and the organic layer
separated and washed further with water (2x 15 mL) and then with 1 M HCL (20
mL), and finally with sodium bicarbonate solution (20 mL). The organic portion was
then dried and solvent evaporated under reduced pressure to give an oily residue
which was chromatographed (20 % ethyl acetate: hexane) and then re-crystallised
from ethanol to give 109 (0.88 g, 48 %) as a crystalline solid. Mp. 94-95 oC. Mass
spectrum (CI+) m/z 356 [MH+1,

81

Br]; HRMS (CI) Found: 356.0639 (2.6 ppm),

required: 356.0633 for C19H19 81BrNO. 1H-NMR (CDCl3, 300 MHz): 2.39; 2.66 (m,
2H, H1`), 2.787 (bs, 2H, H4), 3.28; 3.36 (m, 2H, H3), 5.05- 5.14 (m, 3H, H1 and
H3`), 5.83-6.12 (m, 1H, H2`), 7.07-7.23 (m, 4H, H5, H6, H7, H8), 7.35 (m, 2H, ArHH4” and H5”), 7.57 (dd, J = 3.45, 5.27 Hz, 2H, ArH- H3” and H6”).
13

C-NMR: 29.3 (C4), 41.4 (C1`), 42.0 (C3), 51.2 (C1), 117.8 (C3`), 119.7 (C2”),

126.8 (C7), 127.1 (C6), 127.6 (C5 and C5`), 127.9 (C8), 130.6 (C3”), 134.0 (C2`),
138.0 (C1”) and 168.5 (C=O).
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Synthesis of N-benzoyl-7-methyl-6,7,8,9-tetrahydro-5H-benzocycloheptane5,8-imine (110).
Following the same general method (free radical

9

1

8

2

7

cyclisation reaction) as that used to synthesise 92, 110

N

3

O

5

4

6

(0.53 g, 76 %) was synthesised from 109 (0.90 g, 2.52
1'

6'

2'

mmol) and obtained as a clear oil after chromatography.
Mass spectrum (CI+) m/z 277 [MH+1]; HRMS (CI)

4'

Found: 278.1445 (1.0 ppm), required: 278.1440 for C19H20NO. 1H-NMR (CDCl3,
300 MHz): 1.02 (s, 3H, CH3), 1.74; 1.87 (bm, 1H, H7), 2.65-2.93 (m, 2H, H9), 3.723.80 (m, 1H, H8), 4.66-4.82 (m, 1H, H5), 7.12 (bs, 4H, H1-H4), 7.34 (bs, 3H, ArH3`,4` 5`) and 7.47 (bs, 2H, ArH- H2` and H6`).

13

C-NMR: 16.6 (CH3), 27.2 (C9),

30.2 (C7), 33.4 (C6), 46.0 (C5), 60.6 (C8), 125.0- 127.0 (9Ar-C), 135.2 (C1`) and
167.9 (C=O).

Synthesis of N-benzo[b]thien-2-oyl-7-methyl-6,7,8,9-tetrahydro-5H-benzo
cycloheptene-5,8-imine (112).
Following the same method (free radical

O
1

3'

9
8
7

4

1' S

4'

5
6

cyclisation reaction) as that used to synthesise

N

7'

92, 112 (0.50 g, 89 %) was synthesised from
53 (0.70 g, 1.70 mmol) was obtained as a clear

oil after chromatography (30 % ethyl acetate: hexane). A GC-MS analysis indicated 3
peaks of similar mass (m/z 333) corresponding to isomeric products. Further
purification was attempted via multi-development preparative plate chromatography,
but mixtures were still obtained. Mass spectrum (CI+) m/z 334 [MH+1]. HRMS (EI)
Found: 333.1187 (4.9 ppm), required: 333.1171 for C21H19NOS. Band 2 from the
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preparative plate was analysed as follows by GC-HRMS (EI). Peak 1 band 2 Found:
333.1187 (1.7 ppm), required: 333.1181 for C21H19NOS; Peak 2 band 2 Found:
333.1187 (0.8 ppm), required: 333.1184 for C21H19NOS; Peak 3 band 2 Found:
333.1187 (3.8 ppm), required: 333.1174 for C21H19NOS.

1

H-NMR (CDCl3, 300

MHz): 1.02 (s, 3H, CH3), 1.74; 1.87 (bm, 1H, H7), 2.65-2.93 (m, 2H, H9), 3.72-3.80
(m, 1H, H8), 4.66-4.82 (m, 1H, H5), 7.45 (m, 2H, ArH- H5 and H6), 7.78 (dd, J =
3.45, 5.3 Hz, 2H, ArH- H4 and H7), 7.81 (s, 1H, H3`).

13

C-NMR: 16.6 (CH3), 27.2

(C9), 30.2 (C7), 33.4 (C6), 46.0 (C5), 60.6 (C8), 119.6 (C3), 122.8 (C7), 123.8 (C4),
125.8 (C5), 126.6 (C6), 167.9 (C=O).

Synthesis of 1-(3-chlorobenzo[b]thien-2-oyl)-2,5-dihydropyrrole(113).
Anhydrous dichloromethane (30 mL) was added to a
Cl

mixture
N

S
O

of

78

(0.70

g,

2.41

mmol)

and

benzylidenebis(tricyclohexylphosphine)dichlororutheni
um. (Grubbs’ I catalyst) (0.0335 g, 0.042 mmol, 10 %).

The mixture was stirred under nitrogen at room temperature overnight. The reaction
mixture was then vacuum filtered and solvent evaporated to give a dark green
residue which was then flash chromatographed (DCM) to give 113 (0.46 g, 73 %)
as a colourless oil which solidified rapidly. Mp. 104-106 oC. Mass spectrum (CI+),
m/z 265 [MH+, 35Cl]; HRMS (CI) Found: 264.0249 (+ 0.0 ppm), required: 264.0249
for C10H1135ClNOS. 1H-NMR (CDCl3, 300 MHz): 4.31; 4.48 (d, J = 3.3 Hz, 2H, 2x
CH2), 5.79; 5.93 (q, J = 3 Hz, 1H, 2x CH), 7.53 (m, 2H, ArH- H5 and H6), 7.88 (dd,
J = 3.45, 5.28 Hz, 2H, ArH- H4 and H7). 13C-NMR: 64.1 (C2`; C5`), 122.7 (C7).
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122.9 (C4), 125.6 (C5), 126.7 (C6), 128.5 (C3`; C4`), 129.7 (C3), 135.8 (C3a), 137.6
(C2a) and 161.7 (C=O).

Synthesis of 113 using polymer supported Grubbs’ I catalyst.
Dry dichloromethane (25 mL) was added to a mixture of 23 (0.46 g, 1.56 mmol) and
polymer

supported

benzylidene-bis(tricyclohexylphosphine)dichlororuthenium

(polymer supported Grubbs’ I catalyst) (0.0330 g, 0.042 mmol).The mixture was
then stirred overnight at room temperature under argon. The reaction mixture was
vacuum filtered and the recovered catalyst washed once with dichloromethane, dried
in vacuo and stored under nitrogen. The combined filtrate and washings were
evaporated to afford a clear oil, which was flash chromatographed (DCM). This gave
the product as a clear oil initially which then solidified rapidly to give colourless
crystals of 113 (0.35 g, 85 %). Mp.105-106 oC. Mass spectrum (CI+), m/z 265 [MH+1,
35

Cl]. The 1H-NMR and

13

C-NMR data was consistent with that of the desired

product 113 as shown above.

Synthesis of 1-(3-bromobenzo[b]thien-2-oyl)-2,5-dihydropyrrole(114).
Following the same method as that used to prepare 113,

Br

N

S
O

114 (0.24 g, 80 %) was prepared from 25 (0.34 g, 1.01
mmol) and homogeneous Grubbs’ I catalyst (0.030 g,

0.037 mmol) as a crystalline solid after flash chromatography (DCM). Mp.118-120
o

C. Mass spectrum (CI+) m/z 309 [MH+1,

81

Br]; HRMS (CI) Found: 307.9744 (2.0

ppm), required: 307.9738 for C10H1181BrNOS. 1H-NMR (CDCl3, 300 MHz): 4.31;
4.48 (d, J = 3.3 Hz, 2H, 2x CH2), 5.79; 5.93 (q, J = 3 Hz, 1H, 2x CH), 7.53 (m, 2H,
ArH- H5 and H6), 7.88 (dd, J = 3.45, 5.3 Hz, 2H, ArH- H4 and H7). 13C-NMR: 64.1
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(C2`; C5`), 122.7 (C7). 122.9 (C4), 125.6 (C5), 126.7 (C6), 128.5 (C3`; C4`), 129.7
(C3), 135.8 (C3a), 137.6 (C2a) and 161.7 (C=O).

Synthesis of methyl 3-allylbenzo[b]thiophene-2-carboxylate (116).
The acid 25 (1.0 g, 3.89 mmol)was converted to its methyl
ester derivative 115 by heating it at reflux in methanol (15
OMe

S

mL) and a catalytic amount of concentrated sulfuric acid
O

overnight. Compound 115 was obtained as a white solid (0.9 g, 90 %). A glass highpressure tube was flushed with nitrogen and a mixture of palladium(II) chloride (0.1
g, 0.85 mmol) and triphenylphosphine (0.23g, 0.87 mmol) added, and to this mixture
was then added the methyl ester 115 (0.5 g, 1.85 mmol) in anhydrous DMF (15 mL)
and stirring continued. Allyltributyltin (0.6 mL) was then injected into the reaction
mixture and the tube sealed. The mixture was heated at 90 oC with stirring for 2h, and
then at 100 oC for 36h. The reaction mixture was then cooled to room temperature and
the solvent evaporated under reduced pressure to give a yellow oil. The oil was then
purified via chromatography (10 % ethyl acetate: 40-60 pet. spirit) to give 116 (0.21
g, 50 %) as a yellow oil. Mass spectrum (CI+) m/z 233 [MH+1]; HRMS (CI) Found:
232.0558 (1.0 ppm), required: 232.0555 for C13H13O2S.

1

H-NMR (CDCl3, 300

MHz): 3.91 (s, 3H, CH3), 4.15 (d, J = 4.2 Hz, 2H, H1`), 5.04-5.13 (m, 2H, H3`), 5.976.06 (m, 1H, H2`), 7.46 (m, 2H, ArH- H5 and H6), 7.85 (m, 2H, ArH- H4 and H7).
13

C-NMR: 31.6 (C1`), 52.4 (CH3), 116.2 (C3`), 122.9 (C7), 124.1 (C4), 124.7 (C5),

124.8 (C6), 127.4 (C2), 135.4 (C2`), 140.9 (C3b), 142.7 (C3a) and 163.6 (C=O).

Synthesis of 3-allylbenzo[b]thiophene-2-carboxylic acid (117).
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3'
1'

4
3

7

S

2'

LiOH (10 mL) in tetrahydrofuran (15 mL) was heated at

OH

2

A mixture of 116 (0.17g, 0.73 mmol) and 2 % aqueous

reflux for 3h. The reaction mixture was then cooled to

1

O

room temperature and the solvent was concentrated under

reduced pressure and then the residue acidified with 1 M HCl at 5-10 oC (ice bath).
The precipitate was vacuum filtered, washed with distilled water (20 mL) and then
dried under vacuum to give 117 (0.14g, 93 %) as a white solid. Mass spectrum (CI+)
m/z 218 [MH+1]. 1H-NMR (CD3COCD3, 300 MHz): 4.13 (d, J = 4.2 Hz, 2H, H1`),
4.97; 5.14 (m, 2H, H3`), 5.96; 6.05 (m, 1H, H2`), 7.52 (m, 2H, ArH- H5 and H6),
7.97 (dd, J = 3.45, 5.26 Hz, 2H, ArH- H4 and H7).

13

C-NMR: 31.6 (C1`), 116.2

(C3`), 122.9 (C7), 124.1 (C4), 124.7 (C5), 124.8 (C6), 127.4 (C2), 135.4 (C2`), 140.9
(C3b), 142.7 (C3a) and 163.6 (C=O).

Synthesis of (1-allyl-1,2,3,4-tetrahydroisoquinolin-2-yl)(3-allylbenzo[b]thien2-yl)methanone (118).
The isoquinoline 32 (0.11 g, 0.063 mmol)

3"

2"

5'

4'
3

5
6

S

3'

N 2'

2

1'

6'

was added to a cooled mixture (ice bath) of

7'

117 (0.14 g, 0.61 mmol), 1,3-dicyclohexyl-

8'

O

1"

2"

3"

carbodiimide (0.13 g, 0.63 mmol), and 1hydroxybenzotriazole (0.10 g, 0.74 mmol) in

dry DMF (10 mL). The mixture was stirred at room temperature under nitrogen for
24h. The precipitated dicyclohexylurea was removed by vacuum filtration. Solvent
was then evaporated under reduced pressure to give an oily residue which was then
taken up in ethyl acetate (20 mL) and the mixture urea re-filtered. The filtrate was
then washed with distilled water (40 mL), dried and the solvent evaporated to give a
yellow oil. The oil was further purified via column chromatography (20 % ethyl
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acetate: 40-60 pet. spirit) to give 118 (0.10 g, 55 %) as clear oil. Mass spectrum (CI+),
.

372 [MH+1]; 332 (C21H18NOS ). HRMS (EI) Found: 332.1500 (4.8 ppm), required:
332.1503 for C21H18NOS. 1H-NMR (CDCl3, 300 MHz): 2.70;2.95 (m, 2H, H1” allyl
THIQ), 3.50;3.66 (m, 2H, H4`), 3.66-3.88 (m, H3` and H1” allyl BTP), 4.85-5.18 (m,
5H, 2x H3” (CH2) and H1`), 5.91-6.02 (m, 2H, 2x H2”), 7.11-7.36 (m, 4H, ArH
THIQ), 7.42 (m, 2H, ArH- H5 and H6), 7.79 (m, 2H, ArH- H4 and H7). 13C-NMR:
29.8 (C4`), 31.7 (C1”, allyl BTP), 41.5 (C1”, allyl THIQ), 41.8 (C3`), 52.2 (C1`),
116.6 (C3”, THIQ), 118.1 (C3”, BTP), 122.7 (C7), 123.3 (C4), 124.7 (C6), 125.5
(C5), 127.0 (C5`), 135.0 (C2`, THIQ), 135.4 (C2), 136.6 (C2`,BTP) and 164.7 (C=O).
Note: BTP- benzo[b]thiophene and THIQ- tetrahydroisoquinoline

Synthesis of (1-allyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)(3allylbenzo[b]thien-2-yl)methanone (119).
Following a similar synthetic method as
OMe
N

S
O

OMe

that

used

to

prepare

118,

119

(C26H27NO3S) (0.19 g, 57 %) was
prepared from 34 (0.20 g, 0.85 mmol) and
117 (0.17 g, 0.77 mmol) and obtained as

a colourless oil after chromatography (30 % ethyl acetate: 40-60 pet. spirit). Mass
.

spectrum (CI+), 434 [MH+1]; 392 (C23H22NOS ). HRMS (CI) Found: 332.1721 (3.2
ppm), required: 332.1718 for C26H28NO3S. 1H-NMR (CDCl3, 300 MHz): 2.70;2.95
(m, 2H, H1” allyl THIQ), 3.50;3.66 (m, 2H, H4`), 3.66-3.81 (m, H3` and H1” allyl
BTP), 3.86 (s, 3H, 2x CH3), 4.85-5.18 (m, 5H, 2x H3” (CH2) and H1`), 5.91-6.02 (m,
2H, 2x H2`), 6.57 (s, 2H, ArH THIQ), 7.42 (m, 2H, ArH- H5 and H6), 7.79 (m, 2H,
ArH- H4 and H7).

13

C-NMR: 29.8 (C4`), 31.7 (C1”, allyl BTP), 41.5 (C1”, allyl
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THIQ), 41.8 (C3`), 52.2 (C1`), 56.1 (2x CH3), 56.1 (2x CH3), 110.5 (C5`; C8`), 116.6
(C3”, THIQ), 118.1 (C3”, BTP), 123.0 (C7), 123.3 (C4), 124.7 (C6), 125.5 (C5),
135.0 (C2`, THIQ), 135.4 (C2), 136.6 (C2`,BTP) 148.1 (C6`; C7`) and 165.0 (C=O).

Synthesis of 5,8,16,17-tetrahydroazonino[3,4-b]benzo[b]thieno[3,2-a]
isoquinolin-14(4bH)-one (120).
7

Dry dichloromethane (10 mL) was added to

6
4

3

10

2
14

11

S

13

O

15

N

1

a mixture of 118, (0.1 g, 0.26 mmol) and
polymer supported Grubbs’ I catalyst (0.15
g) under nitrogen and the mixture heated at

reflux over 12h. The reaction mixture was then cooled to room temperature and then
filtered to recover the catalyst. The filtrate was evaporated under reduced pressure to
afford a clear oil which solidified rapidly. The crude product was further purified via
column chromatography (30 % ethyl acetate: pet. spirit) to give a colourless solid
which was re-crystallised from ethanol to 120 (0.07 g, 78 %) as a give highly
crystalline solid. Note: A similar reaction was also attempted using the homogeneous
Grubbs’ I catalyst to give 120 (0.18 g, 75 %) as a crystalline solid after
chromatography and re-crystallisation. Mp. 233-245 oC. Mass spectrum (CI+), 346
[MH+1]; HRMS (CI) Found: 345.1187 (1.3 ppm), required: 345.1182 for C22H19NOS.
1

H-NMR (CDCl3, 300 MHz): 2.73-2.86 (m, 4H, H5 and H16), 3.71 (dd, J = 16.65,

Hz, 2H, H17), 3.71; 4.10 (q, J = 13.8 Hz, 2H, H8), 5.02 (t, J = 6.6 Hz, 1H, H15a),
5.99 (q, J = 3.3 Hz, 1H, H7), 6.17 (q, J = 10.3 Hz, 1H, H6), 6.92-7.16 (m, 4H, ArHH1-H4), 7.46 (m, 2H, ArH- H5 and H6), 7.82 (dd, J = 3.45, 5.3 Hz, 2H, ArH- H4 and
H7).

13

C-NMR: 27.9 (C8), 28.2 (C17), 36.2 (C5) 36.7 (C16), 59.0 (4b), 122.8 (C9
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and C12), 125.8-127.1 (C1-C3, C10 and C11), 129.4 (C7), 130.2 (C6), 133.2 (C13a),
138.0 (C4a), 138.9 (C17a), 140.0 (C8a) and 164.3 (C=O).

Attempted synthesis of (3-allylbenzo[b]thien-2-yl)(1-vinyl-1,2,3,4-tetrahydroisoquinolin-2-yl)methanone (122).
To a cooled solution (ice bath, sodium chloride)
of 3,4-dihydroisoquinoline (36) (0.80 g , 6.06
mmol) in dry ether (15 mL) was added a 1 M

N
S

solution in THF of vinylmagnesium bromide

O

(2.4 mL) under nitrogen. The reaction mixture was stirred for 5 minutes after which
116 (0.87 g, 3.75 mmol) in dry diethyl ether (10 mL) was added. The temperature
was raised to room temperature and stirring continued with periodic TLC monitoring
for 2h. The reaction was worked up by evaporating the solvent under reduced pressure
and the dark oil obtained was taken up in diethyl ether (25 mL) and washed once with
distilled water (15 mL). Organic solvent was dried and evaporated to give an oil. A
TLC analysis of the oil revealed no products and only starting material was present.

Synthesis of (benzo[b]thien-2-yl)(1H-indol-1-yl)methanone (124).
Anhydrous DMF (10 mL) was syringed in to a

3
3'

5'
6'

S

2

flask containing sodium hydride (0.082 g, 3.51

N1

2'

4

1'

O

5

7
6

mmol) under nitrogen and the solution cooled to
5 oC (ice bath) with stirring. Indole (123) (0.16

g, 1.36) dissolved in dry DMF (10 mL) was then added and stirring maintained for 45
minutes between 0-5 oC. The reaction mixture was then warmed to room temperature
and stirring continued for a further 45 minute after which time the temperature was
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dropped to -60 oC (liquid nitrogen: chloroform). The acid chloride 26 (0.27 g, 1.37)
dissolved in dry DMF (15 mL) was then added slowly and the mixture warmed to
room temperature and stirring maintained over 12h. After all the substrate had
reacted, (TLC analysis) the solvent was concentrated in vacuo to give a brown solid
residue. Distilled water (20 mL) was added to the flask containing the residue and the
mixture stirred for 1h, after which time it was extracted with dichloromethane (2x 25
mL). The aqueous layer was washed once with dichloromethane (15 mL). Pooled
organic solvents were then dried and evaporated under reduced pressure to give a
brown oil which solidified rapidly. The solid was purified by column chromatography
(40 % ethyl acetate: hexane) to give 124 (0.27 g, 71 %) as a brown crystalline solid.
.

Mp. 44-47 oC. Mass spectrum (CI+), 278 [MH+1]; 161 (C9H5OS ). HRMS (CI) Found:
278.1223 (3.2 ppm), required: 278.1220 for C17H12NOS. 1H-NMR (CDCl3, 300
MHz): 6.71 (d, J = 3.6 Hz, 1H, H3), 7.28 (d, J = 15.6 Hz, 1H, H2), 7.33-7.46 (m, 4H,
H5; H6, H5`; H6`), 7.74 (d, J = 3.9 Hz, 1H, H4), 7.90 (s, 1H, H3`), 7.93 (dd, J = 3.45,
Hz, 5.3 2H, ArH- H4 and H7). 8.44 (dd, J = 1.2, 2.6 Hz, 1H, H7). 13C-NMR: 102.8
(C3), 111.2 (C7), 120.0 (C4), 120.9 (C6), 121.2 (C3`), 122.2-125.5 (C5, C6, C4`C7`), 125.8 (C2), 130.4 (C3a) and138.7 (C7a)
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Synthesis of (3-bromobenzo[b]thien-2-yl)(1H-indol-1-yl)methanone (125).
In the same manner as that reported for 124,

Br

reaction of the bromo substituted acid chloride 27

N

S

(0.60 g, 2.33 mmol) and indole 123 (0.34 g, 2.90

O

mmol) yielded 125 after chromatography (40 %
ethyl acetate: hexane) as a brown solid (0.20 g, 45 %). Mass spectrum (CI+), m/z 356
.

.

.

[MH+1, 81Br], 276 (C17H10NOS ), 239 (C9H4BrOS ) and 211 (C8H4BrS ). HRMS (CI)
Found: 356.1211 (3.2 ppm), required: 356.1213 for C17H1181BrNOS. 1H-NMR
(CDCl3, 300 MHz): 6.71 (d, J = 3.6 Hz, 1H, H3), 7.26 (d, J = 15.6 Hz, 1H, H2), 7.337.44 (m, 4H, H5; H6, H5`; H6`), 7.74 (d, J = 3.9 Hz, 1H, H4), 7.93 (dd, J = 3.45, 5.26
Hz, 2H, ArH- H4 and H7). 8.44 (dd, J = 1.2, 2.5 Hz, 1H, H7). 13C-NMR: 102.6 (C3),
111.3 (C7), 120.0 (C4), 120.9 (C6), 122.2-125.5 (C5, C6, C4`-C7`), 125.8 (C2), 130.2
(C3a), 138.7 (C7a) and 164.3 (C=O).

Synthesis of 11H-benzo[b]thieno[2,3-c]pyrrolo[2,3-a]indol-11-one (126).
6

9

5c

N 12

S

10

O

To a mixture of 124 (0.22 g, 0.79 mmol) and

5

5a

5b

1

4

palladium(II) acetate (0.17 g, 0.75 mmol) was
added glacial acetic acid (70 mL) and the mixture

heated to 100 oC with continuous stirring under nitrogen for 7h. After the reaction
came to completion (TLC monitoring; 30 % ethyl acetate: hexane, bright yellow
spot), the reaction mixture was cooled to room temperature and solvent evaporated
under reduced pressure to give a black residue. The crude residue was dissolved in
dichloromethane (15 mL) and vacuum filtered through celite to remove suspended
palladium(0) particles. After solvent evaporation, the impure solid was purified by
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chromatography (40 % ethyl acetate: hexane) to give 126 (0.03 g, 14 %) as a deep
orange coloured solid. The product was further purified by multi-development
preparative plate chromatography (20 % ethyl acetate: hexane) and 3 bands isolated of
which the (most polar) 3rd band (6.6 mg, 3 %) was the compound 126. Mass spectrum
(CI+), m/z 276 [MH+1]; HRMS (CI) Found: 276.0483 (0.3 ppm), required: 276.0483
for C17H10NOS. 1H-NMR (CDCl3, 300 MHz): 6.57 (s, 1H, H5), 7.00-7.17 (m, 2H,
H2 and H3), 7.25-7.55 (m, 3H, H1, H7 and H8), 7.72 (d, J = 3.9 Hz, 1H, H4), 8.06
(m, 2H, H6 and H9). 13C-NMR: 102.1 (C5), 111.4 (C1), 119.6 (C2), 121.7 (C3 and
C9), 124.7-124.9 (C5a, C7 and C8), 128.0 (C4a) 135.2 (C12a) and 162.9 (C=O).

Synthesis of 126 from 125.
In the same manner as that described for 124 above, 125 (0.20 g, 0.75 mmol) was
reacted to form 126 (0.05 g, 23 %), which was isolated after chromatography as a
deep orange coloured solid. Mass spectrum (CI+), m/z 276 [MH+1]; HRMS (CI)
Found: 276.0483 (1.2 ppm), required: 276.0479 for C17H10NOS.

1

H-NMR (CDCl3,

300 MHz): 6.58 (s, 1H, H5), 7.01-7.16 (m, 2H, H2 and H3), 7.28-7.57 (m, 3H, H1,
H7 and H8), 7.70 (d, J = 3.9 Hz, 1H, H4), 8.06 (m, 2H, H6 and H9). 13C-NMR: 102.1
(C5), 111.2 (C1), 119.7 (C2), 121.5 (C3 and C9), 124.7-124.9 (C5a, C7 and C8),
128.3 (C4a) 135.2 (C12a) and 162.9 (C=O).

Attempted synthesis of 126 in the presence of copper(II) acetate.
To a mixture of 124 (0.40 g, 1.43 mmol) and palladium(II) acetate (0.2 g, 0.88 mmol)
and glacial acetic acid (70 mL) was added copper(II) acetate (0.72 g, 3.61 mmol) in
acetic anhydride (15 mL) and the mixture heated at reflux with continuous stirring
under nitrogen for 12h. After 12h, a TLC analysis of the reaction mixture indicated
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primarily the presence of the starting material. The reaction conditions were
maintained for a further 48h with periodic monitoring by TLC and mass spectroscopy,
however the formation of 126 was not evident. The reaction mixture was then cooled
to room temperature, and solvent evaporated under reduced pressure to give a crude
residue which was chromatographed (40 % ethyl acetate: hexane) to give what was
identified as the starting material 124 (0.38g) as a brown solid. Mass spectrum (CI+),
278 [MH+1]. 1H-NMR (CDCl3, 300 MHz): 6.71 (d, J = 3.6 Hz, 1H, H3), 7.26 (d, J =
15.6 Hz, 1H, H2), 7.33-7.46 (m, 4H, H5; H6, H5`; H6`), 7.74 (d, J = 3.9 Hz, 1H, H4),
7.90 (s, 1H, H3`), 7.95 (dd, J = 3.45, 5.24 Hz, 2H, ArH- H4 and H7). 8.44 (m, 1H,
H7).
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6.3 Experimental for Chapter 4 (biological testing)

6.3.1. Antibacterial assay
Sample preparation.
Pure samples of the benzo[b]thiophene derivatives were carefully weighed out
(approx. 2 mg) on an analytical balance and packed in small glass sample tubes.
These samples were then sent for antibacterial assays to the staff at Avexa Ltd
(formally-Amrad, Melbourne) who carried out the antibacterial assays through Dr. J.
Deadman. All assays used the Staphylococcus aureus strain ATCC 6538P, or
vancomycin resistant enterococci (VRE) strains 243, 449, 820 and 987 (Enterococcus
faecium). It should be noted however that two strains, VRE 243 and 987, although
designated as VRE, were in fact sensitive to vancomycin.

Antibacterial testing methodology.
The Mueller-Hinton Broth (MHB) medium culture media was prepared with
final concentrations of 1 µg/ mL MgCl2 and 2 µg/ mL CaCl2 and was pre-warmed for
2-3h at 37 oC before use. Mueller-Hinton Agar (MHA) medium culture was then
prepared at concentrations of 1.5 % agar (Merck Agar 1.01614). Staphylococcus
aureus was streaked onto MHA and the plate was incubated overnight at 37 oC. From
this plate, 10 cryovial were prepared by looping several colonies into 0.5 mL of 20 %
glycerol solution and immediately stored at minus 140 oC. A cryovial was removed
from minus 140 oC storage and thawed to room temperature. The MHA plate was
streaked with bacterial suspension and incubated at 37 oC overnight to create a parent
plate (P1). The parent plate was then stored at 4 oC. A daughter plate (D1) was
incubated at 37 oC overnight and its loop of colony used to inoculate a 125 mL flask
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containing 20 mL of MHB containing 25 µg/ mL CaCl2. 2H2O) and 12.5 µg/ mL
MgCl2. 6H2O. The flask was swirled at 260 rpm at 37 oC for 18h on an orbital
incubator shaker. The parent plates P1 and P2 were each used twice to generate two
daughter plates (D1 and D2) before being discarded.
The standardised inocula for assays was prepared as 1/10 dilution of seed
cultures by adding 250 µL of the cultures to 2,250 µL of MHB in a disposable cuvette
and the required dilution factor was calculated by dividing the observed OD650.
Sufficient volumes of the final inoculum cultures were prepared in pre-warmed MHB
(37 oC) by diluting the standardised cultures to the required final concentration (108
dilution).

Assay Procedure for 96-well Microtitre Plates.
To each well of the 96-well microtitre plate was added 50 µL of liquid
medium and 50 µL of peptoid test solution initially prepared by dissolving in 2.5 %
DMSO and added in triplicate to the top of the microtitre plate. A vancomycin control
set (triplicate) and a compound negative control set (triplicate) were also set up on
each plate. The inoculated culture medium was incubated at 37 oC for 30 min with
continuous shaking at 130 rpm. Using the multi-channel pipette and multi-stepper
pipette the adding, transferring and mixing of the inoculum were performed on the
wells of the plates. The plates were then incubated at 37 oC on a 90 % relative
humidity environment for 18h with continued shaking (100 rpm). The activities were
reported in minimum inhibitory concentration (MIC) value which is a standard
measure of the lowest concentration of the antibiotic that results in the inhibition of
visible bacteria growth under standard conditions. The MIC was also determined for
DMSO (2.5 %) as a control measure. The test results are summarised in Table 4.4.
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6.3.2. Antimalarial assay
Sample preparation.
Purified samples of the benzo[b]thiophene derivatives to be tested were
carefully weighed out (10-12 mg) on an analytical balance and packed in small glass
sample tubes. These samples were then sent for antimalarial testing at the National
Centre for Genetic Engineering and Biotechnology (BIOTEC), National Science and
Technology Development Agency (NSTDA), Bangkok. The in vitro tests were
undertaken by Dr. Sumalee Kamchonwongpaisan.

Antimalarial assay method.
Samples were made up in DMSO solution and using the Microdilution
Radioisotope Technique, the in vitro antimalarial activity testing was carried out. Two
strains of Plasmodium falciparum were used for these tests, the double mutant K1
CB1 strain, which is a multidrug resistant/ antifolate resistant Plasmodium
falciparum, and a wild type antifolate sensitive strain TM4/ 8.2 of Plasmodium
falciparum. The test sample (25 µl, in the culture medium) was placed in triplicate in
a 96-well plate where parasitised erythrocytes (200 µl) with a cell suspension (1.5 %)
of parasitemia (0.5-1 %) were then added to the wells. The range of the final
concentrations of the samples was varied from 1 x 10-5 to 1 x 10-8 g/ mL with 0.1% of
the organic solvent. The plates were then cultured under standard conditions for 24h
after which 3H-hypoxanthine (25 µL, 0.5 mCi) was added. The culture was incubated
for 18-20h after which the DNA from the parasite was harvested from the culture onto
glass fibre filters and a radiation counter used to determine the amount of 3Hhypoxanthine present. The inhibitory concentration of the sample was determined
from its dose-response curves or by calculation.
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The Trager and Jensen method153 was used to culture Plasmodium falciparum
K1 CB1 strain. The parasites were maintained in human red blood cells in a culture
medium. RPMI 1640 was supplemented with 25 mM HEPES, 0.2 % sodium
bicarbonate, and 8 % human serum, at 37 oC in a carbon dioxide gas incubator154.
The test results are given in Table 4.1, Table 4.2 and in Appendix 1.
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Appendices
Appendix 1: Antimalarial activities for both fused and non-fused
benzo[b]thiophene derivatives showing the standard deviation figures for the
IC50 values
Compound
Number.

Antimalarial activity against K1 CB1 and TM4/ 8.2 strains of
P. falciparum. The (IC50) values are reported in µM and µg/ mL.
K1

92
105
30
29
106
81
80
61
63
85
60
54
76
53
59
70
62
50
52
51
71
84
55
82
75
66
72
73
113
114
120
96

µM
3.9 +/- 2.5
3.63 +/- 0.34
13.0 +/- 4.4
13.7 (18.2, 9.2)
14.2 +/- 0.89
17.9 +/- 6.1
18.2 +/- 5.2
18.3 +/- 4.3
18.4 +/- 3.2
19.1 +/- 6.5
20.0 +/- 3.5
22.7 +/- 7.5
23.2 +/- 9.5
23.5 +/- 3.5
28.89 +/- 2.82
37.1
43.0 +/- 2.36
46.92
51.1
54.13
> 50.0
58.71 +/- 4.0
65.97
71.3, 14.8
> 20
> 50
> 50
> 50
> 50
> 50
> 20
> 100

TM4
µg/ mL
1.00
2.01
4.84
4.49
3.08
8.40
7.73
9.18
7.82
8.55
10.03
7.56
11.34
9.69
13.20
14.51
16.4 +/-0.9
18.2 +/- 5.6
18.8 +/- 5.6
23.4 +/- 4.3
23.6+/- 1.6
24.2 +/- 3.4
28.96
> 50
-

µM
3.7 +/- 1.8
3.32 +/- 0.65
< 1, 0.30
> 20
18.8 (18.6, 9.1)
14.3 +/- 4.9
16.5 +/- 3.4
18.9
17.2 +/- 6.6
22.3 +/- 7.0
15.4 +/- 5.3
28.95
> 50
26.2
16.5
> 50
> 50
66.12
> 50
> 20
> 50
> 50
> 50
> 50
> 20
> 100

µg/ mL
0.95
1.84
0.10
8.82
6.07
8.03
8.03
7.70
7.43
7.53
13.22
9.97
6.40
24.19
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Appendix 2: 1H-NMR of benzo[b]thiophene derivative 92 synthesised via free
radical cyclisation.

221

Appendix 3: 1H-NMR of the de-allylated benzo[b]thiophene derivative 106.

222

Appendix 4: 1H-NMR of the 9-membered ring derivative 120 synthesised via
ring closing metathesis reaction using Grubbs` I catalyst.
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Appendix 5: 1H-NMR of benzo[b]thiophene derivative 126 acquired through
palladium-assisted cyclisation reaction.
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Appendix 6: 1H-NMR of 2,5-dihydropyrrole derivative 114.
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